<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002763.pub2" GROUP_ID="SYMPT" ID="368799123011523048" MERGED_FROM="" MODIFIED="2017-10-11 16:34:06 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="18" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2017-10-11 16:33:26 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2009-01-14 14:49:03 +0000" MODIFIED_BY="[Empty name]">Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults</TITLE>
<CONTACT>
<PERSON ID="5475F46C82E26AA20187B79619319C6E" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sheena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Derry</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Officer</POSITION>
<EMAIL_1>sheena.derry@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225405</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-10-11 16:33:01 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="B5F896A482E26AA200F0756DB7DAE524" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gaskell</LAST_NAME>
<SUFFIX/>
<POSITION>Honorary Research Associate</POSITION>
<EMAIL_1>helen.gaskell@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP/>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 01865 234972</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5475F46C82E26AA20187B79619319C6E" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sheena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Derry</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Officer</POSITION>
<EMAIL_1>sheena.derry@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225405</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7899" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>R Andrew</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moore</LAST_NAME>
<SUFFIX>DSc</SUFFIX>
<POSITION>Research Director</POSITION>
<EMAIL_1>andrew.moore@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225401</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7877" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Henry</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>McQuay</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Pain Research</POSITION>
<EMAIL_1>henrymcquay@gmail.com</EMAIL_1>
<EMAIL_2>henrymcquay@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>West Wing (Level 6)</ADDRESS_1>
<ADDRESS_2>John Radcliffe Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 9DU</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 231515</PHONE_1>
<PHONE_2>+44 1865 851138</PHONE_2>
<FAX_1>+44 1865 223844</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-09-24 11:33:00 +0100" MODIFIED_BY="Jessica Thomas">
<UP_TO_DATE>
<DATE DAY="13" MONTH="5" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="5" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="7" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2017-10-11 16:33:26 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-10-11 16:33:26 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="11" MONTH="10" YEAR="2017"/>
<DESCRIPTION>
<P>No new studies likely to change the conclusions are expected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-10-11 16:33:20 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-10-11 16:33:20 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="18" MONTH="8" YEAR="2016"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-08-18 10:05:54 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="24" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-09-24 11:33:00 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Revised estimates of efficacy and harm, new efficacy outcomes added. The new review includes 20 studies, with 2641 participants, compared with 7 studies and 769 participants from the original review. The new review, with more participants in comparisons, provides better estimates of efficacy and harm, some of which have changed substantially from the previous review, and show that single dose oxycodone is an effective analgesic at doses over 5 mg. Efficacy increases when combined with paracetamol. Oxycodone 10 mg plus paracetamol 650 mg provides good analgesia over four to six hours to about half of those treated, comparable to commonly used non-steroidal anti-inflammatory drugs, but with the benefit of longer duration of action. Nausea, vomiting, dizziness and somnolence were more common than with oxycodone than placebo. The title also now states that the review is limited to adults and oral administration only. </P>
<P>Changes to authorship: Jayne Rees (neè Edwards) worked on the original version of this review but was not involved in this update and Sheena Derry and Helen Gaskell were involved with the update of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-09-24 11:33:00 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>New studies added in December 2008 and the analysis was updated. An updated search prior to publication in May 2009 found two additional studies that are awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-15 15:07:11 +0000" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="23" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-05-13 10:50:30 +0100" MODIFIED_BY="Jessica R Thomas">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Oxford Pain Research funds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-05-13 10:50:30 +0100" MODIFIED_BY="Jessica R Thomas">
<SOURCE MODIFIED="2008-08-01 13:39:36 +0100" MODIFIED_BY="Sheena Derry">
<NAME>NHS Cochrane Collaboration Programme Grant Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-12-02 12:11:32 +0000" MODIFIED_BY="[Empty name]">
<NAME>European Union Biomed 2 Grant no. BMH4 CT95 0172</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-05-13 10:50:30 +0100" MODIFIED_BY="Jessica R Thomas">
<NAME>NIHR Biomedical Research Centre Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-18 10:07:35 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2009-05-13 11:01:59 +0100" MODIFIED_BY="Jessica R Thomas">
<TITLE MODIFIED="2009-05-13 11:01:31 +0100" MODIFIED_BY="Jessica R Thomas">Single dose oxycodone and oxycodone plus paracetamol (also known as acetaminophen) for analgesia in adults with acute postoperative pain</TITLE>
<SUMMARY_BODY MODIFIED="2009-05-13 11:01:59 +0100" MODIFIED_BY="Jessica R Thomas">
<P>This review update assessed evidence from 2641 participants in 20 randomised, double blind, placebo-controlled clinical trials of oxycodone, with or without paracetamol, in adults with moderate to severe acute postoperative pain. Oral oxycodone 10 mg plus paracetamol 650 mg provided effective analgesia. About half of those treated experienced at least half pain relief over 4 to 6 hours, and the effects lasting up to 10 hours. Higher doses gave more effect. Associated adverse events (predominantly nausea, vomiting, dizziness and somnolence) were more frequent with oxycodone or oxycodone plus paracetamol than with placebo, but studies of this type are of limited use for studying adverse effects. Limited information about oxycodone on its own suggests that it provided analgesia at doses greater than 5 mg, and that addition of paracetamol made it more effective.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-13 13:45:58 +0100" MODIFIED_BY="Jessica R Thomas">
<ABS_BACKGROUND MODIFIED="2009-05-13 10:57:37 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Oxycodone is a strong opioid agonist used to treat severe pain. It is commonly combined with milder analgesics such as paracetamol. This review updates a previous review that concluded, based on limited data, that all doses of oxycodone exceeding 5 mg, with or without paracetamol, provided analgesia in postoperative pain, but with increased incidence of adverse events compared with placebo. Additional new studies provide more reliable estimates of efficacy and harm.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-12-18 15:04:49 +0000" MODIFIED_BY="[Empty name]">
<P>To assess efficacy, duration of action, and associated adverse events of single dose oral oxycodone, with or without paracetamol, in acute postoperative pain in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-05-13 13:45:58 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Cochrane CENTRAL, MEDLINE, EMBASE and Oxford Pain Relief Database, searched in May 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-12-05 09:36:54 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo-controlled trials of single dose orally administered oxycodone, with or without paracetamol, in adults with moderate to severe acute postoperative pain.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-05-13 10:56:00 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Two review authors independently assessed trial quality and extracted data. Pain relief or pain intensity data were extracted and converted into the dichotomous outcome of number of participants with at least 50% pain relief over 4 to 6 hours, from which relative risk and number-needed-to-treat-to-benefit (NNT) were calculated. Numbers of participants remedicating over specified time periods, and time-to-use of rescue medication, were sought as additional measures of efficacy. Adverse events and withdrawals information was collected.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-05-13 10:58:51 +0100" MODIFIED_BY="Jessica R Thomas">
<P>This updated review includes 20 studies, with 2641 participants. For oxycodone 15 mg alone compared with placebo, the NNT for at least 50% pain relief was 4.6 (95% Confidence Interval 2.9 to 11). For oxycodone 10 mg plus paracetamol 650 mg, the NNT was 2.7 (2.4 to 3.1). A dose response was demonstrated for this outcome with combination therapy. Duration of effect was 10 hours with oxycodone 10 mg plus paracetamol 650 mg, and 4 hours with half that dose. Fewer participants needed rescue medication over 6 hours at the higher dose. Adverse events occurred more frequently with combination therapy than placebo, but were generally described as mild to moderate in severity and rarely led to withdrawal.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-05-13 10:59:34 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Single dose oxycodone is an effective analgesic in acute postoperative pain at doses over 5 mg; oxycodone is two to three times stronger than codeine. Efficacy increases when combined with paracetamol. Oxycodone 10 mg plus paracetamol 650 mg provides good analgesia to half of those treated, comparable to commonly used non-steroidal anti-inflammatory drugs, with the benefit of longer duration of action.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-13 13:58:04 +0100" MODIFIED_BY="Jessica R Thomas">
<BACKGROUND MODIFIED="2009-04-28 13:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in The Cochrane Database of Systematic Reviews (Issue 4, 2000) on 'Single dose oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain' (<LINK REF="REF-Edwards-2000" TYPE="REFERENCE">Edwards 2000</LINK>). The title now states that the review is limited to adults and oral administration only.</P>
<P>Acute pain occurs as a result of tissue damage either accidentally due to an injury or as a result of surgery. Acute postoperative pain is a manifestation of inflammation due to tissue injury. The management of postoperative pain and inflammation is a critical component of patient care. This is one of a series of reviews whose aim is to increase awareness of the range of analgesics that are potentially available, and present evidence for relative analgesic efficacy through indirect comparisons with placebo, in very similar trials performed in a standard manner, with very similar outcomes, and over the same duration. Such relative analgesic efficacy does not in itself determine choice of drug for any situation or patient, but guides policy-making at the local level. Recently published reviews include paracetamol (<LINK REF="REF-Toms-2008" TYPE="REFERENCE">Toms 2008</LINK>), celecoxib (<LINK REF="REF-Derry-2008" TYPE="REFERENCE">Derry 2008</LINK>), naproxen (<LINK REF="REF-Derry-C-2009a" TYPE="REFERENCE">Derry C 2009a</LINK>), ibuprofen (<LINK REF="REF-Derry-C-2009b" TYPE="REFERENCE">Derry C 2009b</LINK>), diclofenac (<LINK REF="REF-Derry-P-2009" TYPE="REFERENCE">Derry P 2009</LINK>) and etoricoxib (<LINK REF="REF-Clarke-2009" TYPE="REFERENCE">Clarke 2009</LINK>).</P>
<P>Single dose trials in acute pain are commonly short in duration, rarely lasting longer than 12 hours. The numbers of participants are small, allowing no reliable conclusions to be drawn about safety. To show that the analgesic is working it is necessary to use placebo (<LINK REF="REF-McQuay-2005" TYPE="REFERENCE">McQuay 2005</LINK>). There are clear ethical considerations in doing this. These ethical considerations are answered by using acute pain situations where the pain is expected to go away, and by providing additional analgesia, commonly called rescue analgesia, if the pain has not diminished after about an hour. This is reasonable, because not all participants given an analgesic will have significant pain relief. Approximately 18% of participants given placebo will have significant pain relief (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>), and up to 50% may have inadequate analgesia with active medicines. The use of additional or rescue analgesia is hence important for all participants in the trials.</P>
<P>Clinical trials measuring the efficacy of analgesics in acute pain have been standardised over many years. Trials have to be randomised and double blind. Typically, in the first few hours or days after an operation, patients develop pain that is moderate to severe in intensity, and will then be given the test analgesic or placebo. Pain is measured using standard pain intensity scales immediately before the intervention, and then using pain intensity and pain relief scales over the following 4 to 6 hours for shorter acting drugs, and up to 12 or 24 hours for longer acting drugs. Pain relief of half the maximum possible pain relief or better (at least 50% pain relief) is typically regarded as a clinically useful outcome. For patients given rescue medication it is usual for no additional pain measurements to be made, and for all subsequent measures to be recorded as initial pain intensity or baseline (zero) pain relief (baseline observation carried forward). This process ensures that analgesia from the rescue medication is not wrongly ascribed to the test intervention. In some trials the last observation is carried forward, which gives an inflated response for the test intervention compared to placebo, but the effect has been shown to be negligible over 4 to 6 hours (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>). Patients usually remain in the hospital or clinic for at least the first six hours following the intervention, with measurements supervised, although they may then be allowed home to make their own measurements in trials of longer duration.</P>
<P>Oxycodone is a strong opioid agonist, developed in the early 20th century, and chemically related to codeine. It is considered to be comparable to morphine for efficacy, and similar for adverse events, with the exception of hallucinations, which tend to occur rarely with oxycodone (<LINK REF="REF-Poyhia-1993" TYPE="REFERENCE">Poyhia 1993</LINK>). Like morphine, it can be administered via a variety of routes including oral or rectal, and intramuscular, intravenous, or subcutaneous injection. Its analgesic potency makes it useful for the management of severe pain, usually acute postoperative, post-traumatic or cancer pain. Oxycodone is commonly combined with milder analgesics, such as paracetamol. The purpose is to increase efficacy by simultaneously using drugs with distinct mechanisms of action with the aim of reducing the amount of opioid required for a given level of response, and so reducing adverse events (<LINK REF="REF-Edwards-2002" TYPE="REFERENCE">Edwards 2002</LINK>). Repeated administration of oxycodone can cause dependence and tolerance, and its potential for abuse is well known. Regulation of supply varies between countries, but in many, all oxycodone preparations are controlled substances.</P>
<P>This quantitative systematic review assesses the efficacy and adverse effects of single-dose oral oxycodone, alone and in combination with paracetamol, compared with placebo in the treatment of adults with moderate to severe postoperative pain. The previous review (<LINK REF="REF-Edwards-2000" TYPE="REFERENCE">Edwards 2000</LINK>) found seven studies with oxycodone alone, or with paracetamol, with oxycodone at oral doses of 5 mg to 30 mg. Results for efficacy and adverse events were based on small numbers of patients, emphasising the need to update the review with trials published since 2000.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-12-01 12:12:34 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the analgesic efficacy and safety of oral oxycodone alone or in combination with paracetamol in the treatment of acute postoperative pain, using methods that permit comparison with other analgesics evaluated in the same way, using wider criteria of efficacy recommended by an in-depth study at the individual patient level (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-13 12:18:38 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-05-13 11:19:45 +0100" MODIFIED_BY="Jessica R Thomas">
<CRIT_STUDIES MODIFIED="2009-05-13 11:19:05 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Studies were included if they were full publications of double blind trials of a single dose oral oxycodone, alone or in combination with paracetamol, compared with placebo for the treatment of moderate to severe postoperative pain in adults, with at least 10 participants randomly allocated to each treatment group. Multiple dose studies were included if appropriate data from the first dose were available, and cross-over studies were included provided that data from the first arm were presented separately.</P>
<P> Studies were excluded if they were:</P>
<UL>
<LI>posters or abstracts not followed up by full publication;</LI>
<LI>reports of studies concerned with pain other than postoperative pain (including experimental pain);</LI>
<LI>studies using healthy volunteers;</LI>
<LI>studies where pain relief was assessed by clinicians, nurses or carers (i.e., not patient-reported);</LI>
<LI>studies of less than 4 hours' duration or which failed to present data over 4 to 6 hours post-dose.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-12-01 12:12:54 +0000" MODIFIED_BY="[Empty name]">
<P>Studies of adult participants (15 years old or above) with established moderate to severe postoperative pain were included. For studies using a visual analogue scale (VAS), pain of at least moderate intensity was assumed when the VAS score was greater than 30 mm (<LINK REF="REF-Collins-1997" TYPE="REFERENCE">Collins 1997</LINK>). Studies of participants with postpartum pain were included provided the pain investigated resulted from episiotomy or Caesarean section (with or without uterine cramp). Studies investigating participants with pain due to uterine cramps alone were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-01-14 14:07:26 +0000" MODIFIED_BY="[Empty name]">
<P>Orally administered oxycodone, alone or in combination with paracetamol, and matched placebo for relief of postoperative pain.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-05-13 11:19:45 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Data collected included the following.</P>
<UL>
<LI>characteristics of participants;</LI>
<LI>pain model;</LI>
<LI>patient-reported pain at baseline (physician, nurse, or carer reported pain was not included in the analysis);</LI>
<LI>patient-reported pain relief and/or pain intensity expressed hourly over 4 to 6 hours using validated pain scales (pain intensity and pain relief in the form of visual analogue scales (VAS) or categorical scales, or both), or reported total pain relief (TOTPAR) or summed pain intensity difference (SPID) at 4 to 6 hours;</LI>
<LI>patient-reported global assessment of treatment (PGE), using a standard five-point scale;</LI>
<LI>number of participants using rescue medication, and the time of assessment;</LI>
<LI>time to use of rescue medication;</LI>
<LI>withdrawals - all cause, adverse event;</LI>
<LI>adverse events - participants experiencing one or more, and any serious adverse event, and the time of assessment.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-13 12:18:38 +0100" MODIFIED_BY="[Empty name]">
<P>The following electronic databases were searched:</P>
<UL>
<LI>Cochrane CENTRAL (Issue 3, 1999 for original search, Issue 2 2009 for the update);</LI>
<LI>MEDLINE via Ovid (1966 to October 1999 for the original search and 1999 to May 2009 for the update);</LI>
<LI>EMBASE via Ovid (1980 to October 1999 for the original search and 1999 to May 2009 for the update);</LI>
<LI>Oxford Pain Database (<LINK REF="REF-Jadad-1996a" TYPE="REFERENCE">Jadad 1996a</LINK>);</LI>
<LI>Biological Abstracts (to October 1999 for the original search).</LI>
</UL>
<P>Reference lists of retrieved articles were searched.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the MEDLINE search strategy, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the EMBASE search strategy, and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for the Cochrane CENTRAL search strategy.</P>
<SUBSECTION>
<HEADING LEVEL="3"> Language</HEADING>
<P> No language restriction was applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"> Unpublished studies</HEADING>
<P> Abstracts, conference proceedings and other grey literature were not searched.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-13 11:26:01 +0100" MODIFIED_BY="Jessica R Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors independently assessed and agreed the search results for studies that might be included in the updated review. Disagreements were resolved by consensus or referral to a third review author.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>Two review authors independently assessed the included studies for quality using a five-point scale (<LINK REF="REF-Jadad-1996b" TYPE="REFERENCE">Jadad 1996b</LINK>).</P>
<P>The scale used is as follows.</P>
<UL>
<LI>Is the study randomised? If yes give one point.</LI>
<LI>Is the randomisation procedure reported and is it appropriate? If yes add one point, if no deduct one point.</LI>
<LI>Is the study double blind? If yes then add one point.</LI>
<LI>Is the double blind method reported and is it appropriate? If yes add one point, if no deduct one point.</LI>
<LI>Are the reasons for patient withdrawals and dropouts described? If yes add one point.</LI>
</UL>
<P>The results are described in the 'Methodological quality of included studies' section below, and in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data management</HEADING>
<P>Data were extracted by two review authors and recorded on a standard data extraction form. Data suitable for pooling were entered into RevMan 5.0.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data Analysis</HEADING>
<P>QUOROM guidelines were followed (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>). For efficacy analyses we used the number of participants in each treatment group who were randomised, received medication, and provided at least one post-baseline assessment. For safety analyses we used number of participants who received study medication in each treatment group. Analyses were planned for different doses. Sensitivity analyses were planned for pain model (dental versus other postoperative pain), trial size (39 or fewer versus 40 or more per treatment arm), and quality score (two versus three or more). A minimum of two studies and 200 participants were required for any analysis (<LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Number of participants achieving at least 50% pain relief</HEADING>
<P>For each study, mean TOTPAR (total pain relief) or SPID (summed pain intensity difference) for active and placebo groups were converted to %maxTOTPAR or %maxSPID by division into the calculated maximum value (<LINK REF="REF-Cooper-1991" TYPE="REFERENCE">Cooper 1991</LINK>). The proportion of participants in each treatment group who achieved at least 50%maxTOTPAR was calculated using verified equations (<LINK REF="REF-Moore-1996" TYPE="REFERENCE">Moore 1996</LINK>; <LINK REF="REF-Moore-1997a" TYPE="REFERENCE">Moore 1997a</LINK>; <LINK REF="REF-Moore-1997b" TYPE="REFERENCE">Moore 1997b</LINK>). These proportions were then converted into the number of participants achieving at least 50%maxTOTPAR by multiplying by the total number of participants in the treatment group. Information on the number of participants with at least 50%maxTOTPAR for active treatment and placebo was then used to calculate relative benefit, and number needed to treat to benefit (NNT) when there was a statistically significant effect. Pain measures accepted for the calculation of TOTPAR or SPID were:</P>
<UL>
<LI>five-point categorical pain relief (PR) scales with comparable wording to "none, slight, moderate, good or complete";</LI>
<LI>four-point categorical pain intensity (PI) scales with comparable wording to "none, mild, moderate, severe";</LI>
<LI>Visual analogue scales (VAS) for pain relief;</LI>
<LI>VAS for pain intensity.</LI>
</UL>
<P>If none of these measures were available, numbers of participants reporting "very good or excellent" on a five-point categorical global scale with the wording "poor, fair, good, very good, excellent" were taken as those achieving at least 50% pain relief (<LINK REF="REF-Collins-2001" TYPE="REFERENCE">Collins 2001</LINK>).</P>
<P>Further details of the scales and derived outcomes are in the glossary (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> Secondary outcomes:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Use of rescue medication</HEADING>
<P>Numbers of participants requiring rescue medication were used to calculate relative risk (RR) and numbers needed to treat to prevent (NNTp) use of rescue medication for treatment and placebo groups. Median (or mean) time to use of rescue medication was used to calculate the weighted mean of the median (or mean) for the outcome. Weighting was by number of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Adverse events</HEADING>
<P>Numbers of participants reporting adverse events for each treatment group were used to calculate RR and numbers needed to treat to harm (NNH) estimates for:</P>
<UL>
<LI>any adverse event;</LI>
<LI>any serious adverse event (as reported in the study);</LI>
<LI>withdrawal due to an adverse event.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Withdrawals</HEADING>
<P>Withdrawals for reasons other than lack of efficacy (participants using rescue medication - see above) and adverse events were noted, as were exclusions from analysis where data were presented.</P>
<P>Relative benefit (RB) or RR estimates were calculated with 95% confidence intervals (CI) using a fixed-effect model (<LINK REF="REF-Morris-1995" TYPE="REFERENCE">Morris 1995</LINK>). NNT, NNTp and NNH with 95% CI were calculated using the pooled number of events by the method of Cook and Sackett (<LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>). A statistically significant difference from control was assumed when the 95% CI of the RB did not include the number one.</P>
<P>Homogeneity of studies was assessed visually (<LINK REF="REF-L_x0027_Abb_x00e8_-1987" TYPE="REFERENCE">L'Abbè 1987</LINK>). The z test (<LINK REF="REF-Tram_x00e8_r-1997" TYPE="REFERENCE">Tramèr 1997</LINK>) was used to determine if there was a significant difference between NNTs for different doses of active treatment, or between groups in the sensitivity analyses.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-13 13:58:04 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY_DESCRIPTION MODIFIED="2009-05-13 13:58:04 +0100" MODIFIED_BY="Jessica R Thomas">
<P>The original review included seven studies (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>; <LINK REF="STD-Young-1979" TYPE="STUDY">Young 1979</LINK>). One of these studies (<LINK REF="STD-Young-1979" TYPE="STUDY">Young 1979</LINK>) has not been included in the current review because on looking at the study again it appears that pain relief may not have been patient-reported.</P>
<P>New searches in December 2008 identified 15 more recent studies that were potentially relevant; 14 of these fit the inclusion criteria (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>). One study, <LINK REF="STD-de-Beer-2005" TYPE="STUDY">de Beer 2005</LINK>, was excluded after reading the full paper because it had no placebo control.</P>
<P>An updated search in May 2009 identified two additional studies (<LINK REF="STD-Daniels-2009" TYPE="STUDY">Daniels 2009</LINK>; <LINK REF="STD-Stegmann-2008" TYPE="STUDY">Stegmann 2008</LINK>). These studies are awaiting classification and are not included in this analysis.</P>
<P>Twenty studies are included in total for this updated review. All of the included studies had more than one active treatment arm. The active treatments used were oxycodone alone (immediate release and controlled release formulations), oxycodone plus paracetamol, and other analgesic drugs (mostly non-steroidal anti-inflammatory drugs (NSAIDs) but also other opioids). Some studies used both oxycodone alone <I>and</I> oxycodone plus paracetamol active treatment arms.</P>
<P>The majority of studies used the immediate release form of oxycodone but in two studies controlled release oxycodone (oxycodone CR) was also used as an active treatment (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). There were no studies in which oxycodone CR was used as the only active treatment.</P>
<P>In studies using oxycodone alone (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>), the dose of oxycodone ranged between 5 mg and 15 mg and the dose of oxycodone CR ranged between 10 mg and 30 mg. In studies using oxycodone plus paracetamol (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>;  <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>;  <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>;  <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) the dose of oxycodone ranged between 5 mg and 15 mg, and the dose of paracetamol ranged between 325 mg and 1000 mg. In studies using oxycodone plus paracetamol several different combinations of dosages of the two drugs were used. Higher doses of oxycodone tended to be used with higher doses of paracetamol.</P>
<P>Overall, 482 participants received oxycodone alone, 1192 received oxycodone plus paracetamol, and 967 received placebo. For the comparison of oxycodone alone versus placebo, 482 participants were treated with oxycodone and 363 with placebo. For the comparison of oxycodone plus paracetamol versus placebo, 1192 participants were treated with oxycodone plus paracetamol and 704 with placebo.</P>
<P>Twelve studies enrolled participants after extraction of at least one impacted molar ("dental pain") (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>). The other studies enrolled participants with pain after a variety of different types of surgery including orthopaedic, abdominal surgery (including general, obstetric and gynaecological) (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>).</P>
<P>The duration of the single dose phase was 4 hours in one study (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>), 6 hours in six studies (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>), 8 hours in 6 studies (<LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>) and 24 hours in six studies (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>).</P>
<P>Full details are given in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-01-15 16:36:17 +0000" MODIFIED_BY="Jessica R Thomas">
<P>All included studies were randomized, double-blind, and placebo-controlled. Five studies were given a quality score of five (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>), eleven a score of four (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>), and four a score of three (<LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>).</P>
<P>Full details are given in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-13 11:52:09 +0100" MODIFIED_BY="Jessica R Thomas">
<SUBSECTION>
<HEADING LEVEL="3">Oxycodone (Alone)</HEADING>
<P>Seven studies had treatment arms using oxycodone alone (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>); in five studies only the immediate release formulation of oxycodone was used (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>), in one study only the controlled release formulation of oxycodone (oxycodone CR) was used (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>), and in one study (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) both the immediate release and the controlled release formulations of oxycodone were used.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: Participants achieving at least 50% pain relief over 4 to 6 hours</HEADING>
<P>(Table 1; Summary of results A).</P>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 5 mg versus placebo</HEADING>
<P>In three studies using oxycodone 5 mg (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>) there were data from 317 participants (Analysis 1.1).</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours was 25% (39/157; range 13% to 37%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 20% (32/160; range 11% to 29%).</LI>
<LI>The RB of treatment compared with placebo was 1.3 (0.84 to 1.9). The NNT was not calculated.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 10 mg versus placebo</HEADING>
<P>One study used oxycodone 10 mg (99 participants in the comparison) (<LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>). There were insufficient data for analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 15 mg versus placebo</HEADING>
<P>In two studies using oxycodone 15 mg (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) there were data from 228 participants (Analysis 2.1).</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours was 54% (61/113; range 47% to 73%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 32% (37/115; range 30% to 33%).</LI>
<LI>The RB of treatment compared with placebo was 1.7 (1.2 to 2.3), giving an NNT for at least 50% pain relief over 4 to 6 hours of 4.6 (2.9 to 11).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone CR 10 mg, Oxycodone CR 20 mg, Oxycodone CR 30 mg</HEADING>
<P>One treatment arm used oxycodone CR 10 mg in 30 participants (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) two used oxycodone CR 20 mg in a total of 85 participants (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), and one used oxycodone CR 30 mg in 30 participants (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). There were insufficient data at each dose for formal analysis but the limited data available suggest that treatment with oxycodone CR 20 mg shows benefit compared with placebo (Analysis 3.1).</P>
<TABLE COLS="6" ROWS="4">
<TR>
<TD COLSPAN="6">
<P>
<B>Summary of results A: participants with &#8805; 50% pain relief over 4 to 6 hours</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Dose (mg) </B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Studies</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Oxycodone<B> (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Placebo (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>NNT (95%CI)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Oxycodone 5 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>317</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>Not calculated</P>
</TD>
</TR>
<TR>
<TD>
<P>Oxycodone 15 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>228</P>
</TD>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER">
<P>4.6 (2.9 to 11)</P>
</TD>
</TR>
</TABLE>
<P>See also Analysis 1.1; Analysis 2.1 and Analysis 3.1.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis of primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Methodological quality</HEADING>
<P>All studies scored three or more for quality, so no sensitivity analysis was carried out for this criterion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pain model dental versus other surgery and trial size</HEADING>
<P>There were insufficient data at any dose to compare dental surgery with other types of surgery, or for larger versus smaller studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Use of rescue medication</HEADING>
<P>Six studies reported on participants requiring rescue medication, four studies at 6 hours (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK> ), one study at 8 hours (<LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>) and one study (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) at 12 hours (Table 1).</P>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 5 mg</HEADING>
<P>In two studies using oxycodone 5 mg (<LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>), there were data from 237 participants on the requirement for rescue medication at 6 hours (Analysis 1.2).</P>
<UL>
<LI>The proportion of participants requiring rescue medication after active treatment was 83% (95/115; range 83% to 83%).</LI>
<LI>The proportion of participants requiring rescue medication after placebo was 88% (107/122; range 84% to 92%).</LI>
<LI>The RB of treatment compared with placebo was 0.94 (0.85 to 1.1).</LI>
</UL>
<P>There were few data on time to use of rescue medication. The weighted mean of the median time to use of rescue medication was 2.3 hours for oxycodone 5 mg and 2.1 hours for placebo (237 participants) (<LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>). One study (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>) reported a similar result for mean time to use of rescue medication.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone other doses</HEADING>
<P>In one study using oxycodone 10 mg (<LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>) there were data on participants using rescue medication at 8 hours. In studies using oxycodone 15 mg, there were data on participants using rescue medication at 6 hours (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>), and at 12 hours (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). There were insufficient data for analysis. There were no data for time to use of rescue medication.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone CR</HEADING>
<P>In one study using oxycodone CR 10 mg there were data on participants using rescue medication at 12 hours <I>(</I>
<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). In studies using oxycodone CR 20 mg there were data on participants using rescue medication at 6 hours (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>), and at 12 hours (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). In one study using oxycodone CR 30 mg there were data on participants using rescue medication at 12 hours (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). There were insufficient data for analysis. Only one study (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>), using oxycodone CR 20 mg, reported on time to use of rescue medication.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Adverse events</HEADING>
<P>(Table 2)</P>
<P>Five studies reported the number of participants with one or more adverse events for each treatment arm in single dose studies (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>). The time over which the information was collected was not always explicitly stated and varied between trials. In some cases, the rescue medication was a further dose of the active drug, or was not specified. In multiple dose studies, there was either no single dose data (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>) or active treatment data but no placebo data (<LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>). Adverse events, where described, were mild to moderate in severity, and predominantly nausea, vomiting, and dizziness. There was no unambiguous report of a serious adverse event in a single dose study or during the single dose phase of a multiple dose study. <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK> reported two serious adverse events in the single dose phase, but it is not stated in in which of the five treatment arms these adverse events occurred.</P>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 5 mg versus placebo</HEADING>
<P>In three studies using oxycodone 5 mg (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>; <LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>), there were data on having an adverse event from 317 participants (Analysis 1.3).</P>
<UL>
<LI>The proportion of participants having an adverse event after active treatment was 31% (48/157; range 19% to 44%).</LI>
<LI>The proportion of participants having an adverse event after placebo was 29% (46/160; range 11% to 55%).</LI>
<LI>The RR of treatment compared with placebo was 1.1 (0.80 to 1.6).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone other doses</HEADING>
<P>In one study using both oxycodone 10 mg and oxycodone 15 mg (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), there were insufficient data for analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone CR</HEADING>
<P>One study using oxycodone CR 10 mg (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), two studies using oxycodone CR 20 mg (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), and one study using oxycodone CR 30 mg (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) provided data on participants with at least one adverse event; there were insufficient data for analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Withdrawals</HEADING>
<P>(Table 2)</P>
<P>Exclusions may not be of any particular consequence in single dose acute pain studies, where most exclusions result from patients not having moderate or severe pain (<LINK REF="REF-McQuay-1982" TYPE="REFERENCE">McQuay 1982</LINK>).</P>
<P>Participants who took rescue medication were classified as withdrawals due to lack of efficacy, and details, where available, are reported under 'Use of rescue medication' above. Withdrawals due to adverse events were uncommon. In active treatment arms, one participant vomited at an unknown time (<LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>). There were two withdrawals because of unspecified adverse events in a placebo arm (<LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>). In one multi-dose study there were no data specifically from the single dose phase (<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>).</P>
<P>Withdrawals for other reasons, such as loss to follow up, were generally rare. A number of studies (e.g., <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>) reported exclusions from efficacy analyses due to protocol violations and invalid data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxycodone plus paracetamol</HEADING>
<P>In all studies using oxycodone plus paracetamol, the immediate release formulation of oxycodone was used.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: Participants achieving at least 50% pain relief over 4 to 6 hours</HEADING>
<P>(Table 1; Summary of results B)</P>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 5 mg plus paracetamol versus placebo</HEADING>
<P>In three studies using oxycodone 5 mg plus paracetamol 325 mg (<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>), there were data from 388 participants (Analysis 4.1; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours with active treatment was 27% (60/221; range 21% to 41%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 8% (14/167; range 0% to 16%).</LI>
<LI>The RB of treatment compared with placebo was 3.6 (2.1 to 6.3), giving an NNT for at least 50% pain relief over 4 to 6 hours of 5.4 (3.9 to 8.8).</LI>
</UL>
<P>One treatment arm used oxycodone 5 mg with paracetamol 500 mg in 45 participants (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>), and another treatment arm used oxycodone 5 mg with paracetamol 1000 mg in 40 participants (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>). There were insufficient data for analysis of these dose combinations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 10 mg plus paracetamol versus placebo</HEADING>
<P>In ten studies using oxycodone 10 mg plus paracetamol 650 mg (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), there were data from 1043 participants (Analysis 5.1; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> - see total).</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours with active treatment was 51% (346/680; range 28% to 90%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 14% (49/363; range 0% to 38%).</LI>
<LI>The RB of treatment compared with placebo was 3.9 (2.9 to 5.2), giving an NNT for at least 50% pain relief over 4 to 6 hours of 2.7 (2.4 to 3.1).</LI>
</UL>
<P>In two studies (three active treatment arms) using oxycodone 10 mg with paracetamol 1000 mg (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>), there were data from 289 participants. (In <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>, efficacy data from two centres were reported as separate sets of data - shown as Study A and Study B in '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.) (Analysis 6.1; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours with active treatment was 68% (100/147; range 61% to 76%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 13% (19/142; range 6% to 29%).</LI>
<LI>The RB of treatment compared with placebo was 4.9 (3.2 to 7.6), giving an NNT for at least 50% pain relief over 4 to 6 hours of 1.8 (1.6 to 2.2).</LI>
</UL>
<P>There was a significant difference between oxycodone 5 mg plus paracetamol 325 mg and oxycodone 10 mg plus paracetamol 650 mg (z = 4.15, P &lt; 0.00006), and between oxycodone 10 mg plus paracetamol 650 mg and oxycodone 10 mg plus paracetamol 1000 mg (z = 3.14, P &lt; 0.0019).</P>
<TABLE COLS="6" ROWS="5">
<TR>
<TD COLSPAN="6">
<P>
<B>Summary of results B: participants with &#8805; 50% pain relief over 4 to 6 hours</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Dose (mg) </B>
</P>
<P>
<B>(Oxycodone/paracetamol)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Studies</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Oxycodone/</B>
</P>
<P>
<B>paracetamol(%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Placebo (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>NNT (95%CI)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>5/325</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>388</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>5.4 (3.9 to 8.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>10/650</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>1043</P>
</TD>
<TD ALIGN="CENTER">
<P>51</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>2.7 (2.4 to 3.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>10/1000</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>289</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
</TD>
<TD ALIGN="CENTER">
<P>1.8 (1.6 to 2.2)</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis of primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Methodological quality</HEADING>
<P>All studies scored three or more for quality, so no sensitivity analysis was carried out for this criterion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pain model dental versus other surgery</HEADING>
<P>For this analysis there were sufficient data only for the oxycodone 10 mg plus paracetamol 650 mg dose (Analysis 5.1; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>In the six studies in dental pain using oxycodone 10 mg with paracetamol 650 mg (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>) there were data from 673 participants.</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours with active treatment was 51% (252/496; range 28% to 59%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 6% (11/177; range 0% to 12%).</LI>
<LI>The RB of treatment compared with placebo was 6.8 (3.9 to 12) giving an NNT for at least 50% pain relief over 4 to 6 hours of 2.3 (2.0 to 2.6).</LI>
</UL>
<P>In the four studies in other types of surgery (mainly obstetric and gynaecological) using oxycodone 10 mg with paracetamol 650 mg (<LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), there were data from 370 participants.</P>
<UL>
<LI>The proportion of participants experiencing at least 50% pain relief over 4 to 6 hours with active treatment was 51% (93/184; range 32% to 90%).</LI>
<LI>The proportion of participants experiencing at least 50% pain relief with placebo was 20% (37/186; range 0% to 38%).</LI>
<LI>The RB of treatment compared with placebo was 2.5 (1.9 to 3.4) giving an NNT for at least 50% pain relief over 4 to 6 hours of 3.3 (2.5 to 4.7).</LI>
</UL>
<P>The NNT for at least 50% pain relief in these studies was lower (better) for dental studies than other types of surgery, but the difference was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trial size</HEADING>
<P>Seven studies (eight active treatment arms, 934 participants) using oxycodone 10 mg plus paracetamol 650 mg, had more than 40 participants in each treatment arm (<LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>), and three studies (156 participants) had fewer than 40 in each treatment arm (<LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). (In <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>, efficacy data from two centres were reported as separate sets of data- shown as Study A and Study B in '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.) There were insufficient data from small studies for this analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Use of rescue medication</HEADING>
<P>(Table 1; Summary of results C)</P>
<P>Thirteen studies reported on participants requiring rescue medication: one at 2 hours (<LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>), nine at 6 hours (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), three at 8 hours (<LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>) and two at 24 hours (<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>). Two studies (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980)</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>) did not provide usable data on participants requiring rescue medication.</P>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 5 mg plus paracetamol versus placebo</HEADING>
<P>In three studies using oxycodone 5 mg plus paracetamol 325 mg (<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>), there were data from 388 participants on the requirement for rescue medication at 6 hours (Analysis 4.2).</P>
<UL>
<LI>The proportion of participants requiring rescue medication after active treatment was 66% (146/221; range 49% to 78%).</LI>
<LI>The proportion of participants requiring rescue medication after placebo was 85% (142/167; range 73% to 93%).</LI>
<LI>The RB of treatment compared with placebo was 0.77 (0.68 to 0.86), giving an NNTp for rescue medication at 6 hours of 5.3 (3.7 to 9.3).</LI>
</UL>
<P>In one study using oxycodone 5 mg plus paracetamol 325 mg (<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>) reporting participants using rescue medication over 24 hours, there were insufficient data for analysis<I>.</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 10 mg plus paracetamol</HEADING>
<P>Eight studies using oxycodone 10 mg plus paracetamol 650 mg provided data on numbers of participants using rescue medication, one at 2 hours (<LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>), five at 6 hours, and three at 8 hours.</P>
<P>In five studies using oxycodone 10 mg plus paracetamol 650 mg (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), there were data from 526 participants on the requirement for rescue medication at 6 hours (Analysis 5.2; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<UL>
<LI>The proportion of participants requiring rescue medication after active treatment was 55% (192/352; range 38% to 83%).</LI>
<LI>The proportion of participants requiring rescue medication after placebo was 83% (144/174; range 72% to 100%).</LI>
<LI>The RB of treatment compared with placebo was 0.78 (0.71 to 0.87), giving an NNTp for rescue medication at 6 hours of 3.5 (2.8 to 4.9).</LI>
</UL>
<P>In three studies using oxycodone 10 mg plus paracetamol 650 mg<I> (</I>
<LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>), there were data from 310 participants on the requirement for rescue medication at 8 hours (Analysis 5.3).</P>
<UL>
<LI>The proportion of participants requiring rescue medication after active treatment was 86% (133/154; range 73% to 93%).</LI>
<LI>The proportion of participants requiring rescue medication after placebo was 88% (138/156; range 73% to 100%).</LI>
<LI>The RB of treatment compared with placebo was 0.98 (0.90 to 1.1).</LI>
</UL>
<P>In one study (two active treatment arms) using oxycodone 10 mg plus paracetamol 1000 mg<I> (</I>
<LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>), there were data from 205 participants on the requirement for rescue medication at 24 hours. (In <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>, rescue medication data from two centres were reported as separate sets of data - shown as 'Study A' and 'Study B' in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.) (Analysis 6.2).</P>
<UL>
<LI>The proportion of participants requiring rescue medication after active treatment was 67% (68/102; range 55% to 78%).</LI>
<LI>The proportion of participants requiring rescue medication after placebo was 87% (90/103; range 85% to 90%).</LI>
<LI>The RB of treatment compared with placebo was 0.76 (0.65 to 0.89) giving an NNTp for rescue medication at 24 hours of 4.8 (3.1 to 10).</LI>
</UL>
<TABLE COLS="6" ROWS="6">
<TR>
<TD COLSPAN="6">
<P>
<B>Summary of results C: participants using rescue medication</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Time assessed </B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Studies</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Oxycodone/ </B>
</P>
<P>
<B>paracetamol (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Placebo (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>NNTp (95%CI)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>6 hours (5/325 mg)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>388</P>
</TD>
<TD ALIGN="CENTER">
<P>66</P>
</TD>
<TD ALIGN="CENTER">
<P>85</P>
</TD>
<TD ALIGN="CENTER">
<P>5.3 (3.7 to 9.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>6 hours (10/650 mg)</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>526</P>
</TD>
<TD ALIGN="CENTER">
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
<TD ALIGN="CENTER">
<P>3.5 (2.8 to 4.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>8 hours (10/650 mg)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>310</P>
</TD>
<TD ALIGN="CENTER">
<P>86</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>Not calculated</P>
</TD>
</TR>
<TR>
<TD>
<P>24 hours (10/1000 mg)</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>205</P>
</TD>
<TD ALIGN="CENTER">
<P>67</P>
</TD>
<TD ALIGN="CENTER">
<P>87</P>
</TD>
<TD ALIGN="CENTER">
<P>4.8 (3.1 to 10)</P>
</TD>
</TR>
</TABLE>
<P>Ten studies reported on the median time to use of rescue medication (Summary of results D).</P>
<P>The weighted mean of the median time to use of rescue medication was 4.3 hours for oxycodone 5 mg plus paracetamol 325 mg (388 participants) (<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>), 9.8 hours for oxycodone 10 mg plus paracetamol 650 mg (727 participants) (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>), and 8.7 hours for oxycodone 10 mg plus paracetamol 1000 mg (206 participants) (<LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>). The corresponding median times to use of rescue medication with placebo were 2.0, 1.5 and 1.1 hours respectively. (In <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>, rescue medication data from two centres were reported as separate sets of data - shown as 'Study A' and 'Study B' in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.)</P>
<TABLE COLS="6" ROWS="6">
<TR>
<TD COLSPAN="5">
<P>
<B>Summary of results D: weighted mean of median time to use of rescue medication</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Dose (mg)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Studies</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Oxycodone/</B>
</P>
<P>
<B>paracetamol (h)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Placebo (h)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>5/325</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>388</P>
</TD>
<TD ALIGN="CENTER">
<P>4.3</P>
</TD>
<TD ALIGN="CENTER">
<P>2.0</P>
</TD>
</TR>
<TR>
<TD>
<P>10/650</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>727</P>
</TD>
<TD ALIGN="CENTER">
<P>9.8</P>
</TD>
<TD ALIGN="CENTER">
<P>1.5</P>
</TD>
</TR>
<TR>
<TD>
<P>10/1000</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>206</P>
</TD>
<TD ALIGN="CENTER">
<P>8.7</P>
</TD>
<TD ALIGN="CENTER">
<P>1.1</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Adverse events</HEADING>
<P>(Table 2; Summary of results E)</P>
<P>Twelve studies reported the number of participants with one or more adverse event for each treatment arm in single dose studies (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>). The time over which the information was collected was not always explicitly stated and varied between trials. There were no specific single dose adverse event data in the multiple dose studies, and it was not clear whether reported adverse events occurred during the single or multiple dose phases. Few studies reported whether adverse event data continued to be collected after rescue medication had been taken. In some cases, the rescue medication was a further dose of the active drug, or was not specified. Adverse events, where described, were mild to moderate in severity, and predominantly nausea, vomiting, dizziness and somnolence. There was no report of a serious adverse event in a single dose study or during the single dose phase of a multiple dose study.</P>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 5 mg plus paracetamol versus placebo</HEADING>
<P>In three studies using oxycodone 5 mg plus paracetamol 325 mg (<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>), there were data from 388 participants (Analysis 4.3).</P>
<UL>
<LI>The proportion of participants having an adverse event after active treatment was 48% (107/221; range 28% to 65%).</LI>
<LI>The proportion of participants having an adverse event after placebo was 26% (44/167; range 11% to 48%).</LI>
<LI>The RR of treatment compared with placebo was 1.6 (1.2 to 2.1), giving an NNH of 4.5 (3.2 to 7.9).</LI>
</UL>
<P>In one study using oxycodone 5 mg plus paracetamol 500 mg (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>) and in one study using oxycodone 5 mg plus paracetamol 1000 mg<I> (</I>
<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>) there were insufficient data for analysis of this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oxycodone 10 mg plus paracetamol versus placebo</HEADING>
<P>In one study using oxycodone 10 mg plus paracetamol 325 mg (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>) there were insufficient data for analysis.</P>
<P>In six studies using oxycodone 10 mg plus paracetamol 650 mg (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>), there were data from 552 participants (Analysis 5.4; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<UL>
<LI>The proportion of participants having an adverse event after active treatment was 58% (199/343; range 12% to 81%).</LI>
<LI>The proportion of participants having an adverse event after placebo was 29% (61/209; range 10% to 70%).</LI>
<LI>The RR of treatment compared with placebo was 1.8 (1.4 to 2.3), giving an NNH of 3.5 (2.7 to 4.8).</LI>
</UL>
<P>In two studies using oxycodone 10 mg plus paracetamol 1000 mg (<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>) there were data from 288 participants (Analysis 6.3).</P>
<UL>
<LI>The proportion of participants having an adverse event after active treatment was 68% (100/147; range 64% to 70%).</LI>
<LI>The proportion of participants having an adverse event after placebo was 43% (61/141; range 16% to 53%).</LI>
<LI>The RR of treatment compared with placebo was 1.6 (1.3 to 2.0), giving an NNH of 4.0 (2.8 to 7.3).</LI>
</UL>
<P>No clear dose response for this outcome was seen in these studies.</P>
<TABLE COLS="6" ROWS="5">
<TR>
<TD COLSPAN="6">
<P>
<B>Summary of results E: participants with at least one adverse event</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Dose (mg) </B>
</P>
<P>
<B>(Oxycodone/paracetamol)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Studies</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Oxycodone/</B>
</P>
<P>
<B>paracetamol (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Placebo (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>NNH (95%CI)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>5/325</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>388</P>
</TD>
<TD ALIGN="CENTER">
<P>48</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>4.5 (3.2 to 7.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>10/650</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>552</P>
</TD>
<TD ALIGN="CENTER">
<P>58</P>
</TD>
<TD ALIGN="CENTER">
<P>29</P>
</TD>
<TD ALIGN="CENTER">
<P>3.5 (2.7 to 4.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>10/1000</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>288</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P>4.0 (2.8 to 7.3)</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Withdrawals</HEADING>
<P>(Table 2)</P>
<P>Exclusions may not be of any particular consequence in single dose acute pain studies, where most exclusions result from participants not having moderate or severe pain (<LINK REF="REF-McQuay-1982" TYPE="REFERENCE">McQuay 1982</LINK>).</P>
<P>Participants who took rescue medication were classified as withdrawals due to lack of efficacy, and details are reported under 'Use of rescue medication' above. Withdrawals for other reasons (e.g., adverse events, protocol violations) and exclusions were not reported consistently.</P>
<P>Apart from lack of efficacy, in most studies, most reported withdrawals were due to adverse events. No withdrawal data were given in one study (<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>) and in one multi-dose study (<LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>) there were no data specifically from the single dose phase. No withdrawals or exclusions were reported in seven studies (<LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>; <LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>; <LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>; <LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>; <LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>; <LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>; <LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>).</P>
<P>In active treatment arms, in one study (<LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>) there was one withdrawal for nausea, and in one study (<LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>) there was one exclusion for syncope, headache and vomiting (but the time of withdrawal was not stated). There was only one withdrawal because of an adverse event in a placebo arm (one participant with severe headache in <LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>).</P>
<P>Withdrawals for other reasons, such as loss to follow up, were generally rare. A number of studies (e.g., <LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>; <LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>; <LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>; <LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>) reported exclusions from efficacy analyses due to protocol violations and invalid data, including insufficient baseline pain, not taking the medication, vomiting within 1 hour, and use of rescue medication within 1 hour.</P>
<P>See also <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-13 11:58:33 +0100" MODIFIED_BY="Jessica R Thomas">
<P>This updated review includes 14 additional studies, but excluded one study (<LINK REF="STD-Young-1979" TYPE="STUDY">Young 1979</LINK>) that had been included in the previous version. Results are now available from 2641 participants in 20 studies, compared with 769 in the seven studies in the previous review. All the studies were of adequate methodological quality to minimize bias. The additional data available in this updated review results in substantial changes to measures of efficacy and harm compared with the previous review, where most comparisons were based on small numbers of participants.</P>
<P>Most of the data were for the combination of oxycodone 10 mg with paracetamol 650 mg, where there were more than 1000 participants in comparisons with placebo. Results for other dose combinations and for oxycodone alone are based on many fewer participants and should be interpreted with caution.</P>
<P>As before, no benefit could be shown of oxycodone 5 mg alone over placebo, but oxycodone 15 mg was again shown to be superior to placebo with NNT for at least 50% pain relief over 4 to 6 hours compared to placebo of 4.6 (2.9 to 11) based on two trials, a higher (worse) NNT than in the previous review where it was calculated as 2.4 (1.5 to 4.9) based on a single trial. This underlines the fact that small data sets do not accurately measure effect size (<LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>). About half of the participants treated with oxycodone 15 mg achieved at least 50% pain relief, compared with about a third treated with placebo. There were insufficient data for analysis of oxycodone 10 mg.</P>
<P>In comparison with placebo, at doses of oxycodone 5 mg plus paracetamol 325 mg, oxycodone 10 mg plus paracetamol 650 mg, and oxycodone 10 mg plus paracetamol 1000 mg, the NNTs were 5.4 (3.9 to 8.8), 2.7 (2.4 to 3.1), and 1.8 (1.6 to 2.2) respectively. For the combination of oxycodone 10 mg plus paracetamol 650 mg there were sufficient numbers (over 1000 participants) to be confident of the result. Again, this comparison differs from the findings in the previous version of the review, with much smaller numbers, in which NNTs were about 2.5 in each case.</P>
<P>There now appears to be a dose response. As increased efficacy is associated with higher dosages of both oxycodone and paracetamol, it is not clear how much the increase in efficacy is due to either drug individually, or is due to their use in combination (<LINK REF="REF-Edwards-2002" TYPE="REFERENCE">Edwards 2002</LINK>). There were insufficient data for direct comparison of efficacy of oxycodone plus paracetamol with the same dose of oxycodone alone (as there were few studies using oxycodone alone, and fewer studies which included active treatment arms of both oxycodone alone and oxycodone plus paracetamol at the same dose of oxycodone). However, there was sufficient information for indirect comparison of oxycodone 5 mg and oxycodone 5 mg plus paracetamol 325 mg; oxycodone 5 mg was no more effective than placebo, but the NNT for at least 50% pain relief for oxycodone 5 mg plus paracetamol 325 mg was 5.4.</P>
<P>Indirect comparisons of NNTs for at least 50% pain relief over 4 to 6 hours in reviews of other analgesics using identical methods indicate that oxycodone 15 mg, and oxycodone 5 mg plus paracetamol 325 mg, have similar efficacy to aspirin 600 or 650 mg at 4.4 (4.0 to 4.9) (<LINK REF="REF-Oldman-1999" TYPE="REFERENCE">Oldman 1999</LINK>) or paracetamol 600 or 650 mg at 4.6 (3.9 to 5.5.) (<LINK REF="REF-Toms-2008" TYPE="REFERENCE">Toms 2008</LINK>). Oxycodone 10 mg plus paracetamol 650 mg has equivalent efficacy to naproxen 500 mg (2.7 (2.3 to 3.3) (<LINK REF="REF-Derry-C-2009a" TYPE="REFERENCE">Derry C 2009a</LINK>), ibuprofen 400 mg (2.5 (2.4 to 2.6)), (<LINK REF="REF-Derry-C-2009b" TYPE="REFERENCE">Derry C 2009b</LINK>), lumiracoxib 400 mg (2.7 (2.2 to 3.5), <LINK REF="REF-Roy-2007" TYPE="REFERENCE">Roy 2007</LINK>) and celecoxib 400 mg (2.5 (2.2 to 2.9) (<LINK REF="REF-Derry-2008" TYPE="REFERENCE">Derry 2008</LINK>), and is better than paracetamol 1000 mg (3.6 (3.2 to 4.1), <LINK REF="REF-Toms-2008" TYPE="REFERENCE">Toms 2008</LINK>). Based on very limited data, oxycodone 10 mg plus paracetamol 1000 mg had equivalent efficacy to rofecoxib 50 mg (2.2 (2.0 to 2.5) (<LINK REF="REF-Barden-2005" TYPE="REFERENCE">Barden 2005</LINK>) and etoricoxib 120 mg (1.9 (1.6 to 2.1), (<LINK REF="REF-Clarke-2009" TYPE="REFERENCE">Clarke 2009</LINK>). A current listing of reviews of analgesics in the single dose postoperative pain model can be found at <A HREF="http://www.medicine.ox.ac.uk/bandolier">www.medicine.ox.ac.uk/bandolier</A>.</P>
<P>Indirect comparison of oxycodone plus paracetamol with codeine plus paracetamol (<LINK REF="REF-Toms-2009" TYPE="REFERENCE">Toms 2009</LINK>) suggests that paracetamol 650 mg combined with oxycodone 10 mg (NNT 2.7 (2.4 to 3.1)) provides better pain relief than when combined with codeine 60 mg (NNT 3.9 (3.3 to 4.7)) (z = 3.27; P &lt; 0.001). This result is not surprising, since oxycodone 10 mg is 2 to 3 times stronger than codeine 60 mg, based on equivalent doses of morphine (<LINK REF="REF-Twycross-2006" TYPE="REFERENCE">Twycross 2006</LINK>). Paracetamol 1000 mg plus oxycodone 10 mg (NNT 1.8 (1.6 to 2.2)) is very similar to paracetamol 1000 mg plus codeine 60 mg (NNT 2.2 (1.8 to 2.9)). However, there are many fewer participants providing data on the efficacy of oxycodone 10 mg with paracetamol 1000 mg or codeine 60 mg with paracetamol 800 to 1000 mg than is available for the corresponding doses of oxycodone or codeine when combined with paracetamol 600 to 650 mg (Summary of Discussion A).</P>
<TABLE COLS="6" ROWS="6">
<TR>
<TD COLSPAN="6">
<P>
<B>Summary of discussion A: comparison of oxycodone plus paracetamol with codeine plus paracetamol</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Studies</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Active (%)</P>
</TH>
<TH>
<P>Placebo (%)</P>
</TH>
<TH>
<P>NNT (95% CI)</P>
</TH>
</TR>
<TR>
<TD>
<P>Oxycodone/paracetamol 10/650 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>1043</P>
</TD>
<TD ALIGN="CENTER">
<P>51</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>2.7 (2.4 to 3.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Codeine/paracetamol 60/600-650 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
</TD>
<TD ALIGN="CENTER">
<P>1413</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
</TD>
<TD ALIGN="CENTER">
<P>3.9 (3.3 to 4.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>Oxycodone/paracetamol 10/1000 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>289</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
</TD>
<TD ALIGN="CENTER">
<P>1.8 (1.6 to 2.2)</P>
</TD>
</TR>
<TR>
<TD>
<P>Codeine/paracetamol 60/800-1000 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>192</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>2.2 (1.8 to 2.9)</P>
</TD>
</TR>
</TABLE>
<P>No sensitivity analyses could be carried out for trial quality (all studies adequate) or size (insufficient studies of small size). It was possible to compare the primary outcome in dental versus other surgery for oxycodone 10 mg plus paracetamol 650 mg, but no significant difference was found.</P>
<P>A controlled release formulation of oxycodone was used in two studies of oxycodone alone; in one study (<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>) in dental pain oxycodone was used at one dose only (oxycodone CR 20 mg), and in one study (<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>) in abdominal/gynaecological surgery pain oxycodone was used at three doses (oxycodone CR 10 mg, oxycodone CR 20 mg, oxycodone CR 30 mg). There are insufficient data to comment on the relative efficacy or harm of oxycodone CR in comparison with oxycodone.</P>
<P>It has been suggested that data on use of rescue medication, whether as a proportion of participants using it, or the median time to use of it, might be helpful both in assessing the usefulness of an analgesic, and possibly also in distinguishing between different doses (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>). There was limited information on which to base a conclusion, but there may be a dose response for the numbers of participants using rescue medication at 6 hours after treatment with oxycodone 5 mg plus paracetamol 325 mg or oxycodone 10 mg plus paracetamol 650 mg, with the NNTp values of 5.3 and 3.5 respectively.</P>
<P>The median time to use of rescue medication in the studies of oxycodone plus paracetamol did appear to be dose-dependent, (about 4 hours for oxycodone 5 mg plus paracetamol 325 mg, about 10 hours for oxycodone 10 mg plus paracetamol 650 mg compared with about 2 hours for placebo). This relatively long duration of action for the higher dose compares favourably with analgesics such as paracetamol (alone) where the median time is under 4 hours (<LINK REF="REF-Toms-2008" TYPE="REFERENCE">Toms 2008</LINK>). There was insufficient data for further analysis of the trials in this review. The full implications of the importance of remedication as an outcome awaits completion of other reviews, allowing examination of a substantial body of evidence.</P>
<P>Reporting of data for adverse events, withdrawals (other than lack of efficacy) or exclusions, and handling of missing data was not always complete. Adverse events were collected using various methods (questioning, patient diary) over different periods of time. This may have included periods after the use of rescue medication, which may cause its own adverse events. A dose of the active treatment was used as rescue medication in some studies. Poor reporting of adverse events in acute pain trials has been noted before (<LINK REF="REF-Edwards-1999" TYPE="REFERENCE">Edwards 1999</LINK>). The usefulness of single dose studies for assessing adverse events is questionable, but it is nonetheless reassuring that serious adverse events and adverse event withdrawals were rare. Significantly more participants experienced at least one adverse event with oxycodone plus paracetamol than placebo, with NNHs of 4.5, 3.5 and 4.0 for oxycodone 5 mg plus paracetamol 325 mg, oxycodone 10 mg plus paracetamol 650 mg, and oxycodone 10 mg plus paracetamol 1000 mg respectively. Where specific adverse events were reported, they were those which might be expected following a surgical procedure under anaesthetic, and/or treatment with an opioid drug or paracetamol. The earlier review considered individual adverse events, based on very limited data which was acknowledged as not being robust. We decided not to analyse individual adverse events because the limited amount of information and inconsistencies of reporting could give misleading results. Long-term, multiple dose studies should be used for meaningful analysis of adverse events since, even in acute pain settings, analgesics are likely to be used in multiple doses.</P>
<P>Lack of information about withdrawals or exclusions may have led to an overestimate of efficacy, but the effect is probably not significant because it is as likely to be related to poor reporting as poor methods. In single dose studies most exclusions occur for protocol violations such as failing to meet baseline pain requirements, or failing to return for post treatment visits after the acute pain results are concluded. Where patients are treated with a single dose of medication and observed, often "on site" for the duration of the trial, it might be considered unnecessary to report on "withdrawals" if there were none. For missing data it has been shown that over the 4 to 6 hour period, there is no difference between baseline observation carried forward, which gives the more conservative estimate, and last observation carried forward (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-05-13 12:00:02 +0100" MODIFIED_BY="Jessica R Thomas">
<IMPLICATIONS_PRACTICE MODIFIED="2009-05-13 12:00:02 +0100" MODIFIED_BY="Jessica R Thomas">
<P>The earlier review had insufficient data to guide clinical practice. In this updated review the most robust evidence is for oxycodone plus paracetamol, with a clear dose response for both the proportion of patients achieving at least 50% pain relief and time to remedication. Of several combinations of oxycodone and paracetamol, most data are available for oxycodone 10 mg plus paracetamol 650 mg, with over 1000 participants. For this combination, the NNT was below three (indicating good effect) and median time to remedication was about 10 hours. This is at least comparable to typically used doses of NSAIDs, with probably longer duration. Since oxycodone 10 mg is two to three times stronger than codeine 60 mg, it is not surprising that oxycodone 10 mg plus paracetamol 650 mg is more effective than codeine 60 mg plus paracetamol 650 mg, which has an NNT of about four and a shorter time median time to remedication.</P>
<P>For oxycodone alone, and for other combinations of oxycodone plus paracetamol, the limited data available makes not only results, but also comparison with other data on other analgesics used in similar clinical situations, much less robust. Limited information on adverse events suggests they are more frequent with oxycodone plus paracetamol than placebo, and while they were reported as mild to moderate in severity, they may become problematic with repeated dosing.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-12-03 09:30:39 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo-controlled trials in moderate to severe postoperative pain are required to better evaluate the effects of oxycodone, with or without paracetamol, and to better establish dose-response relationships. Because the efficacy of oxycodone plus paracetamol is now established, it may be more appropriate for resources to be put towards clinical effectiveness trials to establish which postoperative analgesic protocol leads to the best results for the most patients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-13 11:36:40 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Jayne Rees (nee Edwards) was an author, and Dr Robert Kaiko and Dr Earle Lockhart helped in identifying additional citations for the original review.</P>
<P>The previous review received financial support from:</P>
<UL>
<LI>Biotechnology and Biological Sciences Research Council, UK</LI>
<LI>SmithKline Beecham Consumer Healthcare.</LI>
<LI>European Union Biomed 2 (#BMH4-CT95-0172).</LI>
<LI>NHS R&amp;D Health Technology Evaluation Programmes, UK</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-05-13 12:01:54 +0100" MODIFIED_BY="Jessica R Thomas">
<P>RAM and HJM have undertaken research/consultants for various pharmaceutical companies. RAM and HJM have received lecture fees from pharmaceutical companies for presentations on analgesics research and other healthcare interventions. RAM, HJM, HG and SD have received research support from charities, government and industry sources at various times. Support for this review came from Oxford Pain Research, the NHS Cochrane Collaboration Programme Grant Scheme, and NIHR Biomedical Research Centre Programme.</P>
<P>JR received lecture fees from pharmaceutical companies for presentations on analgesics research and other healthcare interventions, and received research support from charities, government and industry sources at various times.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-12-03 09:30:52 +0000" MODIFIED_BY="[Empty name]">
<P>For the original review: JR was involved with searching, data extraction, analysis, quality scoring and writing. HJM was involved in writing. RAM was involved in data extraction, analysis and writing. </P>
<P>For the update: HG and SD were involved with searching, data extraction, quality scoring, analysis and writing. RAM was involved in analysis and writing. HJM acted as arbitrator and was involved in writing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-12-19 14:43:49 +0000" MODIFIED_BY="[Empty name]">
<P>The title now states that this review is limited to adults and oral administration only.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-08-18 10:07:35 +0100" MODIFIED_BY="Anna Erskine">
<P>A restricted search in August 2016 identified one relevant study (Daniels 2013). However, we did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.</P>
<P>Daniels SE, Spivey RJ, Singla S, Golf M, Clark FJ. Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. Curr Med Res Opin. 2011 Mar;27(3):593-603. doi: 10.1185/03007995.2010.548291. Epub 2011 Jan 13.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-10-11 16:34:06 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2009-05-13 14:00:13 +0100" MODIFIED_BY="Jessica R Thomas">
<INCLUDED_STUDIES MODIFIED="2009-05-13 12:11:12 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Aqua-2007" MODIFIED="2008-07-11 08:42:20 +0100" MODIFIED_BY="[Empty name]" NAME="Aqua 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-07-11 08:41:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R</AU>
<TI>Efficacy and tolerability of oxymorphone Immediate Release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1000-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735984"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735983"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2004a" MODIFIED="2009-01-14 14:50:53 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 2004a" YEAR="">
<REFERENCE MODIFIED="2009-01-14 14:50:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang DJ, Desjardins PJ, King TR, Erb T, Geba GP</AU>
<TI>The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>807-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735986"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735985"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2004b" MODIFIED="2008-10-23 09:12:48 +0100" MODIFIED_BY="[Empty name]" NAME="Chang 2004b" YEAR="2004a">
<REFERENCE MODIFIED="2008-10-23 09:12:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang DJ, Desjardins PJ, Bird SR, Black P, Chen E, Petruschke RA, et al </AU>
<TI>Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>6</NO>
<PG>939-49</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735988"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735987"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1980" NAME="Cooper 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper SA, Precheur H, Rauch D, Rosenheck A, Ladov M, Engel J</AU>
<TI>Evaluation of oxycodone and acetaminophen in treatment of postoperative dental pain</TI>
<SO>Oral Surgery Oral Medicine and Oral Pathology</SO>
<YR>1980</YR>
<VL>50</VL>
<NO>6</NO>
<PG>496-501</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735990"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735989"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniels-2002" MODIFIED="2009-01-15 17:03:09 +0000" MODIFIED_BY="Jessica R Thomas" NAME="Daniels 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-15 17:03:09 +0000" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM</AU>
<TI>The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery</TI>
<SO>Journal of the American Dental Association</SO>
<YR>2002</YR>
<VL>133</VL>
<PG>611-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735992"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735991"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desjardins-2007" MODIFIED="2008-07-11 11:03:54 +0100" MODIFIED_BY="[Empty name]" NAME="Desjardins 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-07-11 11:03:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desjardins PJ, Black PM, Daniels SE, Bird SR, Petruschke RA, Chang DJ, et al</AU>
<TI>A double-blind randomized controlled trial of rofecoxib and multidose oxycodone/acetaminophen in dental impaction pain</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>8</NO>
<PG>1624-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735994"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735993"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fricke-1997" MODIFIED="2008-07-11 10:12:39 +0100" MODIFIED_BY="[Empty name]" NAME="Fricke 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-11 10:12:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fricke JR, Reynolds D</AU>
<TI>Double-masked, single-dose comparison of bromfenac sodium, acetaminophen plus oxycodone, and placebo after oral surgery</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1997</YR>
<VL>58</VL>
<PG>773-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735996"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735995"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gammaitoni-2003" MODIFIED="2008-07-11 11:05:58 +0100" MODIFIED_BY="[Empty name]" NAME="Gammaitoni 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-07-11 11:05:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gammaitoni AR, Galer BS, Bulloch S, Lacouture P, Caruso F, Ma F, et al</AU>
<TI>Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2003</YR>
<VL>43</VL>
<PG>296-304</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2735998"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735997"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gimbel-2004" MODIFIED="2009-05-13 12:11:12 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Gimbel 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-13 12:11:12 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gimbel J, Ahdieh H</AU>
<TI>The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>5</NO>
<PG>1472-7</PG>
<IDENTIFIERS MODIFIED="2009-05-13 12:11:12 +0100" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736000"/><IDENTIFIER MODIFIED="2009-05-13 12:11:12 +0100" MODIFIED_BY="Jessica R Thomas" TYPE="DOI" VALUE="10.1213/01.ANE.0000132548.91622.B3 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2735999"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1997" NAME="Johnson 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson GH, Van Wagoner JD, Brown J, Cooper SA</AU>
<TI>Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain</TI>
<SO>Clinical Therapeutics</SO>
<YR>1997</YR>
<VL>19</VL>
<PG>507-19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736002"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736001"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korn-2004" MODIFIED="2008-07-11 11:11:16 +0100" MODIFIED_BY="[Empty name]" NAME="Korn 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-11 11:11:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korn S, Vassil TC, Kotey PN-A, Fricke JR</AU>
<TI>Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: a randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>5</NO>
<PG>769-78</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736004"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736003"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Litkowski-2005" MODIFIED="2008-07-11 10:36:09 +0100" MODIFIED_BY="[Empty name]" NAME="Litkowski 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-07-11 10:36:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Litkowski LJ, Christensen SE, Adamson DN, Van Dyke T, Han S-H, Newman KB</AU>
<TI>Analgesic efficacy and tolerability of oxycodone 5 mg/ ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/ acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>27</VL>
<PG>418-29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736006"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736005"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmstrom-2005" MODIFIED="2008-07-11 10:39:17 +0100" MODIFIED_BY="[Empty name]" NAME="Malmstrom 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-07-11 10:39:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmstrom K, Ang J, Fricke JR, Shingo S, Reicin A</AU>
<TI>The analgesic effect of etoricoxib relative to that of two opioid-acetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>141-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736008"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736007"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmstrom-2006" MODIFIED="2008-07-11 10:44:53 +0100" MODIFIED_BY="[Empty name]" NAME="Malmstrom 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-07-11 10:44:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmstrom K, Kotey P, McGratty M, Ramakrishnan R, Gottesdiener K, Reicin A, et al</AU>
<TI>Dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2006</YR>
<VL>46</VL>
<PG>917-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palangio-2000" MODIFIED="2008-07-11 10:49:24 +0100" MODIFIED_BY="[Empty name]" NAME="Palangio 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-07-11 10:49:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palangio M, Wideman GL, Keffer M, Landau CJ, Morris E, Doyle RT, et al</AU>
<TI>Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of postoperative obstetric or gynecologic pain</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<PG>600-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736012"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736011"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reines-1994" NAME="Reines 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reines HD, Adams D, Hawkes T, Reynolds JC, Brown J, Bynum L, et al</AU>
<TI>Evaluation of oral ketorolac, oxycodone plus acetaminophen, and placebo for pain relief after orthopedic surgery</TI>
<SO>Current Therapeutic Research</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>6</NO>
<PG>615-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736013"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singla-2005" MODIFIED="2008-07-11 10:55:25 +0100" MODIFIED_BY="[Empty name]" NAME="Singla 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-07-11 10:55:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singla N, Pong A, Newman K; MD-10 Study Group</AU>
<TI>Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>27</VL>
<PG>45-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736016"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736015"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1993" NAME="Sunshine 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Olson NZ, Zighelboim I, De Castro A</AU>
<TI>Ketoprofen, acetaminophen plus oxycodone, and acetaminophen in the relief of postoperative pain</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>5</NO>
<PG>546-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736018"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736017"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1996" MODIFIED="2008-08-13 15:14:42 +0100" MODIFIED_BY="[Empty name]" NAME="Sunshine 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-13 15:14:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Olson NZ, Colon A, Rivera J, Kaiko RF, Fitzmartin RD, et al</AU>
<TI>Analgesic efficacy of controlled-release oxycodone in postoperative pain</TI>
<SO> Journal of Clinical Pharmacology</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>7</NO>
<PG>595-603</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736019"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Dyke-2004" MODIFIED="2008-07-11 11:00:20 +0100" MODIFIED_BY="[Empty name]" NAME="Van Dyke 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-11 11:00:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Dyke T, Litkowski LJ, Kiersch TA, Zarringhalam NM, Zheng H, Newman K</AU>
<TI>Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: a double-blind, placebo- and active-controlled parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>2003-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736022"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736021"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-05-13 10:54:10 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-1923" MODIFIED="2008-10-02 11:11:13 +0100" MODIFIED_BY="[Empty name]" NAME="Beck 1923" YEAR="1923">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beck O</AU>
<TI>Uber experiences with Eukodal</TI>
<TO>Uber Erfahrungen mit Eukodal</TO>
<SO>Munch Med Wachr</SO>
<YR>1923</YR>
<VL>70</VL>
<PG>908</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736024"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736023"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belam-1957" MODIFIED="2008-10-02 11:11:18 +0100" MODIFIED_BY="[Empty name]" NAME="Belam 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belam OH</AU>
<TI>(No title cited)</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1957</YR>
<VL>29</VL>
<PG>190-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736026"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736025"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyd-1959" MODIFIED="2008-10-02 11:14:56 +0100" MODIFIED_BY="[Empty name]" NAME="Boyd 1959" YEAR="1959">
<REFERENCE MODIFIED="2008-10-02 11:14:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyd RH</AU>
<TI>A clinical trial of dihydrocodeine pectinate</TI>
<SO>Anaesthesia</SO>
<YR>1959</YR>
<VL>14</VL>
<PG>144-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736028"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736027"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brittain-1959" MODIFIED="2008-10-02 11:13:53 +0100" MODIFIED_BY="[Empty name]" NAME="Brittain 1959" YEAR="1959">
<REFERENCE MODIFIED="2008-10-02 11:13:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brittain GJC</AU>
<TI>Dihydrocodeinone pectinate</TI>
<SO>Lancet</SO>
<YR>1959</YR>
<VL>2</VL>
<NO>7102</NO>
<PG>544-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736030"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736029"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Beer-2005" MODIFIED="2009-01-12 10:19:02 +0000" MODIFIED_BY="[Empty name]" NAME="de Beer 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-12 10:19:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Beer JdeV, Winemaker MJ, Donnelly GA, Miceli PC, Reiz JL, Harsanyi Z, et al</AU>
<TI>Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement</TI>
<SO>Canadian Journal of Surgery</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>4</NO>
<PG>277-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736032"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736031"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dionne-1986" MODIFIED="2008-10-02 11:18:03 +0100" MODIFIED_BY="[Empty name]" NAME="Dionne 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dionne RA</AU>
<TI>Suppression of dental pain by the preoperative administration of flurbiprofen</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>3A</NO>
<PG>41-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736034"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736033"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMahon-1987" MODIFIED="2008-10-02 11:17:38 +0100" MODIFIED_BY="[Empty name]" NAME="McMahon 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMahon FG, Arndt WF Jr, Newton JJ, Montgomery PA, Perhach JL</AU>
<TI>Clinical experience with flupirtine in the U.S</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1987</YR>
<VL>63</VL>
<NO>Suppl 3</NO>
<PG>81-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736035"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1993" MODIFIED="2008-10-02 11:19:06 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore CH</AU>
<TI>Combination low-dose epidural morphine and parenteral ketorolac tromethamine for postcesarean pain relief</TI>
<SO>The Journal of the American Association of Nurse Anesthetists</SO>
<YR>1993</YR>
<VL>61</VL>
<NO>4</NO>
<PG>426-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736038"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736037"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrison-1971" MODIFIED="2008-10-02 11:22:17 +0100" MODIFIED_BY="[Empty name]" NAME="Morrison 1971" YEAR="1971">
<REFERENCE MODIFIED="2008-10-02 11:22:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrison D, Loan WB, Dundee JW</AU>
<TI>Controlled comparison of the efficacy of fourteen preparations in the relief of postoperative pain</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>3</VL>
<NO>5769</NO>
<PG>287-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736040"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owen-1997" MODIFIED="2008-12-22 12:41:51 +0000" MODIFIED_BY="[Empty name]" NAME="Owen 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-12-22 12:41:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen H</AU>
<TI>Pain control in the week following laparoscopic surgery: A comparison of sustained-release ibuprofen and paracetamol</TI>
<SO>Minimally Invasive Therapy and Allied Technology</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>235-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736042"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736041"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rittenberg-1985" MODIFIED="2009-01-12 10:20:02 +0000" MODIFIED_BY="[Empty name]" NAME="Rittenberg 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-01-12 10:20:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rittenberg MH, Koolpe H, Keeler L, McNamara T, Bagley DH</AU>
<TI>Pain control: comparison of percutaneous and operative nephrolithotomy</TI>
<SO>Urology</SO>
<YR>1985</YR>
<VL>25</VL>
<NO>5</NO>
<PG>468-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736043"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roehrich-1993" MODIFIED="2008-12-22 12:44:57 +0000" MODIFIED_BY="[Empty name]" NAME="Roehrich 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-12-22 12:44:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roehrich M</AU>
<TI>(No title cited)</TI>
<SO>Pharmacy and Therapeutics</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>989-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736046"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736045"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siegied-1918" MODIFIED="2009-05-13 10:54:10 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Siegied 1918" YEAR="1918">
<REFERENCE MODIFIED="2009-05-13 10:54:10 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siegied</AU>
<TI>The new narcotic Eukodal</TI>
<TO>Das neue narkoticum Eukodal</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1918</YR>
<VL>14</VL>
<PG>185</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736048"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736047"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1986" MODIFIED="2008-12-22 12:49:44 +0000" MODIFIED_BY="[Empty name]" NAME="Sunshine 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-12-22 12:49:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Laska EM, Olson NZ</AU>
<TI>Analgesic effects of oral oxycodone and codeine in the treatment of patients with postoperative, postfracture, or somatic pain</TI>
<SO>Advances in Pain Research and Therapy</SO>
<YR>1986</YR>
<VL>8</VL>
<PG>225-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736050"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736049"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takki-1973" MODIFIED="2008-10-02 11:30:24 +0100" MODIFIED_BY="[Empty name]" NAME="Takki 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takki S, Tammisto T</AU>
<TI>A comparison of pethidine, piritramide and oxycodone in patients with pain following cholecystectomy</TI>
<SO>Anaesthesist</SO>
<YR>1973</YR>
<VL>22</VL>
<NO>4</NO>
<PG>162-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736052"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736051"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tigerstedt-1981a" MODIFIED="2008-12-22 12:50:45 +0000" MODIFIED_BY="[Empty name]" NAME="Tigerstedt 1981a" YEAR="1981">
<REFERENCE MODIFIED="2008-12-22 12:50:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tigerstedt I, Leander P, Tammisto T</AU>
<TI>Postoperative analgesics for superficial surgery. Comparison of four analgesics</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1981</YR>
<VL>25</VL>
<NO>6</NO>
<PG>543-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736054"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736053"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tigerstedt-1981b" MODIFIED="2008-10-02 11:31:25 +0100" MODIFIED_BY="[Empty name]" NAME="Tigerstedt 1981b" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tigerstedt I, Tammisto T, Leander P</AU>
<TI>Buprenorphine vs. oxycodone as a routine postoperative analgesic</TI>
<SO>Nordic Symposium on Temgesic. A new perspective of pain - Buprenorphone. Proceedings of the Nordic Symposium on Temgesic</SO>
<YR>1981</YR>
<CY>Copenhagen</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736056"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736055"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1979" MODIFIED="2008-09-26 14:48:12 +0100" MODIFIED_BY="[Empty name]" NAME="Young 1979" YEAR="1979">
<REFERENCE MODIFIED="2008-09-26 14:46:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young RE</AU>
<TI>A comparison of analgesic effectiveness of oral butorphanol/acetaminophen, oxycodone/acetaminophen and placebo in hospitalized postsurgical patients</TI>
<SO>Journal of Medicine</SO>
<YR>1979</YR>
<VL>10</VL>
<NO>6</NO>
<PG>417-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736058"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736057"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-05-13 14:00:13 +0100" MODIFIED_BY="Jessica R Thomas">
<STUDY DATA_SOURCE="PUB" ID="STD-Daniels-2009" MODIFIED="2009-05-13 14:00:05 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Daniels 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-05-13 14:00:05 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J</AU>
<TI>A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2009</YR>
<VL>Feb 10</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736060"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736059"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmann-2008" MODIFIED="2009-05-13 14:00:13 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Stegmann 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-05-13 14:00:13 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmann JU, Weber H, Steup A, Okamoto A, Upmalis D, Daniels S</AU>
<TI>The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2008</YR>
<VL>Oct 10</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736062"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736061"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-05-13 12:12:27 +0100" MODIFIED_BY="Jessica R Thomas">
<ADDITIONAL_REFERENCES MODIFIED="2009-05-13 12:12:27 +0100" MODIFIED_BY="Jessica R Thomas">
<REFERENCE ID="REF-Barden-2005" MODIFIED="2008-12-04 13:42:38 +0000" MODIFIED_BY="[Empty name]" NAME="Barden 2005" TYPE="COCHRANE_REVIEW">
<AU>Barden J, Rees J, Moore RA, McQuay HJ</AU>
<TI>Single dose oral rofecoxib for postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-12-04 13:42:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-04 13:42:38 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004604.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2009" MODIFIED="2009-04-28 16:07:55 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2009" TYPE="COCHRANE_REVIEW">
<AU>Clarke R, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral etoricoxib for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-04-28 12:58:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-04-28 12:58:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004309.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-1997" NAME="Collins 1997" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Moore RA, McQuay HJ</AU>
<TI>The visual analogue pain intensity scale: what is moderate pain in millimetres?</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>72</VL>
<PG>95-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2001" MODIFIED="2008-12-01 12:22:51 +0000" MODIFIED_BY="[Empty name]" NAME="Collins 2001" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Edwards J, Moore RA, Smith LA, McQuay HJ</AU>
<TI>Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>1-2</NO>
<PG>189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" MODIFIED="2008-12-22 12:51:29 +0000" MODIFIED_BY="[Empty name]" NAME="Cook 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cook D, Sackett DL</AU>
<TI>On the clinically important difference</TI>
<SO>ACP Journal Club (Annals of Internal Medicine)</SO>
<YR>1992</YR>
<VL>117</VL>
<PG>A16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1991" NAME="Cooper 1991" TYPE="BOOK_SECTION">
<AU>Cooper SA</AU>
<TI>Single-dose analgesic studies: the upside and downside of assay sensitivity</TI>
<SO>The design of analgesic clinical trials (Advances in Pain Research and Therapy)</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>117-24</PG>
<ED>Max MB, Portenoy RK, Laska EM</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Derry-2008" MODIFIED="2008-12-01 11:56:41 +0000" MODIFIED_BY="[Empty name]" NAME="Derry 2008" TYPE="COCHRANE_REVIEW">
<AU>Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral celecoxib for acute postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-12-01 11:56:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-01 11:56:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004233"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-C-2009a" MODIFIED="2009-05-13 12:11:19 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Derry C 2009a" TYPE="COCHRANE_REVIEW">
<AU>Derry C, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-05-13 12:11:19 +0100" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER MODIFIED="2009-05-13 12:11:19 +0100" MODIFIED_BY="Jessica R Thomas" TYPE="DOI" VALUE="10.1002/14651858.CD004234.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-C-2009b" MODIFIED="2009-04-28 13:01:07 +0100" MODIFIED_BY="[Empty name]" NAME="Derry C 2009b" TYPE="COCHRANE_REVIEW">
<AU>Derry C, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral ibuprofen for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-01-14 14:33:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="DOI" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-P-2009" MODIFIED="2009-04-28 13:00:39 +0100" MODIFIED_BY="[Empty name]" NAME="Derry P 2009" TYPE="COCHRANE_REVIEW">
<AU>Derry P, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral diclofenac for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-04-28 13:00:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-04-28 13:00:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004768.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Edwards-1999" MODIFIED="2009-01-12 11:10:20 +0000" MODIFIED_BY="[Empty name]" NAME="Edwards 1999" TYPE="JOURNAL_ARTICLE">
<AU>Edwards JE, McQuay HJ, Moore RA, Collins SL</AU>
<TI>Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>6</NO>
<PG>427-37</PG>
<IDENTIFIERS MODIFIED="2008-11-18 15:28:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-11-18 15:28:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0885-3924(99)00093-7"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2002" MODIFIED="2009-05-13 12:11:31 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Edwards 2002" TYPE="JOURNAL_ARTICLE">
<AU>Edwards JE, McQuay HJ, Moore RA</AU>
<TI>Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>2</NO>
<PG>121-30</PG>
<IDENTIFIERS MODIFIED="2009-05-13 12:11:31 +0100" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER MODIFIED="2009-05-13 12:11:31 +0100" MODIFIED_BY="Jessica R Thomas" TYPE="DOI" VALUE="10.1016/S0885-3924(01)00404-3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996a" NAME="Jadad 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Carroll D, Moore A, McQuay H</AU>
<TI>Developing a database of published reports of randomised clinical trials in pain research</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996b" NAME="Jadad 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x0027_Abb_x00e8_-1987" MODIFIED="2009-05-13 11:26:01 +0100" MODIFIED_BY="Jessica R Thomas" NAME="L'Abbè 1987" TYPE="JOURNAL_ARTICLE">
<AU>L'Abbé KA, Detsky AS, O'Rourke K</AU>
<TI>Meta-analysis in clinical research</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>107</VL>
<PG>224-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1982" MODIFIED="2009-01-12 10:50:53 +0000" MODIFIED_BY="[Empty name]" NAME="McQuay 1982" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ, Bullingham RE, Moore RA, Evans PJ, Lloyd JW</AU>
<TI>Some patients don't need analgesics after surgery</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1982</YR>
<VL>75</VL>
<NO>9</NO>
<PG>705-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-2005" MODIFIED="2009-01-12 10:54:07 +0000" MODIFIED_BY="[Empty name]" NAME="McQuay 2005" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ, Moore RA</AU>
<TI>Placebo</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2005</YR>
<VL>81</VL>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" MODIFIED="2008-12-01 12:19:47 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS MODIFIED="2008-12-01 12:19:47 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-01 12:19:47 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0140-6736(99)04149-5    "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1996" NAME="Moore 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<NO>2-3</NO>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997a" NAME="Moore 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Verification from independent data</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>1-2</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997b" NAME="Moore 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, Moore O, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Use of pain intensity and visual analogue scales</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>3</NO>
<PG>311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1998" MODIFIED="2009-05-13 12:11:54 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Moore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ</AU>
<TI>Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>3</NO>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2003" MODIFIED="2008-12-22 12:28:33 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2003" TYPE="BOOK">
<AU>Moore RA, Edwards JE, Barden J, McQuay HJ</AU>
<SO>Bandolier's Little Book of Pain</SO>
<YR>2003</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2005" MODIFIED="2008-11-18 15:17:09 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2005" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Edwards JE, McQuay HJ</AU>
<TI>Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results</TI>
<SO>Pain</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>3</NO>
<PG>322-31</PG>
<IDENTIFIERS MODIFIED="2008-11-18 15:17:09 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-11-18 15:17:09 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.pain.2005.05.001"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morris-1995" NAME="Morris 1995" TYPE="BOOK_SECTION">
<AU>Morris JA, Gardner MJ</AU>
<TI>Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates</TI>
<SO>Statistics with confidence - confidence intervals and statistical guidelines</SO>
<YR>1995</YR>
<PG>50-63</PG>
<ED>Gardner MJ, Altman DG</ED>
<PB>British Medical Journal</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oldman-1999" MODIFIED="2008-12-01 12:03:19 +0000" MODIFIED_BY="[Empty name]" NAME="Oldman 1999" TYPE="COCHRANE_REVIEW">
<AU>Oldman A, Smith LA, Collins S, Carroll D, Wiffen PJ, McQuay HJ, et al</AU>
<TI>Single dose oral aspirin for acute pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-12-01 12:03:19 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-01 12:03:19 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002067"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poyhia-1993" NAME="Poyhia 1993" TYPE="JOURNAL_ARTICLE">
<AU>Poyhia R, Vainio A, Kalso E</AU>
<TI>A review of oxycodone's clinical pharmacokinetics and pharmacodynamics</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>2</NO>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1993" NAME="Reynolds 1993" TYPE="BOOK">
<AU>Reynolds JEF</AU>
<SO>Martindale: the extra pharmacopoeia</SO>
<YR>1993</YR>
<EN>30th</EN>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roy-2007" MODIFIED="2008-12-22 12:54:02 +0000" MODIFIED_BY="[Empty name]" NAME="Roy 2007" TYPE="COCHRANE_REVIEW">
<AU>Roy YM, Derry S, Moore RA</AU>
<TI>Single dose oral lumiracoxib for postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-12-22 12:54:02 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-22 12:54:00 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006865"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Toms-2008" MODIFIED="2008-12-01 11:57:41 +0000" MODIFIED_BY="[Empty name]" NAME="Toms 2008" TYPE="COCHRANE_REVIEW">
<AU>Toms L, McQuay HJ, Derry S, Moore RA</AU>
<TI>Single dose oral paracetamol (acetaminophen) for postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-12-01 11:57:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-01 11:57:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004602.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Toms-2009" MODIFIED="2009-05-13 12:12:27 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Toms 2009" TYPE="COCHRANE_REVIEW">
<AU>Toms L, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-05-13 12:12:27 +0100" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER MODIFIED="2009-05-13 12:12:27 +0100" MODIFIED_BY="Jessica R Thomas" TYPE="DOI" VALUE="10.1002/14651858.CD001547.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tram_x00e8_r-1997" MODIFIED="2009-05-13 11:25:52 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Tramèr 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ</AU>
<TI>Impact of covert duplicate results on meta-analysis: a case study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>635-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Twycross-2006" MODIFIED="2009-05-13 10:45:51 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Twycross 2006" TYPE="BOOK_SECTION">
<AU>Twycross R, Wilcock A</AU>
<TI>Analgesics, Chapter 5</TI>
<SO>Hospice and Palliative Care Formulary</SO>
<YR>2006</YR>
<PG>226</PG>
<PB>Palliativedrugs.com Ltd</PB>
<CY>Nottingham</CY>
<IDENTIFIERS MODIFIED="2008-12-22 12:31:21 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-22 12:31:21 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="ISBN" TYPE="OTHER" VALUE="0-9552547-0-1"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-01-12 11:28:34 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Edwards-2000" MODIFIED="2009-01-12 11:28:34 +0000" MODIFIED_BY="[Empty name]" NAME="Edwards 2000" TYPE="COCHRANE_REVIEW">
<AU>Edwards JE, Moore RA, McQuay HJ</AU>
<TI>Single dose oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-12-01 11:52:19 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-12-01 11:52:19 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002763"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-13 12:39:45 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-13 12:03:59 +0100" MODIFIED_BY="Jessica R Thomas" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-01-12 09:50:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aqua-2007">
<CHAR_METHODS MODIFIED="2008-08-08 11:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60 mins, then hourly up to 6 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-08 11:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Abdominal surgery</P>
<P>Mean age 43 years</P>
<P>N = 331</P>
<P>M = 4, F = 327</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 09:50:06 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 15 mg, n = 83</P>
<P>Oxymorphone 10 mg, n = 82</P>
<P>Oxymorphone 20 mg, n = 81</P>
<P>Placebo, n = 85</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-10 12:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale and 100 mm VAS</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants reporting any and serious adverse events</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 11:52:27 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1 </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-12 09:50:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2004a">
<CHAR_METHODS MODIFIED="2008-10-23 09:13:49 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 90, 120 mins, then hourly up to 12 hours, then at 14, 16, 20, and 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-08 11:49:27 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 22 years</P>
<P>N = 225</P>
<P>M = 90, F = 135</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 09:50:33 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 100</P>
<P>Etoricoxib 120 mg, n = 100</P>
<P>Placebo, n = 25</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale and 100 mm VAS</P>
<P>PR: std 5 point scale and 100 mm VAS</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 11:53:01 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-02 11:09:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2004b">
<CHAR_METHODS MODIFIED="2008-08-08 12:08:53 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 30, 60, 90, 120 mins, then hourly up to 12 hours, then at 14, 16, 20, and 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-08 12:06:09 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 22 years</P>
<P>N = 271</P>
<P>M = 122, F = 149</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-19 11:35:19 +0100" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 120</P>
<P>Rofecoxib 50 mg, n = 121</P>
<P>Placebo, n = 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-02 11:09:20 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 11:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 09:48:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cooper-1980">
<CHAR_METHODS MODIFIED="2008-08-08 12:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose, 6 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, then hourly up to 4 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-08 12:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 23 years</P>
<P>N = 247</P>
<P>M = 93, F = 154</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 09:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 5 mg, n = 42</P>
<P>Oxycodone 5 mg + paracetamol 500 mg, n = 45</P>
<P>Oxycodone 5 mg + paracetamol 1000 mg, n = 40</P>
<P>Oxycodone 10 mg + paracetamol 1000 mg, n = 45</P>
<P>Paracetamol 500 mg, n = 37</P>
<P>Placebo, n = 38</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-14 09:40:31 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 12:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-12 11:53:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniels-2002">
<CHAR_METHODS MODIFIED="2009-01-12 09:51:28 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 120 mins, then hourly up to 8 hours then at 10, 12, 16 and 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:12 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Study A:</P>
<P>Mean age 23 years</P>
<P>N = 205</P>
<P>M = 86, F = 119<BR/>
<BR/>Study B:</P>
<P>Mean age 23 years</P>
<P>N = 201</P>
<P>M = 80, F = 121</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 11:53:47 +0000" MODIFIED_BY="[Empty name]">
<P>Study A:<BR/>Oxycodone 10 mg + paracetamol 10 mg, n = 51</P>
<P>Valdecoxib 20 mg, n = 52</P>
<P>Valdecoxib 40 mg, n = 50</P>
<P>Placebo, n = 52</P>
<P>
<BR/>Study B:<BR/>Oxycodone 10 mg + paracetamol 10 mg, n = 51</P>
<P>Valdecoxib 20 mg, n = 49</P>
<P>Valdecoxib 40 mg, n = 50</P>
<P>Placebo, n = 51</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-14 09:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: non-std 4 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 12:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 14:35:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Desjardins-2007">
<CHAR_METHODS MODIFIED="2008-10-16 14:33:58 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, and at prespecified time intervals to 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:15 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 22 years</P>
<P>N = 270</P>
<P>M = 96, F = 174</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-19 11:35:25 +0100" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 122</P>
<P>Rofecoxib 50 mg, n = 118</P>
<P>Placebo, n = 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with serious adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 13:36:11 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-12 11:52:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fricke-1997">
<CHAR_METHODS MODIFIED="2008-10-16 14:06:40 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 30, 60, 90, 120 mins, then hourly up to 8 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:18 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 24 years</P>
<P>N = 128</P>
<P>M = 47, F = 81<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 11:52:33 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 32</P>
<P>Bromfenac 25 mg, n = 30</P>
<P>Bromfenac 50 mg, n = 33<BR/>
</P>
<P>Placebo, n = 33</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale and 100 mm VAS</P>
<P>PR: std 5 point scale and 100 mm VAS</P>
<P>PGE: std 5 point scale</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 13:47:48 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W0</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-12 11:54:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gammaitoni-2003">
<CHAR_METHODS MODIFIED="2008-08-08 13:57:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60 mins, then hourly up to 8 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:23 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 19 years</P>
<P>N = 150</P>
<P>M = 61, F = 89<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 11:54:23 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 325 mg, n = 59</P>
<P>Oxycodone CR 20 mg, n = 61<BR/>
</P>
<P>Placebo, n = 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-18 10:23:31 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale and 100 mm VAS</P>
<P>PR: std 5 point scale and 100 mm VAS</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 13:58:31 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 14:35:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gimbel-2004">
<CHAR_METHODS MODIFIED="2008-10-16 14:34:06 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 5 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 90, 120 mins, then hourly up to 8 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>Total hip or knee replacement surgery</P>
<P>Mean age 64 years</P>
<P>N = 300</P>
<P>M = 119, F = 181<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-08 14:03:00 +0100" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg, n = 60</P>
<P>Oxymorphone 10 mg, n = 59</P>
<P>Oxymorphone 20 mg, n = 59</P>
<P>Oxymorphone 30 mg, n = 65</P>
<P>Placebo, n = 57</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:13:41 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale and 100 mm VAS</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 14:03:55 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-13 12:03:30 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Johnson-1997">
<CHAR_METHODS MODIFIED="2008-10-16 14:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 5 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 60 mins then hourly to 8 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:30 +0100" MODIFIED_BY="[Empty name]">
<P>Gynaecological surgery</P>
<P>Mean age 41 years</P>
<P>N = 238</P>
<P>All F<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:03:30 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 47</P>
<P>Bromfenac 50 mg, n = 47</P>
<P>Bromfenac 100 mg, n = 48</P>
<P>Ibuprofen 400 mg, n = 48<BR/>
</P>
<P>Placebo, n = 48</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-10 14:57:47 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 14:22:32 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-15 17:00:36 +0000" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Korn-2004">
<CHAR_METHODS MODIFIED="2009-01-15 17:00:36 +0000" MODIFIED_BY="Jessica R Thomas">
<P>RCT, DB, single dose, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 30, 60 mins, then hourly to 6 hours, then at 8, 12, 24 hours.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-08 14:17:03 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 21 years</P>
<P>N = 212</P>
<P>M = 78, F = 134<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 11:55:00 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 5 mg + paracetamol 325 mg , n = 91</P>
<P>Rofecoxib 50 mg, n = 90<BR/>
</P>
<P>Placebo, n = 31</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-14 09:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 14:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-13 12:03:39 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Litkowski-2005">
<CHAR_METHODS MODIFIED="2008-08-08 14:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 90, 120 mins, then hourly up to 6 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:33 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 19 years</P>
<P>N = 248</P>
<P>M = 108, F = 140</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:03:39 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Oxycodone 5 mg + paracetamol 325 mg, n = 61</P>
<P>Hydrocodone 7.5 mg + paracetamol 500 mg, n = 63</P>
<P>Oxycodone 5 mg + ibuprofen 400 mg , n = 62<BR/>
</P>
<P>Placebo, n = 63</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:19:08 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale and 100 mm VAS</P>
<P>PR: std 5 point scale and 100 mm VAS</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 14:35:50 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-12 09:54:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malmstrom-2005">
<CHAR_METHODS MODIFIED="2008-10-16 14:34:16 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose , 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 90, 120 mins then hourly up to 8 hours, then at 10, 12, 20 and 24 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:37 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 23 years</P>
<P>N = 302</P>
<P>M = 113, F = 189</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 09:54:36 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10mg + paracetamol 650 mg, n = 102</P>
<P>Etoricoxib 120 mg, n = 100</P>
<P>Codeine 60 mg + paracetamol 600 mg, n = 50<BR/>
</P>
<P>Placebo, n = 50</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-15 13:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-15 13:38:05 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 14:35:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malmstrom-2006">
<CHAR_METHODS MODIFIED="2008-10-16 14:33:19 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose, 4 parallel groups </P>
<P>Medication administered when baseline pain reached a moderate to severe intensity </P>
<P>Pain assessed at 0, 5, 10, 20, 30, 45, 60, 90, 120 mins then hourly up to 6 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:40 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar </P>
<P>Mean age 23 years </P>
<P>N = 60 </P>
<P>M = 11, F = 49</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-16 14:33:14 +0100" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 20 </P>
<P>Lidocaine IV 4 mg/kg, n = 20 </P>
<P>Active placebo, n = 10 </P>
<P>Placebo, n = 10</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-15 13:42:27 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 14:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-13 11:25:03 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Palangio-2000">
<CHAR_METHODS MODIFIED="2009-05-13 11:25:03 +0100" MODIFIED_BY="Jessica R Thomas">
<P>RCT, DB, single dose, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 60, 90, 120, 150, 240 mins, then hourly up to 8 hours post-dose</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:44 +0100" MODIFIED_BY="[Empty name]">
<P>Gynaecological or obstetric surgery</P>
<P>Mean age 41 years</P>
<P>N = 180</P>
<P>All F</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 11:56:12 +0000" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 59</P>
<P>Hydrocodone 15 mg + ibuprofen 400 mg, n = 61<BR/>
</P>
<P>Placebo, n = 60</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-14 09:19:32 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 14:25:00 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1 </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-13 12:03:59 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Reines-1994">
<CHAR_METHODS MODIFIED="2008-10-16 14:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose, 3 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 30, 60, mins, then hourly up to 6 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:50 +0100" MODIFIED_BY="[Empty name]">
<P>Orthopaedic surgery</P>
<P>Mean age 42 years</P>
<P>N = 218</P>
<P>M = 126, F = 92<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:03:59 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Oxycodone 5 mg + paracetamol 325 mg, n = 69</P>
<P>Ketorolac 10 mg, n = 76<BR/>
</P>
<P>Placebo, n = 73</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-14 09:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>PI: non-std 5 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 16:06:58 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-13 11:25:10 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Singla-2005">
<CHAR_METHODS MODIFIED="2008-10-16 14:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose, 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 90, 120 mins, then hourly up to 6 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:55 +0100" MODIFIED_BY="[Empty name]">
<P>Abdominal or pelvic surgery</P>
<P>Mean age 42 years</P>
<P>N = 456</P>
<P>All F</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 11:25:10 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Oxycodone 5 mg, n = 52</P>
<P>Oxycodone 5 mg + ibuprofen 400 mg, n = 169</P>
<P>Ibuprofen 400 mg, n = 175</P>
<P>Placebo, n = 60</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-14 09:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-01 13:49:42 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 14:35:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sunshine-1993">
<CHAR_METHODS MODIFIED="2008-08-08 16:27:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 5 parallel groups</P>
<P>Medication administered when baseline pain reached a severe intensity</P>
<P>Pain assessed at 0, 30, 60 mins, then hourly up to 8 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:35:59 +0100" MODIFIED_BY="[Empty name]">
<P>Caesarian section</P>
<P>Mean age 26 years</P>
<P>N = 240</P>
<P>All F<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-19 11:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 48</P>
<P>paracetamol 650 mg, n = 48</P>
<P>Ketoprofen 50 mg, n = 48</P>
<P>Ketoprofen 100 mg, n = 48<BR/>
</P>
<P>Placebo, n = 48</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with serious adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-08 16:25:22 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 14:36:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sunshine-1996">
<CHAR_METHODS MODIFIED="2008-10-16 14:32:43 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single and multiple dose phases, 6 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity </P>
<P>Pain assessed at 0, then hourly up to 12 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:36:04 +0100" MODIFIED_BY="[Empty name]">
<P>Abdominal or gynaecological surgery </P>
<P>Mean age 32 years </P>
<P>n = 182 </P>
<P>All F </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-02 11:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>Oxycodone 15 mg, n = 31 </P>
<P>Oxycodone 10 mg + paracetamol 650 mg, n = 30 </P>
<P>Oxycodone CR 10 mg, n = 30 </P>
<P>Oxycodone CR 20 mg, n = 30 </P>
<P>Oxycodone CR 30 mg, n = 30 </P>
<P>Placebo, n = 31</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale and 100 mm VAS</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-13 15:17:53 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R2, DB1, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-15 17:00:52 +0000" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Van-Dyke-2004">
<CHAR_METHODS MODIFIED="2008-08-08 16:42:10 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, single dose , 4 parallel groups</P>
<P>Medication administered when baseline pain reached a moderate to severe intensity</P>
<P>Pain assessed at 0, 15, 30, 45, 60, 90, 120 mins then hourly up to 6 hours.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 14:36:08 +0100" MODIFIED_BY="[Empty name]">
<P>Impacted third molar</P>
<P>Mean age 24.5 years</P>
<P>N = 498</P>
<P>M = 219, F = 279</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-15 17:00:52 +0000" MODIFIED_BY="Jessica R Thomas">
<P>Oxycodone 5 mg, n = 63</P>
<P>Oxycodone 5 mg + ibuprofen 400 mg, n = 187</P>
<P>Ibuprofen 400 mg, n = 186<BR/>
</P>
<P>Placebo, n = 62</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-16 14:27:57 +0100" MODIFIED_BY="[Empty name]">
<P>PI: std 4 point scale</P>
<P>PR: std 5 point scale</P>
<P>PGE: std 5 point scale</P>
<P>Time to use of rescue medication</P>
<P>Number of participants using rescue medication</P>
<P>Number of participants with any, and serious, adverse events</P>
<P>Number of participants withdrawing due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-01 13:50:10 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R1, DB2, W1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations: DB = double blind; PGE = patient global evaluation; N = total number in study; n = number in treatment arm; PI = pain intensity; PR = pain relief; R = randomised; RCT = randomised controlled trial; std = standard; W = withdrawals<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-12-03 08:48:43 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Beck-1923">
<CHAR_REASON_FOR_EXCLUSION>
<P>Could not be retrieved by the British Library</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Belam-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Could not be retrieved by the British Library</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boyd-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Could not be retrieved by the British Library</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:37:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brittain-1959">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:37:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised, not double blind, baseline pain intensity not specified, included children, pain outcome data not provided therefore no extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-03 08:48:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Beer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-03 08:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:37:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dionne-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control, medication administered both pre- and post-operatively, baseline pain intensity not assessed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:37:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMahon-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:37:56 +0100" MODIFIED_BY="[Empty name]">
<P>Number of patients per group not stated, included individuals under 18 years, non-standard pain scale for pain relief</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moore-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Oxycodone used as pre-medication only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:38:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morrison-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:38:06 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised, no placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Owen-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Oxycodone used as supplementary medication only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:38:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rittenberg-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:38:15 +0100" MODIFIED_BY="[Empty name]">
<P>Not an RCT, assessed 2 surgical techniques not analgesic efficacy of oxycodone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roehrich-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reference could not be traced</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siegied-1918">
<CHAR_REASON_FOR_EXCLUSION>
<P>Could not be retrieved by the British Library</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sunshine-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included post-fracture and somatic pain - data not segregated according to pain model</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-02 11:33:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takki-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-02 11:33:13 +0100" MODIFIED_BY="[Empty name]">
<P>Did not state it was randomised. No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:38:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tigerstedt-1981a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:38:26 +0100" MODIFIED_BY="[Empty name]">
<P>Inappropriate randomisation (birth dates), no placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 14:39:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tigerstedt-1981b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 14:39:20 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised, not double blind, no placebo control, baseline pain intensity not stated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-02 11:35:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Young-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-02 11:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>Pain intensity rated by observer and reported global appears to be patient and observer combination</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-05-13 12:39:45 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-05-13 12:38:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniels-2009">
<CHAR_METHODS MODIFIED="2009-05-13 12:30:44 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, placebo and active control. Multiple dose study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-13 12:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Bunionectomy surgery, experiencing moderate to severe postoperative pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:38:19 +0100" MODIFIED_BY="[Empty name]">
<P>Tapentadol IR 50 mg, 75 mg, 100 mg, oxycodone HCl IR 15 mg, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-13 12:34:29 +0100" MODIFIED_BY="[Empty name]">
<P>Pain intensity use of rescue medication, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-05-13 12:38:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stegmann-2008">
<CHAR_METHODS MODIFIED="2009-05-13 12:35:16 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, DB, placebo and active control. Multiple dose study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-13 12:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Bunionectomy surgery, experiencing moderate to severe postoperative pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 12:37:21 +0100" MODIFIED_BY="[Empty name]">
<P>Tapentadol IR 50 mg, 100 mg, oxycodone HCl IR 10 mg, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-13 12:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Pain intensity, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES>
<P>HCl - hydrochloride; IR - immediate release</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-10-16 14:01:47 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-10-16 14:01:47 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-09-18 15:04:03 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-05-13 12:08:32 +0100" MODIFIED_BY="Jessica R Thomas">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-05-13 12:06:18 +0100" MODIFIED_BY="Jessica R Thomas" NO="1">
<TITLE MODIFIED="2008-08-01 13:31:18 +0100" MODIFIED_BY="Sheena Derry">Summary of outcomes: analgesia and rescue medication</TITLE>
<TABLE COLS="7" ROWS="22">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" COLSPAN="3" VALIGN="MIDDLE">
<P>
<B>Analgesia</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Rescue medication</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Treatment</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>PI or PR</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Number with 50% PR</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>PGR: v good or excellent</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Median time to use (h)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>% using</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 15 mg, n = 83</P>
<P>(2) Oxymorphone 10 mg, n = 82</P>
<P>(3) Oxymorphone 20 mg, n = 81</P>
<P>(4) Placebo, n = 85</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 10.5</P>
<P>(4) 8.1</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 39/83</P>
<P>(4) 28/85</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 32</P>
<P>(4) 41</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK> </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 100</P>
<P>(2) Etoricoxib 120 mg, n = 100</P>
<P>(3) Placebo, n = 25</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 12.1</P>
<P>(3) 4.1</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 56/100</P>
<P>(3) 3/25</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 43/97</P>
<P>(3) 1/24</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 7.4</P>
<P>(3) 1.5</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 41</P>
<P>(3) 72<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 120</P>
<P>(2) Rofecoxib 50 mg, n = 121</P>
<P>(3) Placebo, n = 30</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 11.3</P>
<P>(3) 3.1</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 61/120</P>
<P>(3) 2/30</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 56/116</P>
<P>(3) 0/30</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 5.1</P>
<P>(3) 1.6</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 5 mg, n = 42</P>
<P>(2) Oxycodone 5 mg + paracetamol 500 mg, n = 45</P>
<P>(3) Oxycodone 5 mg + paracetamol 1000 mg, n = 40</P>
<P>(4) Oxycodone 10 mg + paracetamol 1000 mg, n = 45</P>
<P>(5) Paracetamol 500 mg, n = 37</P>
<P>(6) Placebo, n = 38</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 4:</P>
<P>(1) 4.8</P>
<P>(2) 7.5</P>
<P>(3) 8.1</P>
<P>(4) 9.4</P>
<P>(5) 5.1</P>
<P>(6) 4.8</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>(1) 12/42</P>
<P>(2) 23/45</P>
<P>(3) 22/40</P>
<P>(4) 30/45</P>
<P>(5) 12/37</P>
<P>(6) 11/38</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>Mean:</P>
<P>(1) 2.8</P>
<P>(2) 3.5</P>
<P>(3) 3.2</P>
<P>(4) 3.4</P>
<P>(5) 2.8</P>
<P>(6) 2.5</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Study A:</P>
<P>(1) Oxycodone 10 mg + paracetamol 1000 mg, n = 51</P>
<P>(2) Valdecoxib 20 mg, n = 52</P>
<P>(3) Valdecoxib 40 mg, n = 50</P>
<P>(4) Placebo, n = 52</P>
<P>
<BR/>Study B:</P>
<P>(1) Oxycodone 10 mg + paracetamol 1000 mg, n = 51</P>
<P>(2) Valdecoxib 20 mg, n = 49</P>
<P>(3) Valdecoxib 40 mg, n = 50</P>
<P>(4) Placebo, n = 51</P>
</TD>
<TD VALIGN="TOP">
<P>SPID 6:</P>
<P>Study A</P>
<P>(1) 8.7</P>
<P>(4) 1.4</P>
<P/>
<P>Study B</P>
<P>(1) 7.3</P>
<P>(4) 1.0</P>
</TD>
<TD VALIGN="TOP">
<P>Study A:</P>
<P>(1) 39/51</P>
<P>(4) 5/52</P>
<P/>
<P>
<BR/>Study B:</P>
<P>(1) 31/51</P>
<P>(4) 5/52</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>Study A:</P>
<P>(1) 11.3</P>
<P>(4) 1.1</P>
<P>
<BR/>Study B:</P>
<P>(1) 6.1</P>
<P>(4) 1.1</P>
</TD>
<TD VALIGN="TOP">
<P>at 24 h:</P>
<P>Study A:</P>
<P>(1) 55</P>
<P>(4) 85</P>
<P/>
<P>Study B:</P>
<P>(1) 78</P>
<P>(4) 90</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Desjardins 2007  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 122</P>
<P>(2) Rofecoxib 50 mg, n = 118</P>
<P>(3) Placebo, n = 30</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 12.8</P>
<P>(3) 3.9</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 72/122</P>
<P>(3) 3/30</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) &gt;24</P>
<P>(3) 1.83</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 38</P>
<P>(3) 73</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fricke 1997  </P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 32</P>
<P>(2) Bromfenac 25 mg, n = 30</P>
<P>(3) Bromfenac 50 mg, n = 33<BR/>
</P>
<P>(4) Placebo, n = 33</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 9.2</P>
<P>(4) 1.4</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 13/32</P>
<P>(4) 0/33</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 8/32</P>
<P>(4) 3/33</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>at 2 h:</P>
<P>(1) 25</P>
<P>(4) 85</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gammaitoni 2003  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 325 mg, n = 59</P>
<P>(2) OxycodoneCR 20 mg, n = 61<BR/>
</P>
<P>(3) Placebo, n = 30</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 8.1</P>
<P>(2) 6.0</P>
<P>(3) 1.8</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>(1) 18/55</P>
<P>(2) 12/56</P>
<P>(3) 0/30</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 14/55</P>
<P>(2) 13/56</P>
<P>(3) 2/30</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 4.5</P>
<P>(2) 2.75</P>
<P>(3) 1.3</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 48</P>
<P>(2) 51</P>
<P>(3) 83</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gimbel 2004  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg, n = 60</P>
<P>(2) Oxymorphone 10 mg, n = 59</P>
<P>(3) Oxymorphone 20 mg, n = 59</P>
<P>(4) Oxymorphone 30 mg, n = 65</P>
<P>(5) Placebo, n = 57</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 6.9</P>
<P>(5) 5.8</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 15/55</P>
<P>(5) 9/44</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 15/55</P>
<P>(5) 9/44</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>at 8 h:</P>
<P>(1) 42</P>
<P>(5) 47<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 47</P>
<P>(2) Bromfenac 50 mg, n = 47</P>
<P>(3) Bromfenac 100 mg, n = 48</P>
<P>(4) Ibuprofen 400 mg, n = 48<BR/>
</P>
<P>(5) Placebo, n = 48</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 9.7</P>
<P>(5) 5.8</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 20/47</P>
<P>(5) 10/48</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 33/47</P>
<P>(5) 17/47</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 81</P>
<P>(5) 89</P>
<P>at 8 h:</P>
<P>(1) 92</P>
<P>(5) 90</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 5 mg + paracetamol 325 mg , n = 91</P>
<P>(2) Rofecoxib 50 mg, n = 90<BR/>
</P>
<P>(3) Placebo, n = 31</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 5.9</P>
<P>(3) 1.9</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 19/91</P>
<P>(3) 0/31</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 17/91</P>
<P>(3) 1/31</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 3.3</P>
<P>(3) 1.7</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 68</P>
<P>(3) 90</P>
<P>at 24 h:</P>
<P>(1) 95</P>
<P>(3) 97</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 5 mg + paracetamol 325 mg, n = 61</P>
<P>(2) Hydromorphone 7.5 mg + paracetamol 500 mg, n = 63</P>
<P>(3) Ibuprofen 400 mg + oxycodone 5 mg, n = 62<BR/>
</P>
<P>(4) Placebo, n = 63</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 9.5</P>
<P>(4) 5.1</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 25/61</P>
<P>(4) 10/63</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) &gt; 6</P>
<P>(4) 2.14</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 49</P>
<P>(4) 73</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 102</P>
<P>(2) Etoricoxib 120 mg, n = 100</P>
<P>(3) Codeine 60 mg + paracetamol 600 mg, n = 50<BR/>
</P>
<P>(4) Placebo, n = 50</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 10.1</P>
<P>(4) 2.4</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 45/102</P>
<P>(4) 1/50</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>(1) 47/102</P>
<P>(4) 3/50</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 5.3</P>
<P>(4) 1.7</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 57</P>
<P>(4) no data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 20</P>
<P>(2) Lidocaine IV 4 mg/kg, n = 20<BR/>
</P>
<P>(3) Active placebo, n = 10</P>
<P>(4) Placebo, n = 10</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 6.8</P>
<P>(4) 0.8</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>(1) 5/20</P>
<P>(4) 0/9</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 3.1</P>
<P>(4) 1.2</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 75</P>
<P>(4) 100</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 59</P>
<P>(2) Hydrocodone 15 mg + ibuprofen 400 mg, n = 61<BR/>
</P>
<P>(3) Placebo, n = 60</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 8.0</P>
<P>(3) 1.4</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 19/59</P>
<P>(3) 0/60</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 3.75</P>
<P>(3) 1.00</P>
</TD>
<TD VALIGN="TOP">
<P>at 8 h:</P>
<P>(1) 93</P>
<P>(3) 100</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 5 mg + paracetamol 325 mg, n = 69</P>
<P>(2) Ketorolac 10 mg, n = 76<BR/>
</P>
<P>(3) Placebo, n = 73</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 6.3</P>
<P>(3) 3.1</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 16/69</P>
<P>(4) 4/73</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 4.05</P>
<P>(3) 1.94</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 78</P>
<P>(3) 93</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 5 mg, n = 52</P>
<P>(2) Oxycodone 5 mg + ibuprofen 400 mg, n = 169</P>
<P>(3) Ibuprofen 400 mg, n = 175</P>
<P>(4) Placebo, n = 60</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 8.6</P>
<P>(4) 6.4</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 19/52</P>
<P>(4) 14/60</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 2.50</P>
<P>(4) 2.28</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 83</P>
<P>(4) 92</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK> </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 48</P>
<P>(2) Paracetamol 650 mg, n = 48</P>
<P>(3) Ketoprofen 50 mg, n = 48</P>
<P>(4) Ketoprofen 100 mg, n = 48<BR/>
</P>
<P>(5) Placebo, n = 48</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 12.4</P>
<P>(5) 8.8</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 27/48</P>
<P>(5) 18/48</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 73</P>
<P>(5) 73</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK> </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 15 mg, n = 31 </P>
<P>(2) Oxycodone 10 mg + paracetamol 650 mg, n = 30 </P>
<P>(3) Oxycodone CR 10 mg, n = 30 </P>
<P>(4) Oxycodone CR 20 mg, n = 30 </P>
<P>(5) Oxycodone CR 30 mg, n = 30 </P>
<P>(6) Placebo, n = 31</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 15.4</P>
<P>(2) 18.5</P>
<P>(3) 11.7</P>
<P>(4) 15.6</P>
<P>(5) 16.3</P>
<P>(6) 7.5</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 22/30</P>
<P>(2) 27/30</P>
<P>(3) 16/30</P>
<P>(4) 22/30</P>
<P>(5) 24/30</P>
<P>(6) 9/30</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>at 12 h:</P>
<P>(1) 73</P>
<P>(2) 83</P>
<P>(3) 57</P>
<P>(4) 50</P>
<P>(5) 60</P>
<P>(6) 83</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK> </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 5 mg, n = 63</P>
<P>(2) Oxycodone 5 mg + ibuprofen 400 mg, n = 187</P>
<P>(3) Ibuprofen 400 mg, n = 186<BR/>
</P>
<P>(4) Placebo, n = 62</P>
</TD>
<TD VALIGN="TOP">
<P>TOTPAR 6:</P>
<P>(1) 4.3</P>
<P>(4) 4.2</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 8/63</P>
<P>(4) 7/62</P>
</TD>
<TD VALIGN="TOP">
<P>No usable data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 2.1</P>
<P>(4) 2.0</P>
</TD>
<TD VALIGN="TOP">
<P>at 6 h:</P>
<P>(1) 83</P>
<P>(4) 84</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-05-13 12:08:32 +0100" MODIFIED_BY="Jessica R Thomas" NO="2">
<TITLE MODIFIED="2008-08-01 13:34:06 +0100" MODIFIED_BY="Sheena Derry">Summary of outcomes: adverse events and withdrawals</TITLE>
<TABLE COLS="6" ROWS="22">
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Withdrawals</B>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Any</P>
</TH>
<TH>
<P>Serious</P>
</TH>
<TH>
<P>Adverse event</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Aqua-2007" TYPE="STUDY">Aqua 2007</LINK>
</P>
</TD>
<TD>
<P>(1) Oxycodone 15 mg, n = 83</P>
<P>(2) Oxymorphone 10 mg, n = 82</P>
<P>(3) Oxymorphone 20 mg, n = 81</P>
<P>(4) Placebo, n = 85</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data, but reported events were of mild to moderate severity</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 4/83</P>
<P>(4) 4/85</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 3/83</P>
<P>(4) 1/85</P>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chang-2004a" TYPE="STUDY">Chang 2004a</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 100</P>
<P>(2) Etoricoxib 120 mg, n = 100</P>
<P>(3) Placebo, n = 25</P>
</TD>
<TD VALIGN="TOP">
<P>At 24 h:</P>
<P>(1) 71/100</P>
<P>(3) 6/25</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chang-2004b" TYPE="STUDY">Chang 2004b</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 120</P>
<P>(2) Rofecoxib 50 mg, n = 121</P>
<P>(3) Placebo, n = 30</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>None<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cooper-1980" TYPE="STUDY">Cooper 1980</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 5 mg, n = 42</P>
<P>(2) Oxycodone 5 mg + paracetamol 500 mg, n = 45</P>
<P>(3) Oxycodone 5 mg + paracetamol 1000 mg, n = 40</P>
<P>(4) Oxycodone 10 mg + paracetamol 1000 mg, n = 45</P>
<P>(5) Paracetamol 500 mg, n = 37</P>
<P>(6) Placebo, n = 38</P>
</TD>
<TD VALIGN="TOP">
<P>Before rescue medication:</P>
<P>(1) 8/42</P>
<P>(2) 21/45</P>
<P>(3) 19/40</P>
<P>(4) 29/45</P>
<P>(5) 3/37</P>
<P>(6) 6/38</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>Total of 51 pts excluded from analyses: 21 lost to follow up, 10 did not take medication, 20 had protocol violations</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daniels-2002" TYPE="STUDY">Daniels 2002</LINK>  </P>
</TD>
<TD>
<P>Study A:</P>
<P>(1) Oxycodone 10 mg + paracetamol 1000 mg, n = 51</P>
<P>(2) Valdecoxib 20 mg, n = 52</P>
<P>(3) Valdecoxib 40 mg, n = 50</P>
<P>(4) Placebo, n = 52</P>
<P>
<BR/>Study B:</P>
<P>(1) Oxycodone 10 mg + paracetamol 1000 mg, n = 51</P>
<P>(2) Valdecoxib 20 mg, n = 49</P>
<P>(3) Valdecoxib 40 mg, n = 50</P>
<P>(4) Placebo, n = 51</P>
</TD>
<TD VALIGN="TOP">
<P>At 24 h:</P>
<P>Study A + B</P>
<P>(1) 71/102</P>
<P>(4) 55/103</P>
<P>Most mild to moderate in severity</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Desjardins-2007" TYPE="STUDY">Desjardins 2007</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 122</P>
<P>(2) Rofecoxib 50 mg, n = 118</P>
<P>(3) Placebo, n = 30</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>(1) I pt had syncope, headache, vomiting - time of withdrawal not given<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 1 pt had protocol violation</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Fricke-1997" TYPE="STUDY">Fricke 1997</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 32</P>
<P>(2) Bromfenac 25 mg, n = 30</P>
<P>(3) Bromfenac 50 mg, n = 33<BR/>
</P>
<P>(4) Placebo, n = 33</P>
</TD>
<TD VALIGN="TOP">
<P>At 8 h:</P>
<P>(1) 26/32</P>
<P>(4) 11/33</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gammaitoni-2003" TYPE="STUDY">Gammaitoni 2003</LINK>  </P>
</TD>
<TD VALIGN="TOP">
<P>(1) Oxycodone 10 mg + paracetamol 325 mg, n = 59</P>
<P>(2) Oxycodone CR 20 mg, n = 61<BR/>
</P>
<P>(3) Placebo, n = 30</P>
</TD>
<TD VALIGN="TOP">
<P>At 6 h:</P>
<P>(1) 26/59</P>
<P>(2) 34/61</P>
<P>(3) 5/30</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>Vomiting in 1st hr:</P>
<P>(1) 4/59</P>
<P>(2) 5/61</P>
<P>(3) 0/30</P>
<P>so excluded from efficacy analysis</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gimbel-2004" TYPE="STUDY">Gimbel 2004</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg, n = 60</P>
<P>(2) Oxymorphone 10 mg, n = 59</P>
<P>(3) Oxymorphone 20 mg, n = 59</P>
<P>(4) Oxymorphone 30 mg, n = 65</P>
<P>(5) Placebo, n = 57</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose phase:</P>
<P>(1) 16/60</P>
<P>(5) no data</P>
</TD>
<TD VALIGN="TOP">
<P>2 pts, but treatment group not given. No further details</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0/60</P>
<P>(5) 2/57</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
<P>42 pts had invalid data (early remedication or vomiting) or protocol violations and were excluded from the efficacy analysis</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Johnson-1997" TYPE="STUDY">Johnson 1997</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 47</P>
<P>(2) Bromfenac 50 mg, n = 47</P>
<P>(3) Bromfenac 100 mg, n = 48</P>
<P>(4) Ibuprofen 400 mg, n = 48<BR/>
</P>
<P>(5) Placebo, n = 48</P>
</TD>
<TD VALIGN="TOP">
<P>At 8 h:</P>
<P>CNS AEs (mostly somnolence, dizziness):</P>
<P>(1) 10/47</P>
<P>(5) 2/48</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear, probably none in single dose phase</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>2 protocol violations, one each in (2) and (5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Korn-2004" TYPE="STUDY">Korn 2004</LINK>
</P>
</TD>
<TD>
<P>(1) Oxycodone 5 mg + paracetamol 325 mg , n = 91</P>
<P>(2) Rofecoxib 50 mg, n = 90<BR/>
</P>
<P>(3) Placebo, n = 31</P>
</TD>
<TD VALIGN="TOP">
<P>At 14 days:</P>
<P>(1) 59/91</P>
<P>(2) 46/90</P>
<P>(3) 15/31</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Litkowski-2005" TYPE="STUDY">Litkowski 2005</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 5 mg + paracetamol 325 mg, n = 61</P>
<P>(2) Hydromorphone 7.5 mg + paracetamol 500 mg, n = 63</P>
<P>(3) Ibuprofen 400 mg + oxycodone 5 mg, n = 62<BR/>
</P>
<P>(4) Placebo, n = 63</P>
</TD>
<TD VALIGN="TOP">
<P>At 6 h:</P>
<P>(1) 17/61</P>
<P>(4) 7/63</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>(4) 1/63 (severe headache)</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Malmstrom-2005" TYPE="STUDY">Malmstrom 2005</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 102</P>
<P>(2) Etoricoxib 120 mg, n = 100</P>
<P>(3) Codeine 60 mg + paracetamol 600 mg, n = 50<BR/>
</P>
<P>(4) Placebo, n = 50</P>
</TD>
<TD VALIGN="TOP">
<P>At 24 h (unclear, possibly at 7 days):</P>
<P>(1) 64/102</P>
<P>(2) 40/100</P>
<P>(3) 30/50</P>
<P>(4) 19/50</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 1 pt did not return for post study follow up - all other data analysed</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Malmstrom-2006" TYPE="STUDY">Malmstrom 2006</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 20</P>
<P>(2) Lidocaine IV 4 mg/kg, n = 20<BR/>
</P>
<P>(3) Active placebo, n = 10</P>
<P>(4) Placebo, n = 10</P>
</TD>
<TD VALIGN="TOP">
<P>At 6 h:</P>
<P>(1) 12/20</P>
<P>(4) 7/10</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
<P>(4) 1/10 had invalid data (inadequate baseline pain) so excluded from efficacy analysis</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Palangio-2000" TYPE="STUDY">Palangio 2000</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 59</P>
<P>(2) Hydrocodone 15 mg + ibuprofen 400 mg, n = 61<BR/>
</P>
<P>(3) Placebo, n = 60</P>
</TD>
<TD VALIGN="TOP">
<P>At 8 h:</P>
<P>(1) 7/59</P>
<P>(3) 6/60</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Reines-1994" TYPE="STUDY">Reines 1994</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 5 mg + paracetamol 325 mg, n = 69</P>
<P>(2) Ketorolac 10 mg, n = 76<BR/>
</P>
<P>(3) Placebo, n = 73</P>
</TD>
<TD VALIGN="TOP">
<P>At 6 h:</P>
<P>(1) 31/69</P>
<P>(3) 22/73</P>
<P>Most mild to moderate in severity</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 1/69 (nausea)</P>
<P>(3) 0/73</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
<P>24 pts had protocol violations or inadequate baseline pain so were excluded from analyses</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Singla-2005" TYPE="STUDY">Singla 2005</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 5 mg, n = 52</P>
<P>(2) Oxycodone 5 mg + ibuprofen 400 mg, n = 169</P>
<P>(3) Ibuprofen 400 mg, n = 175</P>
<P>(4) Placebo, n = 60</P>
</TD>
<TD VALIGN="TOP">
<P>At 6 h:</P>
<P>(1) 23/52</P>
<P>(4) 33/60</P>
<P>Most mild to moderate in severity</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>(1) 3/52</P>
<P>(4) 1/60</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 1/52 (vomiting)</P>
<P>(4) 0/60</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sunshine-1993" TYPE="STUDY">Sunshine 1993</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 10 mg + paracetamol 650 mg, n = 48</P>
<P>(2) Paracetamol 650 mg, n = 48</P>
<P>(3) Ketoprofen 50 mg, n = 48</P>
<P>(4) Ketoprofen 100 mg, n = 48<BR/>
</P>
<P>(5) Placebo, n = 48</P>
</TD>
<TD VALIGN="TOP">
<P>No single dose data</P>
</TD>
<TD VALIGN="TOP">
<P>"No cases of possible clinical concern" (multiple dose included)</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sunshine-1996" TYPE="STUDY">Sunshine 1996</LINK>  </P>
<P/>
</TD>
<TD>
<P>(1) Oxycodone 15 mg, n = 31 </P>
<P>(2) Oxycodone 10 mg + paracetamol 650 mg, n = 30 </P>
<P>(3) Oxycodone CR 10 mg, n = 30 </P>
<P>(4) Oxycodone CR 20 mg, n = 30 </P>
<P>(5) Oxycodone CR 30 mg, n = 30 </P>
<P>(6) Placebo, n = 31</P>
</TD>
<TD VALIGN="TOP">
<P>Before rescue medication:</P>
<P>(1) 22/31</P>
<P>(2) 19/30</P>
<P>(3) 14/30</P>
<P>(4) 15/30</P>
<P>(5) 22/30</P>
<P>(6) 12/31</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 1 pt vomited within 1 h, so excluded from efficacy analysis</P>
</TD>
<TD VALIGN="TOP">
<P>(6) 1 pt had protocol violation, so excluded from efficacy analysis</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Van-Dyke-2004" TYPE="STUDY">Van Dyke 2004</LINK>  </P>
</TD>
<TD>
<P>(1) Oxycodone 5 mg, n = 63</P>
<P>(2) Oxycodone 5 mg + ibuprofen 400 mg, n = 187</P>
<P>(3) Ibuprofen 400 mg, n = 186<BR/>
</P>
<P>(4) Placebo, n = 62</P>
</TD>
<TD VALIGN="TOP">
<P>At 6 h:</P>
<P>(1) 17/63</P>
<P>(4) 7/62</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>One pt in (2) had no post baseline efficacy data so excluded from efficacy analysis</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>pt - participant</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-05-13 12:13:05 +0100" MODIFIED_BY="Jessica R Thomas">
<COMPARISON ID="CMP-001" MODIFIED="2008-12-18 14:51:27 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Oxycodone 5 mg v placebo</NAME>
<DICH_OUTCOME CHI2="1.0714008495420826" CI_END="1.8780420192705145" CI_START="0.8398207443998885" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2558736587085635" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.273705304933909" LOG_CI_START="-0.07581340206395999" LOG_EFFECT_SIZE="0.09894595143497452" METHOD="MH" MODIFIED="2008-12-18 14:43:15 +0000" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Need to redo to get rid of the subgroup&lt;/p&gt;" NOTES_MODIFIED="2008-12-18 14:43:15 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.5852593211329549" P_Q="1.0" P_Z="0.2671282255831098" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="160" WEIGHT="100.0" Z="1.1097002669432614">
<NAME>Participants with at least 50% pain relief over 4 to 6 hours</NAME>
<GROUP_LABEL_1>Oxycodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxycodone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9688080236218182" CI_START="0.49481443840327866" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.2942033706092016" LOG_CI_START="-0.3055576363925826" LOG_EFFECT_SIZE="-0.005677132891690521" MODIFIED="2008-12-18 14:42:23 +0000" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.35230258437771395" STUDY_ID="STD-Cooper-1980" TOTAL_1="42" TOTAL_2="38" VAR="0.12411711095921624" WEIGHT="36.543694235271786"/>
<DICH_DATA CI_END="2.8022959203179303" CI_START="0.8750501619310036" EFFECT_SIZE="1.565934065934066" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.44751399453836954" LOG_CI_START="-0.05796705049149872" LOG_EFFECT_SIZE="0.1947734720234354" MODIFIED="2008-12-18 14:42:23 +0000" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.296922068022072" STUDY_ID="STD-Singla-2005" TOTAL_1="52" TOTAL_2="60" VAR="0.08816271447850395" WEIGHT="41.13143074099854"/>
<DICH_DATA CI_END="2.9135896859653077" CI_START="0.4341679720152126" EFFECT_SIZE="1.124716553287982" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.46442839106195083" LOG_CI_START="-0.36234221701723296" LOG_EFFECT_SIZE="0.05104308702235895" MODIFIED="2008-12-18 14:42:23 +0000" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="0.48564914776622686" STUDY_ID="STD-Van-Dyke-2004" TOTAL_1="63" TOTAL_2="62" VAR="0.23585509472606248" WEIGHT="22.32487502372967"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6391004240402699" CI_END="1.0509239990649277" CI_START="0.8473177009464236" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9436453289012329" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="107" I2="0.0" I2_Q="100.0" ID="CMP-001.02" LOG_CI_END="0.021571309767358913" LOG_CI_START="-0.07195372084077623" LOG_EFFECT_SIZE="-0.025191205536708654" METHOD="MH" MODIFIED="2008-12-18 14:51:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4240369784721315" P_Q="0.0" P_Z="0.29104014907280507" Q="1.5953264740703872E-32" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="122" WEIGHT="100.0" Z="1.0558425965337292">
<NAME>Participants using rescue medication within 6 hours</NAME>
<GROUP_LABEL_1>Oxycodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0437842203465209" CI_START="0.7796444984570403" EFFECT_SIZE="0.9020979020979021" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="55" LOG_CI_END="0.018610727020080504" LOG_CI_START="-0.10810338135170622" LOG_EFFECT_SIZE="-0.04474632716581285" MODIFIED="2008-12-18 14:45:49 +0000" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.07443249450254005" STUDY_ID="STD-Singla-2005" TOTAL_1="52" TOTAL_2="60" VAR="0.005540196237870654" WEIGHT="49.35036967913287"/>
<DICH_DATA CI_END="1.1520279624231653" CI_START="0.8406965390403602" EFFECT_SIZE="0.9841269841269841" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="52" LOG_CI_END="0.06146302056175864" LOG_CI_START="-0.07536074047241431" LOG_EFFECT_SIZE="-0.006948859955327855" MODIFIED="2008-12-18 14:45:49 +0000" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.08037095452001349" STUDY_ID="STD-Van-Dyke-2004" TOTAL_1="63" TOTAL_2="62" VAR="0.006459490330458076" WEIGHT="50.64963032086713"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.277747245892218" CI_END="1.548725484120195" CI_START="0.80431662106507" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.11609392451752" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="46" I2="68.14143797667738" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.18997444468156088" LOG_CI_START="-0.09457295658372078" LOG_EFFECT_SIZE="0.047700744048920045" METHOD="MH" MODIFIED="2008-12-18 14:50:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04333161915304651" P_Q="1.0" P_Z="0.5110999399368453" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="160" WEIGHT="99.99999999999999" Z="0.6571259477747603">
<NAME>Participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Oxycodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.160907932719149" CI_START="0.46039885964266825" EFFECT_SIZE="1.2063492063492063" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4998118463949925" LOG_CI_START="-0.3368657607405732" LOG_EFFECT_SIZE="0.08147304282720962" MODIFIED="2008-12-18 14:48:52 +0000" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.49146856805238176" STUDY_ID="STD-Cooper-1980" TOTAL_1="42" TOTAL_2="38" VAR="0.24154135338345858" WEIGHT="14.318553728668277"/>
<DICH_DATA CI_END="1.1777083641428105" CI_START="0.5491434986596672" EFFECT_SIZE="0.8041958041958042" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="33" LOG_CI_END="0.07103775944590628" LOG_CI_START="-0.2603141536688065" LOG_EFFECT_SIZE="-0.09463819711145015" MODIFIED="2008-12-18 14:48:52 +0000" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.1946377539820053" STUDY_ID="STD-Singla-2005" TOTAL_1="52" TOTAL_2="60" VAR="0.037883855275159625" WEIGHT="69.64466609522324"/>
<DICH_DATA CI_END="5.358330740005881" CI_START="1.0660425172878738" EFFECT_SIZE="2.3900226757369616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.7290295166865989" LOG_CI_START="0.027774526130779728" LOG_EFFECT_SIZE="0.3784020214086893" MODIFIED="2008-12-18 14:48:52 +0000" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.4119206527206753" STUDY_ID="STD-Van-Dyke-2004" TOTAL_1="63" TOTAL_2="62" VAR="0.1696786241378272" WEIGHT="16.03678017610847"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-05-13 12:12:58 +0100" MODIFIED_BY="Jessica R Thomas" NO="2">
<NAME>Oxycodone 15 mg versus placebo</NAME>
<DICH_OUTCOME CHI2="2.2769687958908" CI_END="2.3005474694491403" CI_START="1.2214385372576353" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6762987012987012" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="37" I2="56.081962923484944" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.3618311989166711" LOG_CI_START="0.08687161817688574" LOG_EFFECT_SIZE="0.2243514085467784" METHOD="MH" MODIFIED="2008-12-19 11:21:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13130840063627092" P_Q="1.0" P_Z="0.0013817391019532155" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="115" WEIGHT="100.0" Z="3.1984386901481177">
<NAME>Participants with at least 50% pain relief over 4 to 6 hours</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxycodone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.085331325003326" CI_START="0.975707741882351" EFFECT_SIZE="1.4264199655765921" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" LOG_CI_END="0.3191750670742679" LOG_CI_START="-0.010680249029270247" LOG_EFFECT_SIZE="0.15424740902249884" MODIFIED="2008-10-31 14:41:22 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.19375864548936667" STUDY_ID="STD-Aqua-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.03754241270187407" WEIGHT="75.45454545454545"/>
<DICH_DATA CI_END="4.399438937037524" CI_START="1.3581978810231965" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6433972941940488" LOG_CI_START="0.132963048571714" LOG_EFFECT_SIZE="0.3881801713828814" MODIFIED="2008-10-31 14:41:24 +0000" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.2998316025688252" STUDY_ID="STD-Sunshine-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.08989898989898992" WEIGHT="24.545454545454543"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-05-13 12:13:05 +0100" MODIFIED_BY="Jessica R Thomas" NO="3">
<NAME>Oxycodone CR versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="80" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-12-19 10:27:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="145" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Participants with at least 50% pain relief over 4 to 6 hours</NAME>
<GROUP_LABEL_1>Oxycodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxycod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="9" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-10-10 16:46:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Oxycodone CR 10 mg</NAME>
<DICH_DATA CI_END="3.3747412388980194" CI_START="0.9365144179743139" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.5282404785516454" LOG_CI_START="-0.02848553211844553" LOG_EFFECT_SIZE="0.2498774732165999" MODIFIED="2008-10-10 16:46:48 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.32702361450580975" STUDY_ID="STD-Sunshine-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.10694444444444445" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="9" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-10-10 16:45:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Oxycodone CR 20 MG</NAME>
<DICH_DATA CI_END="328.3529719966546" CI_START="1.2776439131017903" EFFECT_SIZE="20.482142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="2.5163409515385085" LOG_CI_START="0.10640983025162606" LOG_EFFECT_SIZE="1.3113753908950672" MODIFIED="2008-10-10 16:45:38 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.4156054699953593" STUDY_ID="STD-Gammaitoni-2003" TOTAL_1="55" TOTAL_2="30" VAR="2.003938846680782" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.399438937037524" CI_START="1.3581978810231965" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6433972941940488" LOG_CI_START="0.132963048571714" LOG_EFFECT_SIZE="0.3881801713828814" MODIFIED="2008-10-10 16:43:14 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.2998316025688252" STUDY_ID="STD-Sunshine-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.08989898989898992" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="9" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-10-10 16:42:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Oxycodone CR 30 mg</NAME>
<DICH_DATA CI_END="4.739704072830796" CI_START="1.500328079947824" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.6757512270013727" LOG_CI_START="0.1761862375431895" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2008-10-10 16:42:40 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Sunshine-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.08611111111111111" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-12-18 14:26:14 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Oxycodone 5 mg plus paracetamol 325 mg</NAME>
<DICH_OUTCOME CHI2="1.9816121586517355" CI_END="6.24750646007773" CI_START="2.061206546748445" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5885096093455595" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.795706713870062" LOG_CI_START="0.31412151318560655" LOG_EFFECT_SIZE="0.5549141135278343" METHOD="MH" MODIFIED="2008-10-10 15:32:52 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;check Korn event rates&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 15:32:52 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.3712773938600997" P_Q="1.0" P_Z="6.278156868738532E-6" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="167" WEIGHT="100.0" Z="4.516798587173161">
<NAME>Participants with at least 50% pain relief over 4 to 6 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxycod+paracet</GRAPH_LABEL_2>
<DICH_DATA CI_END="218.25378294786944" CI_START="0.8431245515561054" EFFECT_SIZE="13.565217391304348" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.3389617799796545" LOG_CI_START="-0.07410826397795459" LOG_EFFECT_SIZE="1.1324267580008498" MODIFIED="2008-10-10 09:48:44 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.4174492887100618" STUDY_ID="STD-Korn-2004" TOTAL_1="91" TOTAL_2="31" VAR="2.00916248606466" WEIGHT="5.128124607461374"/>
<DICH_DATA CI_END="4.912909922482971" CI_START="1.3569462487173611" EFFECT_SIZE="2.581967213114754" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="10" LOG_CI_END="0.6913388014791697" LOG_CI_START="0.13256264475053475" LOG_EFFECT_SIZE="0.41195072311485226" MODIFIED="2008-10-10 09:45:06 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.3282278804489852" STUDY_ID="STD-Litkowski-2005" TOTAL_1="61" TOTAL_2="63" VAR="0.10773354150403332" WEIGHT="68.00339153372691"/>
<DICH_DATA CI_END="12.033709218980189" CI_START="1.488222987128729" EFFECT_SIZE="4.231884057971015" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="1.0803995130457735" LOG_CI_START="0.17266800837655233" LOG_EFFECT_SIZE="0.626533760711163" MODIFIED="2008-10-10 09:45:06 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.5332059791861165" STUDY_ID="STD-Reines-1994" TOTAL_1="69" TOTAL_2="73" VAR="0.2843086162398253" WEIGHT="26.868483858811707"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.407977237877348" CI_END="0.8604693895139568" CI_START="0.6845628828732424" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7674929354136448" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="142" I2="16.942736478563358" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.06526457472821064" LOG_CI_START="-0.16458665208732565" LOG_EFFECT_SIZE="-0.11492561340776815" METHOD="MH" MODIFIED="2008-12-18 14:26:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2999953199699449" P_Q="1.0" P_Z="5.739910219259959E-6" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="167" WEIGHT="100.0" Z="4.535750140746075">
<NAME>Participants using rescue medication within 6 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9046360631366342" CI_START="0.6289759250459718" EFFECT_SIZE="0.7543171114599686" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="28" LOG_CI_END="-0.043526103181903676" LOG_CI_START="-0.2013659774796689" LOG_EFFECT_SIZE="-0.12244604033078627" MODIFIED="2008-10-10 10:03:22 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.09271592348248603" STUDY_ID="STD-Korn-2004" TOTAL_1="91" TOTAL_2="31" VAR="0.008596242467210205" WEIGHT="27.280815161156138"/>
<DICH_DATA CI_END="0.9055651013464047" CI_START="0.5009894698194776" EFFECT_SIZE="0.6735566642908054" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="46" LOG_CI_END="-0.043080322667205115" LOG_CI_START="-0.3001714023709888" LOG_EFFECT_SIZE="-0.17162586251909698" MODIFIED="2008-10-10 10:03:22 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.15101657283937167" STUDY_ID="STD-Litkowski-2005" TOTAL_1="61" TOTAL_2="63" VAR="0.022806005272149252" WEIGHT="29.55859122825272"/>
<DICH_DATA CI_END="0.9654861644573852" CI_START="0.7310905635358701" EFFECT_SIZE="0.840153452685422" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="68" LOG_CI_END="-0.015253945336543251" LOG_CI_START="-0.13602882166359126" LOG_EFFECT_SIZE="-0.07564138350006724" MODIFIED="2008-10-10 10:03:22 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.07094376019978775" STUDY_ID="STD-Reines-1994" TOTAL_1="69" TOTAL_2="73" VAR="0.005033017111284989" WEIGHT="43.160593610591135"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.951679500711261" CI_END="2.064521628684793" CI_START="1.1825267410057791" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.562482650561142" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.31481943706262355" LOG_CI_START="0.0728109704161402" LOG_EFFECT_SIZE="0.19381520373938188" METHOD="MH" MODIFIED="2008-12-18 14:26:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.37687582828004285" P_Q="1.0" P_Z="0.0016934132546431978" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="167" WEIGHT="100.0" Z="3.139318423436664">
<NAME>Participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.986571728595874" CI_START="0.9037698677206626" EFFECT_SIZE="1.3399267399267398" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="15" LOG_CI_END="0.2981042506252048" LOG_CI_START="-0.04394214242592082" LOG_EFFECT_SIZE="0.127081054099642" MODIFIED="2008-10-10 10:07:18 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.20091974443518368" STUDY_ID="STD-Korn-2004" TOTAL_1="91" TOTAL_2="31" VAR="0.04036874370389952" WEIGHT="44.18462251628651"/>
<DICH_DATA CI_END="5.619734433257881" CI_START="1.119456954329882" EFFECT_SIZE="2.5081967213114753" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.7497157929897448" LOG_CI_START="0.04900739862391869" LOG_EFFECT_SIZE="0.3993615958068317" MODIFIED="2008-10-10 10:07:18 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.4115995794129786" STUDY_ID="STD-Litkowski-2005" TOTAL_1="61" TOTAL_2="63" VAR="0.16941421377294089" WEIGHT="13.598923108610595"/>
<DICH_DATA CI_END="2.305864431538879" CI_START="0.9638108133748021" EFFECT_SIZE="1.4907773386034255" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" LOG_CI_END="0.36283377027641" LOG_CI_START="-0.016008205485875903" LOG_EFFECT_SIZE="0.17341278239526703" MODIFIED="2008-10-10 10:07:18 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.22253365186079113" STUDY_ID="STD-Reines-1994" TOTAL_1="69" TOTAL_2="73" VAR="0.049521226210499786" WEIGHT="42.216454375102906"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-12-19 11:37:24 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Oxycodone 10 mg plus paracetamol 650 mg</NAME>
<DICH_OUTCOME CHI2="30.100524573629755" CI_END="5.1873122220433325" CI_START="2.928829971391826" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="3.897788540555739" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="48" I2="70.10018885888569" I2_Q="89.7464760572204" ID="CMP-005.01" LOG_CI_END="0.7149423887743301" LOG_CI_START="0.46669416013169807" LOG_EFFECT_SIZE="0.590818274453014" METHOD="MH" MODIFIED="2008-12-19 11:37:24 +0000" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;check malmstrom 2006 data&lt;/p&gt;" NOTES_MODIFIED="2008-12-19 11:37:24 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="4.217728949389432E-4" P_Q="0.0017905573076970605" P_Z="1.0664177179810464E-20" Q="9.752744574261094" RANDOM="NO" SCALE="53.792869566343235" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="680" TOTAL_2="363" WEIGHT="99.99999999999999" Z="9.329231033531304">
<NAME>Participants with at least 50% pain relief over 4-6 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxycod+paracet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5971126394451072" CI_END="11.661990581023247" CI_START="3.9387863315510754" DF="5" EFFECT_SIZE="6.7774692252500675" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="11" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="1.066772686320896" LOG_CI_START="0.5953624221533361" LOG_EFFECT_SIZE="0.831067554237116" MODIFIED="2008-10-10 15:06:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9015983422806545" P_Z="4.826284568705051E-12" STUDIES="6" TAU2="0.0" TOTAL_1="496" TOTAL_2="177" WEIGHT="32.51118232320562" Z="6.9105940147521565">
<NAME>Dental</NAME>
<DICH_DATA CI_END="13.682113711038411" CI_START="1.5916968852705837" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="3" LOG_CI_END="1.1361531954929527" LOG_CI_START="0.20186036642419872" LOG_EFFECT_SIZE="0.6690067809585756" MODIFIED="2008-10-10 11:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.5488082326190782" STUDY_ID="STD-Chang-2004a" TOTAL_1="100" TOTAL_2="25" VAR="0.3011904761904762" WEIGHT="8.66384291512385"/>
<DICH_DATA CI_END="29.42532573531206" CI_START="1.9758702256345095" EFFECT_SIZE="7.625" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="2" LOG_CI_END="1.4687212791370725" LOG_CI_START="0.2957584169005743" LOG_EFFECT_SIZE="0.8822398480188235" MODIFIED="2008-10-10 11:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.6890041915375292" STUDY_ID="STD-Chang-2004b" TOTAL_1="120" TOTAL_2="30" VAR="0.4747267759562842" WEIGHT="5.7758952767492335"/>
<DICH_DATA CI_END="17.442036613399093" CI_START="1.9968623918028332" EFFECT_SIZE="5.901639344262295" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="3" LOG_CI_END="1.2415971938029935" LOG_CI_START="0.30034813771004704" LOG_EFFECT_SIZE="0.7709726657565202" MODIFIED="2008-10-10 11:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.552894354806968" STUDY_ID="STD-Desjardins-2007" TOTAL_1="122" TOTAL_2="30" VAR="0.30569216757741347" WEIGHT="8.692342398397283"/>
<DICH_DATA CI_END="449.18281790240314" CI_START="1.7227979540338536" EFFECT_SIZE="27.818181818181817" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.652423135316732" LOG_CI_START="0.2362343473299779" LOG_EFFECT_SIZE="1.444328741323355" MODIFIED="2008-10-10 11:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="1.4192812543908135" STUDY_ID="STD-Fricke-1997" TOTAL_1="32" TOTAL_2="33" VAR="2.0143592790651614" WEIGHT="0.8890137319623352"/>
<DICH_DATA CI_END="22.50512569912413" CI_START="2.402374670884013" EFFECT_SIZE="7.352941176470588" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="3" LOG_CI_END="1.352281442970278" LOG_CI_START="0.3806407402892869" LOG_EFFECT_SIZE="0.8664610916297825" MODIFIED="2008-10-10 11:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.5707465584538622" STUDY_ID="STD-Malmstrom-2005" TOTAL_1="102" TOTAL_2="50" VAR="0.325751633986928" WEIGHT="7.2673682347255975"/>
<DICH_DATA CI_END="85.74377437030512" CI_START="0.3199957305921706" EFFECT_SIZE="5.238095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9332025968806763" LOG_CI_START="-0.49485581603206447" LOG_EFFECT_SIZE="0.7191733904243057" MODIFIED="2008-10-10 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.426253530827929" STUDY_ID="STD-Malmstrom-2006" TOTAL_1="20" TOTAL_2="9" VAR="2.034199134199134" WEIGHT="1.2227197662473175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.766021245975962" CI_END="3.4108147457183895" CI_START="1.8479325028631135" DF="3" EFFECT_SIZE="2.510568746291923" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="37" I2="69.28124643148678" ID="CMP-005.01.02" LOG_CI_END="0.5328581318679312" LOG_CI_START="0.2666861042382876" LOG_EFFECT_SIZE="0.39977211805310947" MODIFIED="2008-10-10 11:47:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.020663447221281328" P_Z="3.9216944208149245E-9" STUDIES="4" TAU2="0.0" TOTAL_1="184" TOTAL_2="186" WEIGHT="67.48881767679437" Z="5.887462784012896">
<NAME>Other surgery</NAME>
<DICH_DATA CI_END="3.888341008113186" CI_START="1.0729572152643698" EFFECT_SIZE="2.0425531914893615" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5897643456183175" LOG_CI_START="0.030582404589384424" LOG_EFFECT_SIZE="0.3101733751038509" MODIFIED="2008-10-10 11:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.32846624015564496" STUDY_ID="STD-Johnson-1997" TOTAL_1="47" TOTAL_2="48" VAR="0.10789007092198584" WEIGHT="17.85967618468513"/>
<DICH_DATA CI_END="641.9413187580328" CI_START="2.4490127898942418" EFFECT_SIZE="39.65" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.807495330086986" LOG_CI_START="0.3889910532202588" LOG_EFFECT_SIZE="1.5982431916536226" MODIFIED="2008-10-10 11:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.4206413840207648" STUDY_ID="STD-Palangio-2000" TOTAL_1="59" TOTAL_2="60" VAR="2.018221941992434" WEIGHT="0.8950250945375878"/>
<DICH_DATA CI_END="2.3344253035865106" CI_START="0.9638346519561782" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.3681799820324281" LOG_CI_START="-0.015997463921065595" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-10-10 11:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.22566773346211003" STUDY_ID="STD-Sunshine-1993" TOTAL_1="48" TOTAL_2="48" VAR="0.05092592592592593" WEIGHT="32.48941093171444"/>
<DICH_DATA CI_END="5.249239711571791" CI_START="1.7145340076887272" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.720096405695518" LOG_CI_START="0.2341461037438069" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-10-10 11:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.2854496128592251" STUDY_ID="STD-Sunshine-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.08148148148148149" WEIGHT="16.24470546585722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.117715130097242" CI_END="0.8667883880919236" CI_START="0.7063126742043367" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7824472022842647" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="144" I2="81.05855687815796" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.062086915327970595" LOG_CI_START="-0.15100300061897245" LOG_EFFECT_SIZE="-0.10654495797347154" METHOD="MH" MODIFIED="2008-12-18 14:26:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.0009746960668604E-4" P_Q="1.0" P_Z="2.6386941805109217E-6" Q="0.0" RANDOM="NO" SCALE="10.13876326724968" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="352" TOTAL_2="174" WEIGHT="100.0" Z="4.697109182863915">
<NAME>Participants using rescue medication within 6 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7993749785156438" CI_START="0.4056506445958216" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="18" LOG_CI_END="-0.09724944984956169" LOG_CI_START="-0.3918478295735043" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2008-10-10 11:49:38 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.17304854653534243" STUDY_ID="STD-Chang-2004a" TOTAL_1="100" TOTAL_2="25" VAR="0.029945799457994575" WEIGHT="16.74904272001168"/>
<DICH_DATA CI_END="0.7038140781389198" CI_START="0.375608317011518" EFFECT_SIZE="0.5141579731743666" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="22" LOG_CI_END="-0.15254205037820806" LOG_CI_START="-0.42526479981322785" LOG_EFFECT_SIZE="-0.2889034250957179" MODIFIED="2008-10-10 11:49:38 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.16019869301751286" STUDY_ID="STD-Desjardins-2007" TOTAL_1="122" TOTAL_2="30" VAR="0.02566362124451932" WEIGHT="20.538391200891514"/>
<DICH_DATA CI_END="1.06902077967656" CI_START="0.7619577554929691" EFFECT_SIZE="0.9025235032162295" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="43" LOG_CI_END="0.028986147127539368" LOG_CI_START="-0.11806910617335263" LOG_EFFECT_SIZE="-0.044541479522906643" MODIFIED="2008-10-10 11:49:38 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.0863809837241878" STUDY_ID="STD-Johnson-1997" TOTAL_1="47" TOTAL_2="48" VAR="0.007461674349158398" WEIGHT="24.7440170593155"/>
<DICH_DATA CI_END="1.0401628688868247" CI_START="0.5803316407761082" EFFECT_SIZE="0.7769423558897243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.01710134653035266" LOG_CI_START="-0.23632375023530383" LOG_EFFECT_SIZE="-0.10961120185247557" MODIFIED="2008-10-10 11:49:38 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.14886315631460753" STUDY_ID="STD-Malmstrom-2006" TOTAL_1="20" TOTAL_2="9" VAR="0.022160239307947277" WEIGHT="7.485291269360058"/>
<DICH_DATA CI_END="1.1520279624231653" CI_START="0.8406965390403602" EFFECT_SIZE="0.9841269841269841" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="52" LOG_CI_END="0.06146302056175864" LOG_CI_START="-0.07536074047241431" LOG_EFFECT_SIZE="-0.006948859955327855" MODIFIED="2008-10-10 11:49:38 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.08037095452001349" STUDY_ID="STD-Sunshine-1996" TOTAL_1="63" TOTAL_2="62" VAR="0.006459490330458076" WEIGHT="30.483257750421252"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9412925093497784" CI_END="1.0603405592304895" CI_START="0.9005787129954016" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9772001515393961" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.02544537398207585" LOG_CI_START="-0.04547832268276021" LOG_EFFECT_SIZE="-0.01001647435034217" METHOD="MH" MODIFIED="2008-12-18 14:26:24 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.37883821799781814" P_Q="1.0" P_Z="0.5798478077391908" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="154" TOTAL_2="156" WEIGHT="100.0" Z="0.5536070425520666">
<NAME>Participants using rescue medication within 8 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1630987826214192" CI_START="0.8967474651336949" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.06561660116485997" LOG_CI_START="-0.047329842285120556" LOG_EFFECT_SIZE="0.009143379439869719" MODIFIED="2008-10-10 11:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.06634529997643059" STUDY_ID="STD-Johnson-1997" TOTAL_1="47" TOTAL_2="48" VAR="0.004401698828962561" WEIGHT="30.932884365194766"/>
<DICH_DATA CI_END="1.0058612818265529" CI_START="0.8647574153989909" EFFECT_SIZE="0.9326446280991736" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="60" LOG_CI_END="0.002538091364804986" LOG_CI_START="-0.06310570517014345" LOG_EFFECT_SIZE="-0.03028380690266923" MODIFIED="2008-10-10 11:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.038559491026662146" STUDY_ID="STD-Palangio-2000" TOTAL_1="59" TOTAL_2="60" VAR="0.0014868343482352386" WEIGHT="43.621336190403305"/>
<DICH_DATA CI_END="1.2761223447673098" CI_START="0.7836239245401988" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="0.10589231318626292" LOG_CI_START="-0.10589231318626295" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-10 11:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.12440333788202981" STUDY_ID="STD-Sunshine-1993" TOTAL_1="48" TOTAL_2="48" VAR="0.015476190476190473" WEIGHT="25.44577944440193"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.40575772014667" CI_END="2.2581488043145197" CI_START="1.4314220670668028" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7978776457858079" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="61" I2="56.1624915881897" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.35375255705898995" LOG_CI_START="0.1557677080934275" LOG_EFFECT_SIZE="0.2547601325762087" METHOD="MH" MODIFIED="2008-12-18 14:26:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.04390286040162883" P_Q="1.0" P_Z="4.5582957433880044E-7" Q="0.0" RANDOM="NO" SCALE="10.13876326724968" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="343" TOTAL_2="209" WEIGHT="99.99999999999999" Z="5.044029249257053">
<NAME>Participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.009489758338759" CI_START="1.456319332097574" EFFECT_SIZE="2.9583333333333335" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="6" LOG_CI_END="0.7788375993662962" LOG_CI_START="0.1632566146486425" LOG_EFFECT_SIZE="0.47104710700746927" MODIFIED="2008-10-10 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.36159531759816826" STUDY_ID="STD-Chang-2004a" TOTAL_1="100" TOTAL_2="25" VAR="0.13075117370892017" WEIGHT="13.147630163466228"/>
<DICH_DATA CI_END="4.060812460218327" CI_START="1.4631077667843255" EFFECT_SIZE="2.4375" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="11" LOG_CI_END="0.6086129330081294" LOG_CI_START="0.1652763157330194" LOG_EFFECT_SIZE="0.3869446243705744" MODIFIED="2008-10-10 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.2604181235390484" STUDY_ID="STD-Fricke-1997" TOTAL_1="32" TOTAL_2="33" VAR="0.06781759906759907" WEIGHT="14.83322377416703"/>
<DICH_DATA CI_END="2.424997460397884" CI_START="1.1242971844981209" EFFECT_SIZE="1.6511867905056758" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="19" LOG_CI_END="0.38471128811941124" LOG_CI_START="0.05088112309090757" LOG_EFFECT_SIZE="0.21779620560515942" MODIFIED="2008-10-10 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.19609349142371088" STUDY_ID="STD-Malmstrom-2005" TOTAL_1="102" TOTAL_2="50" VAR="0.03845265737874097" WEIGHT="34.92339262170717"/>
<DICH_DATA CI_END="1.4723367690852776" CI_START="0.4989985260012664" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.16800715798204063" LOG_CI_START="-0.30190073724326705" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-10-10 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.27602622373694163" STUDY_ID="STD-Malmstrom-2006" TOTAL_1="20" TOTAL_2="10" VAR="0.07619047619047617" WEIGHT="12.782418214481057"/>
<DICH_DATA CI_END="3.3216677574766336" CI_START="0.4237755203434324" EFFECT_SIZE="1.1864406779661016" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5213561909358119" LOG_CI_START="-0.3728641341915867" LOG_EFFECT_SIZE="0.07424602837211262" MODIFIED="2008-10-10 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.5252694454418323" STUDY_ID="STD-Palangio-2000" TOTAL_1="59" TOTAL_2="60" VAR="0.27590799031477" WEIGHT="8.148216172736424"/>
<DICH_DATA CI_END="2.75181730368413" CI_START="0.9727606423280564" EFFECT_SIZE="1.636111111111111" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.4396195972104003" LOG_CI_START="-0.011994009170771607" LOG_EFFECT_SIZE="0.21381279401981437" MODIFIED="2008-10-10 11:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.26528006791170605" STUDY_ID="STD-Sunshine-1996" TOTAL_1="30" TOTAL_2="31" VAR="0.07037351443123938" WEIGHT="16.165119053442087"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-12-19 11:54:49 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Oxycodone 10 mg plus paracetamol 1000 mg</NAME>
<DICH_OUTCOME CHI2="10.672024005755219" CI_END="7.563229190989055" CI_START="3.2325557979760577" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.9445485509552265" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="19" I2="81.25941247019836" I2_Q="100.0" ID="CMP-006.01" LOG_CI_END="0.8787072611621657" LOG_CI_START="0.509546030085752" LOG_EFFECT_SIZE="0.6941266456239588" METHOD="MH" MODIFIED="2008-10-10 15:25:28 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;NB Cooper data highlighted&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 15:25:28 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.004815047520853266" P_Q="0.0" P_Z="1.6990776864783022E-13" Q="1.0485112044365476E-30" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="142" WEIGHT="100.00000000000001" Z="7.3705639249585815">
<NAME>Participants with at least 50% pain relief over 4 to 6 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxycod+paracet</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9491437866942434" CI_START="1.34306291772569" EFFECT_SIZE="2.303030303030303" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="11" LOG_CI_END="0.5965029465071329" LOG_CI_START="0.12809635829867494" LOG_EFFECT_SIZE="0.3622996524029039" MODIFIED="2008-10-10 11:43:03 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.2751443485636545" STUDY_ID="STD-Cooper-1980" TOTAL_1="45" TOTAL_2="38" VAR="0.0757044125465178" WEIGHT="60.089099459039005"/>
<DICH_DATA CI_END="32.30278265154444" CI_START="3.4364282296127517" EFFECT_SIZE="10.5359477124183" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" LOG_CI_END="1.5092399352771697" LOG_CI_START="0.5361072780257761" LOG_EFFECT_SIZE="1.022673606651473" MODIFIED="2008-10-10 15:23:24 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.5716229399538111" STUDY_ID="STD-Daniels-2002" TOTAL_1="51" TOTAL_2="52" VAR="0.32675278548143827" WEIGHT="14.966587702860377">
<FOOTNOTE>Daniels 2002 Study B</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="18.55335973729099" CI_START="3.409046892422112" EFFECT_SIZE="7.952941176470588" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="5" LOG_CI_END="1.2684225653389951" LOG_CI_START="0.5326329751156913" LOG_EFFECT_SIZE="0.9005277702273432" MODIFIED="2008-10-10 15:23:50 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.43220644751438114" STUDY_ID="STD-Daniels-2002" TOTAL_1="51" TOTAL_2="52" VAR="0.1868024132730015" WEIGHT="24.944312838100625">
<FOOTNOTE>Daniels 2002 Study A</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6311928702523693" CI_END="0.8895225345799285" CI_START="0.6530912555588689" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7621938001300672" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="90" I2="72.46084039786905" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.05084304530939882" LOG_CI_START="-0.18502613110366595" LOG_EFFECT_SIZE="-0.1179345882065324" METHOD="MH" MODIFIED="2008-12-19 11:54:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05670634875512248" P_Q="1.0" P_Z="5.705186393175467E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="103" WEIGHT="99.99999999999999" Z="3.4452560700648514">
<NAME>Participants using rescue medication within 24 hours</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0307029049855163" CI_START="0.733619419950516" EFFECT_SIZE="0.8695652173913043" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="46" LOG_CI_END="0.013133500085395789" LOG_CI_START="-0.1345291807926192" LOG_EFFECT_SIZE="-0.0606978403536117" MODIFIED="2008-12-19 11:15:44 +0000" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.08673778968980479" STUDY_ID="STD-Daniels-2002" TOTAL_1="51" TOTAL_2="51" VAR="0.007523444160272806" WEIGHT="51.35486668111857">
<FOOTNOTE>(2) Daniels 2002 Study B</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8537204687925918" CI_START="0.49312991662845496" EFFECT_SIZE="0.6488413547237076" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="44" LOG_CI_END="-0.06868430581376557" LOG_CI_START="-0.30703864940044523" LOG_EFFECT_SIZE="-0.18786147760710545" MODIFIED="2008-12-19 11:14:24 +0000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.14001052129584515" STUDY_ID="STD-Daniels-2002" TOTAL_1="51" TOTAL_2="52" VAR="0.019602946073534307" WEIGHT="48.64513331888141">
<FOOTNOTE>(1) Daniels 2002 Study A</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.022111867654399" CI_END="1.9939277128657165" CI_START="1.2818072995198226" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5986966870129369" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="61" I2="88.91612058607755" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.29970940950592945" LOG_CI_START="0.10782274043587212" LOG_EFFECT_SIZE="0.20376607497090077" METHOD="MH" MODIFIED="2008-12-19 11:09:17 +0000" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;NB Cooper data highlighted&lt;/p&gt;" NOTES_MODIFIED="2008-12-19 11:09:17 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.002667362735792933" P_Q="1.0" P_Z="3.146378952204691E-5" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="141" WEIGHT="100.0" Z="4.162604626465674">
<NAME>Participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Oxycod+Paracet</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxycod+paracet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.776958832675946" CI_START="1.8979798585425716" EFFECT_SIZE="4.0814814814814815" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="0.9433440613526486" LOG_CI_START="0.27829159936090925" LOG_EFFECT_SIZE="0.610817830356779" MODIFIED="2008-10-10 11:41:17 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.3906551082367282" STUDY_ID="STD-Cooper-1980" TOTAL_1="45" TOTAL_2="38" VAR="0.15261141359144986" WEIGHT="10.624208222964413"/>
<DICH_DATA CI_END="1.6265248947952007" CI_START="1.0447315484182205" EFFECT_SIZE="1.3035650623885917" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="55" LOG_CI_END="0.2112607147678535" LOG_CI_START="0.019004709568318668" LOG_EFFECT_SIZE="0.11513271216808606" MODIFIED="2008-10-10 15:26:24 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.11293212913678102" STUDY_ID="STD-Daniels-2002" TOTAL_1="102" TOTAL_2="103" VAR="0.012753665791366584" WEIGHT="89.37579177703559">
<FOOTNOTE>Daniels 2002 Studies A and B combined</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-12-19 11:37:25 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-10-10 15:33:09 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Oxycodone 5 mg plus paracetamol 325 mg, outcome: 4.1 Participants with at least 50% pain relief over 4 to 6 hours.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzcAAACwCAMAAAAFUmAVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-12-19 11:37:25 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-005.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Oxycodone 10 mg plus paracetamol 650 mg, outcome: 2.1 Participants with at least 50% pain relief over 4-6 hours.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzcAAAHQCAMAAACr0WT7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-12-18 14:29:06 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-006.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Oxycodone 10 mg plus paracetamol 1000 mg, outcome: 6.1 Participants with at least 50% pain relief over 4 to 6 hours.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzAAAADwCAMAAADo1nEAAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-12-18 14:29:06 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-005.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Oxycodone 10 mg plus paracetamol 650 mg, outcome: 2.3 Participants using rescue medication within 6 hours.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzAAAADQCAMAAADvenQ2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAlNElEQVR42u19C3Acx3nmj8fM7AME2AvAIhVRAghESdmxLuYLL8KK
QdoKzTiqc6TcVeWs6FxXsq78UK7CS3zOpeRHqmTF56tynR2f5VRRis++yKF8smJasiKijgYWFNcU
nNKdXScVQFCSSUgCMANAWCx2B4/rnumdnZmd2Z1ZzC5myf8jsfPo19+Pr/vvmf6nGwggEAivaMQi
QCCQMAgEEgaBQMJwdMZEMd5Z1tvISOFsRBI/o5aPuSNaNs4RUWxRTXG7pVkTaOJExy1ZtboZmR6L
1Vy6IPKmlsjbeMjzFhbCqEuQfnNzedZPmNFs7P96eGZxx0D5mHKxIyF6+jGaWxo4DqOjbm678hcP
94OLt9BCl989b8dDnrewEIYcjQiJ54f2dIoRkKPCiREVUiNR+ZQkRlMAW5LYSkkVk4i1V7oMOeiM
i2Kkg95riernYyBvRcT4LMitotQqC9R/+fRZTBSpmCjEMsDTlVm6Mr3ddoL16q2S2Faj4ojCJsvl
GM0Pyz/Ne+SBlMlNl1NkWWOFoZdPncAhb1L95C00IwxMAbwHPjEXGXxh/0BsAs7Dh0Donoy/NnAn
tB07Gz/UBs39sQ17uAZYkXKvDb5DT+euwso8PT8OXcei6b790H0oHj/URVu6p36qgf3cuZBb7SfA
0+06Fls61E1vb7048DfQduhs/ODu2hTHGDSxwwf73mRy0OLZdd83jpjcdDlzPGu8fOoEDnlbcc9b
a8jyFhbCbEIC6P/H4YWJk6vSzI/gbsqhhTWY2juagUNwYBrWQILpK3x80ccYuRuaIdPY+nHYoleZ
BGT2aeeHYVqgwdZgegqGPCUvd4HAjplLp1phA3i6NJ4MZOntK9PwDD1pnYZMbTT9h188r5fKzc+d
YUnuGhwQzG5cTg5ePnUyiynO25kSeTscsrw1RcMhh3DrS4+C/P3XN77d0nfrxS+evrZx4dvXNu+E
B5nj1VsffLT7jQ169Wg3zMzMdMPoDHRD92c2Pv34o+S3f/X2TbfSe9Sr+Ryg+dbvfx/Ob9AgpdOm
MX16883Rb1OPL3zp6fhNt80Y6dIIXqMR0HTHNxpu+xyToupFQXP3d19q+iuW1ZW3h17+k11r3fDa
r55Vuds7r1I3LifLGv3j5VMHdMnLT4X+278x8rahmvPtkLfXw5O3sIwwAvQC/IL24nJGSmZVEI5+
YJjdk3UhZXZM6gfTHDH7UALS8Pqr+Tsr+vkEcH9nRkdznmaialbXCk7CG6/Qg5Euj4Cm2wDH9UMt
MNzS36Wp9G/+87nBVaaYSP1j3G2euXE5jUq0FkyoMc/z9m9NecuY8+2QtwZAwtigjGdU+YPJN+HJ
oRdjQ80gQh9VwZ6E3tmRKL2Y7IEIve7p0tv3qCUHuyaN8RJ+g52L0KPSYBHoYaF7wU9ryvbQHyPd
/epIjHV+PZTRSV2K2hTHhQzrdWP3NK1rrWV+fuwuq5smZ1LPmlhDyQLM27NyPm/t9ZO30Iwwow3x
PU2tezv+4YKiSMc630rCxBzMXFrpurgMVy49kn5pCRakdFNxyFgy/lzhfImdX7mUjqeWYeZA+jaq
E58Z3+dZjMVkFxv9jXQPxlNLjIirE6P06mT6pcUalYc4zB4vLP3WUsuL2kNkQervMLlxOePjvwZa
frXyqRfk8zZ8s2Pe4r1hzltDOBdfynDz4NkoIBAhQ0gJE9lsjCxi7SBCh+ZwirUG9fKYFHFjARdf
IhBIGAQCCYNAIGEQiDoljNwiicfiKbv9SAmbhNTWMVGKqx58eseIBkensXglUTC7CicBSyTUESsf
a9wl1hTI4ogoQ2okUuTOz6z5oJHSMs9HrR2MEHqSjlIaN9UWtiabpqf5bZN2A5zib847oqJ4St0Z
qxIqjApjlWcr1aLJrup+d4vfAvgaX+wwdkI81pLaIWMZ01qym1cW3/nlB7643r/PsvaqxFKs7w1/
969XPvC7L5X36R1sndiMczyv3eItfr7YrDiURcASCfU7JeQx1q+sff443PrHwpm9n3ouH9Dm05qP
boCvrD1D28KM4cWIUZMRHKU0/JDDp88c/ETDU3vu/ib12NC6uq6+rLt0LgtX/3LXghpIvfivR1jJ
PL234mz9zyOyAIvZ3O3nrlCP9yXPbcx+5DHNZfbAr65+7uBf7Uy2zCPMn8E6REfXhLwhAv1T4xEC
EB3ppEzXOsxTktQKuu0J69zg3TTEY4X1w5rdSCoW2a11ILFY3oaEexgZOS3FPNhIQmaEdcLxEXJK
lLZkFi4aIRITrCMmeIsCeNqaXQW3k3EYS3hCndTvKZZQIiad1oNEJWcLUM0+Q5NFjYtS1B6rDHth
nP7J8AXdHkcvR2m3VkAd0UhCshvoTMhwbKJkZ90hRUGOiaqsl4ccPVF4fZaB4Wn4MGzA59nV5twG
tEvc5WgkER1N75TyIuUgJ5XMlirEQI5IndzuyLB3YsiBPE1/9oB26wlhC36TR7ZnKJqQR1d3XiVr
hAOs+s32I819MZkt51HhO6yNQNtk7KxmnDB3VRue4H3WBqPZjRzu/9G6drXwRpENyUPxfi9vfqIX
+mZB7Xv35mTLPx3rojf+pGUwk2WCHe5/a1e/N4MiPW3NroLbyRRj/kIfHfb7LmQPnW2ZZJYvG9ND
D2pB/uXASlvfigMLNfsMTZa2Z3MrA9+xi05r+Sv079PQpNvj6OUY/4LmOrfM82HpHj4BkdJmA/PS
wAv7+6NCt14e3xl4cdNUbbSKzsEX4V6JVlbjbKOcu8yVNXh1J7X9sXXYGCvpQ4j1k+7ByBy3O7LY
O93PsrVF+/CMGF+geblfzvJsReCVcMxhlidg4OF4ytJJwNTPAN6k9f8p1lUzC5NWzUAkk2DO5+0h
NLuRCLQqekNoL7IhuTIFkpcpSAS+Cu3w3TWY+i3NFHJmDvQmcg5+beOMN6MUU9rcTsYhIYkm0846
w9Yp7VXpzF7ubxpa1S87JGSyz1j9g9ZWeMLqnBxU18cHxtfVX47PFexxIjCl20krAhSvVE9MdQ4R
s1RWGbVym3hkVZoBXh5/BtMFbUSA3h/Sw18kvxHr3weRruh+sUfU+qghSOwkYYRBdVAona2ZidW1
iZm83RG3d8rTItrLqqJhpaXvNojGD+6XuqUQZMtEGOHa5AT03Wl2PQqJI7TTTK7Prk/MsRGEXbMa
10U+cu0la4hEAsZoyz6ilxP1tAFHLLmjHsou1R6lmJ74b6m15PQW3HNPPr2jmmNLcuB9e70t5zGl
Te7Y/BmPwJbQ5WRWzSYvb8Bn78nLrPubnBg4MOxAmDGWB51T5L2bl+0GagI0HxWPCEebtQ6GSn8O
8uVmid6Mt+m/ObNUVhm1cJGto0mWrlYeQ0yGPF6/mP5kkk4YssI07Y8Xs5czV1bTf6iRF3Z00f8v
YTf9K50taWhIYm2GZmuTtbZCtr6aas0mGyB9TpiiXcRi7t61+Wyr1lGN72i2zI+VE4vXfs47wKSm
mjHZmHDC0V8/KvJxUgaTapNYujZJczoOPA+a6UITyMYko0m/NZb3kPKYV1qSd1INvIEZpFhmLPLs
Px8Y8qa/muxXVkw2M7aEIkO7hyKJJpZQ1uygXPtYaqjNqcCMWNPwetFw2Uz7yWb6L6LZ4ebtcRpK
GqwISXFCKOqErc8jMxPMSoiXh8UwKJHOrm6KXCWmf/ulxJDwhE7e23eSMHuTanJv6Wyp2YlkJpW3
O7JkS1hR01u8dbLi7m0WBue0xinCb4SDMJGRROIZWtfMfqQBZjs0raaX6eA/hiO63vgk9EzChClE
JvGPNMT90NGlP+NgdiMZmDTmKdyaoQk6dQ/He8urZPqjpd6B8RndosV4xst6zNg9jY/AH3uKgtuv
sFDcTsZxepDsE+eZnJ0jxtNe1odF7/mPr4ODNYFYiLXRIVaB9pNzME8HASFvj6Opsr1PmgWzsad5
uMneCdsa2eGh55mVEC8PQTcM0v3ERPWnwyJEpY4osMSyEvTqfYwytiZnRuI71raEo0KZbLUPxs4e
HcnbHUnmbEWlzsTRKMQe6NCbTEaBiVmttUbF/ywnRmI7T5h3LqbFz6f+t2Y/oiQ/zjK7/uLK1xgx
xmFir9aML6VPXioYJ/w09XvC8dQiDCRX9C5OsxtRLnyVAP+8FLMhubQIysQ7P9aTW7m44GUOA4lW
EBMsva6LRnqx5C2wlFqOX/iGp6xx+xVmV8HtZJwSEtZgTIAr504uXTSWR39r/BY4f3H5postTrFq
9hlMlujE0kftznNJkAQQJiD5at4eRyvHdCOMm/NhwX8FwYHuJnQem3i/cuHYOC+P0QurjYafnzTF
Hvm5DOebltsO0JlNR+McHIxrNBXaNva0Xdq5Rd9NDkt7LU8B1EMX5OMXjnRwu6O8vZPmJ964lP6Y
DPHvLr/vHJ3ZjDUJIHVp2Zr7X8/tSdN2ujPwsryfGae8PO85SjF2eeqzF52eZo5AfX1DK7gnrJGZ
XXdd8PMBjc531gLxEzLM7s8E4mfn4IUw0lZjzMc8a+xDGyDE5pyoBLkbkzCJtXVoOn/ER4h4dD4Q
PyFDy7PDgfgJN2EQCAQCES78QV1I2YwjDCIkqIumiMv7EQgkDAKBhEEgkDAIRD3B+i5W0WdeSpnp
V96b5VA+2LahJ+AjGR7AJqe/YOULwcmbLQqFT2oV7Yd4KFwjasWYDyv6FXEvDktYI8/Kzk6nl9lP
63VJGIV4ao7cm/XAG0VV+WL69RPAJqe/YGUKwYVU9ih4+WhilOGLKVlzUP3U7FpcHAVXS56JAohq
EEavf974C30yrWJ+RQq176GDrNYoo1TBq/9gBEqMqqYobOOB7/G0TFAlXGxwWpf8tJtDXS6UanZs
CXrnlO+wjCulfDvz3o9X2JB9xF2hGP6COXYQhaZunCrEN3HyUZciZcjeXYz6dqh/whQqnNirv9Cb
udb69fMelJQdK/MamTsFeK9jjpP+9zqn2EbfQ5TrqSrCTxiLJu5PgaiahqDUuAF4GyuJP1fiwKLK
ovY+E9pptF5XhGkswRI6XSTea0tR9GktqVY96QmEB74aZAUaWZl0wlYcNwgabeO4rXoURy45VSEj
CqnmGFNIIEx8qWKbVeqqOG5Ilcym+eoad/GVok9HuW9rIGuYME1G/Kr1ZfxbC6FkFJY3JVoQUjZZ
xTlqhxhN7C0Ki1OZwOHPHkbB0g+nDlh+RhN+jNTFkzTvGyqF8CEmMiYA3Q5RJcIgWXZct6ywcrDm
qjTpRyAQSBgEAgmDQCBhEIh6mvQrzjPE4mczbos7nOxklACnnYo/s5ZK7WG8+S/pq8iRP2OswB7G
vOqIuFi8FIUt2N/soD2MZghzna2Msb24dKSHY2kTl+ZZZCcToKWMYkrEewDf9jDe/Jf05eBIjJ7G
pz2MqfSIm8VLUdiC/Q3aw1SRMFpRK8Q+RhCTZUy+v9Kr3trHkZL9fIDwbDhpHt6Iz9jJNmQgQRSB
Qsy58F0GNV+sWnSnyeV+XT/nbvbUe9osYyyaWdmeWwlMIVMMzSRIXtWqORG/xcGXt2xDfa0liItK
dp29BWr2VAxWyxii2IuI1LCavK6Od+ysg/Rfmri2sMYSr+DsYRRcLRYawigGMcpbudSqyhS/qlX1
u1TFr5oXoD0MTz9Mhi92tN44hCG2Lk4hJThj/i4DqaJuoFS+mKoaA0yFGlGNjPBxmWyV0OhW0oqN
Iorb9E6pUS1VbgBSJYXMT3tVKusgKnZF1GSEyT/4L7KmMFm5FBm8ENPDf3c7meB4o/j/TAV/G+Ex
pDf/JXNpLQmzbUtg9jDW9O32MDVWl28gNHj7DBkiBEB7mDCqZMiXEDOmpsEQ3if9Dg8AEDsOtIep
ixEGgUAgYRAIJAwCgYRBIEI76Vd8rwpzMDkJ0gTGnJLfbV6sQvqRypvhjVLWHqbwEpQn7tcexrr/
jtkexmLxUlx/5ppQwjztrzejmebtt2KA6pnA2Bt9ZYunDK4oPvyXX4Xt7qtoz5xK9ocpzjBxs3ix
1kYhbH6XEhwYqkkYxbThld3oxbpjjPvKqCq8vCHBcK4m6ZGaFEnRclSn2gjra7S8pAWjmaeqo5hU
nTBW2xer0YvNzTV/4aolw5DGn+FZAL4Uhw1CgluMWlDU3Hka2tfOxKKSsat6//Jl0Wp6UrIHVWxK
QVU6pdoagHjR/V3FcWyp/uxhPJVmJeZBiKrPYco0U74is8pfIq/QAMT3jIeY0yvXv5OSS/mdeiHP
9jCeShPJsmOEKVmLZZqpdTgKWZen+NxgyJvhjeJhNaRSbCvgwx6GbL8fCP/gU29WZo2e25AHZ6XK
zb7CgcmnIQ33r2wnVj7D29YeLvhsK+QjTCkLjzI2LrXYjqTWW554S6ikPYxDN+/fHsaSgpvFi2Uk
UQgawlQNDVisdQO0h6kflQwRkskY6nbhUckQIQfaw+AIg0AgYRAIJAwCgUDCIBAVT/oLq8rN1zYo
3vdM2YYBi3Ps+bfnvj9MVpEc3vyX8mUywalgf5gii5ei/WHK2sPodxSc9leHMKW/COuxRRctbQ7s
679m25LKpfIbbDu+7BYx/uxhii1enHecKWEPw2kVxufKy3X67eXmMr0cUYwtrPLfgyR8m5iCZYxS
ZoOYQHo4vgjLP/d2tHvd3meafb6qVEJrKua4eYzt5lNQD0/ArTuQaWSwdFt8RDd6aOJgGVPuO/bB
qATEl6YUloZSLLUP7nhRf0t3DWGhkOPmMbabdWwPY7N8KTKJcXV3rOOALTYq0fAq7eCD81XJ/jD5
Xsxl/V59Lxqr170wmj23gYqrJtj6rFnr8GiO4s0EqJL9YUrPkoiXmRaaltWGMM6Tfy9dezhrSKki
0f2uevShJAVQmAqSJmA02vpL4jrGKLWp4mDUpACkUoIUR9mZctieQQ7C8xzGSc/Iq2SWrUjsleiw
QUzAWnbF+8P4Dbgde5giwlayP4xTCqX3h3FIDxEw0B6mfoD2MKFTyRDhZkxNgyE8q2SIUALtYXCE
QSCQMAgEEgaBQOBTMkQooH9huR7Wy1iX95eYIZZcduuwSUzwiyQdDUA8BvQlkLeESsZa5FiBPUzp
/WGKtqCxnZuMh9AepkqEUQiUfWZP3FoYVMsMxpZ2Zd9W9ieQl4RKxurg6N8epvT+MEVb0IDl3GyG
g/vDVGuEsVe3ZWsYo3e033dfHhUoXxSyjTiJj4DeE3KNlbjEWWUUKqJi46Eaw7pLTP6S1BNhrOO7
054wtvvum8QEr5KRSkNWwTbZX6xKtb7Ubu6tircmCfsKGesuMfWgOpoJQ2xzGGv5Ew8Dh/mj5IFv
XEKKvzrgecjgygsJMCEjf86fPrClVZk9TN7A2MG/x6VuuFq5miOM4xzGfcugYo/mTWJIlTqjykN6
3ZclCHlsaVViD8ML0mUuZR30Ay8zhNdJv/deirjcqHYt1azL9JaQT3EC2x+m0G1dB2MIe55c14sv
FfeBxHWQqfImMco2+aJUJyEXhazSxP2GKbNNDY4ItZjDWM1hyuwJU3SjWvu45C0/fE9k/QrkLaGS
voqMVSqxhym9P4w1O4rzdxXQLCZw4Jv++gHaw4RXJUOEkjE1DYYop5Ihwg20h8ERBoFAwiAQSBgE
AoGEQSCQMAgEEgaBQMIgEEgYBAIJg0AgkDAIBBIGgUDCIBBIGAQCCYNAIGEQCAQSBrFTaN1CwiAQ
XrH1WhNBwiAQHseXRVhYztQ3YUY05K86YiYH7ZCIgNoiSlsypHSfbdJu2lPwXHdERfGUyvxGQtJz
dMYkMdYBqi5sZ0wUW9RAIo6NmAorJY3YnOP0htwiiVsqqFui1CKzm+opmnwKdovfAvjamFvMBf88
fjUuiXGV34BUyzFWxpa6ajGS52kymeJaXrknU6WGaHyhP/Pdav0RpilqnM7MdMPoTP6q/xbjtBvY
qXzt/2XJ4dNnBj/R8NSeu785MwMNravrarxBb53LwtW/3LWgUr+x7NuPhiFrDRu75N+ZXs/dnnqF
Cru5+drpAwsB1JDaMkDLY2ZmZmnPRRrdk/0wY6FpQx+98eXheWlwMfvn0QXh0KkcvU0a5Kcv/6eG
+5LnNmY/8phb3AX/PP6W/tNPH5xXtUoYhceGP/fDrcWs7vzOTTT52f/eZyR/84qWJj37H/3/5100
r9TTL2+/qM50WyUMw/jylnaYJ2tNhZvdM/VAGAeV7JQktYJIezFQo5IYTfDb+6eaYA2Gp+HDsAGf
Z3c25zagPaK7Zo5GEtHRNDs9O9gTiqyls/M3QQPcBAK7WsvufQWC6NHuauAdet/4IqVPzub83g32
+2G4PAU5+DpMT8Mwu5GDqQMQhSeELfhNyTXugn8e/yYMz8N63jkKB6Ygy53fSVId4I82C4Gf09Ok
2IDovHYmf5TJGMLxpZ3+0r+3fl+u/zlM22Ts7KE2Wtyj0Cpn0wOr+Z4Vpmjzoxk8B1+Ee6WYDI2z
jXLuct711XwE787X6Y7jgd+euEpbz+oDulazP5AZW2qJdyDZKGVi8/M257uvsd9zkEjAFv1HD/u0
NsLO7qPldL+cvezekgz/PH4BMmOF4ryPOef74yFpjqZ2tRB4n54mxVdgrEMjjC5jGOcv9MD+vrev
/gmThelWXkeZfa2fgk2DMAlaf70/pKd/kfxGrH8fRLqi+8V/EHcz1yEwqrIBNkKSuS9PDtIKSa4M
9P0pvRpbhWgAka7oTVBeS1IVovPB99ucH9LK4aje/IfY4XG9fCiegGj84H6pW9rtEnfBP4//9YmT
DyeNEWZKj1VzPpS8YqRmdx2YePiOBhpKziTDqOZsWrqIuicM7eWO8Ca/+44v/UCve40HtP7uTn8y
SdtMVpimisJi9nLmymfSf8hck2AMronQlELiMpUynRXuhm/Stn3s6GSAn7TrHVyjjTX9lLPruF5i
SeNGUi/axdy9a/PZ1jWXSJP2+PcNfuHlIWKLVdPOtqSEc5oUHxg8+/JWM41jaC0Rwja3so9rZND+
57+qf8LQjkmG49rJKnzsFRORZEg8lF3dEgp9w6SUGBKeYFcC3G4E53UarmzKy41ng9TnF7SRoP8O
9sSs2PUYK8QGpsLK9FwXIKUVdm+zMDjnNgQX/PP419kcxpgmNemxas8Wij/BSNNUdVeVzWFEFsd4
KBvdCnsCu0AZ0/jvEvVPmAj0TMIELWoZ7ofbC/N3WgEQE9WfHpUgKnVENfXmIxL06hPpaO+anBmJ
s9NdIfmcZkSa7aW5iYoXe0CCJ2FXNMjYo/D79Hd0dJRN9hyGiskeWmK0eCbhx+xZuwA9dwF7eJhR
YGLWbS5V8M/jb2RzGGMaQiPppbEy5w1dA9OhPzemab5Ld22CTAcLFaXzyXAyZp/WJfxe5gjUP2Fm
LqVPXlqCb43fAgPJf1F4ikHnL/CTptgjP5fhfNNy2wGqHXc0zsHBuNYO536wsaftktaFr8PXQ5G1
XU1dKzQjLcLw6qUr8B+G3hvoC4ktTadww5XUyfS5BZg/t3IypemBCwfS6dQAnUg1CSB1uVG34J/H
f/7i7mMXjYHxhVR65cAC6A/CEnZtjKfJQqXaltmzidIy7jhj4BWh7vji4+v98t7IkreHILlrCUAE
jBFw/7h9RzpTadAdQ8sbsN86payPr/f72O5i7EPeljLEIjK278AhbjW6Pq2Pz5fSNqUtyIUwQy0P
/he4vgmDQFR1DMX9YRCI6w1IGAQCCYNAIGEQCCQMAoGEQSCuf8IoOoxLKD5zRtV36VXy8pkOVUzI
OOL2wwg7TMu+SFg3dOd80eVTqigm8gVRiUqm9eEKay+W3pzfhoID9ePoM+BmbKFHFSmt4EtchI8R
xtxuFELsvbn5In+u+SFV7vdr1owLOVVMBwTC66TfoanSRmQiBqltw1ZwJECEb4Rxm84rJeb5rDOu
cjOmSdSmy+d8RFoi/BJGU7QcRxDiMBhVu4WRWk01FCPnSBqEH5WsaChh44gxj4ESI0719LHqN2JC
CCMnPyAQZUaYvHrFpvMmLcisddk0MM1nDVQybRwDBbAhI3YKaA+DCAnQHgaBuOHmMAgEAgmDQCBh
EAgkDCJYKFX1vp3AT4VVMIt3JAwCUeEIo9jopFRAXHuYvBFL3oNSvKw5f8eesN2ntj5acWW/Hnex
zIV7VoMa88G8Jru8iHylNuJGRKCfQS5+p2NbxUyAFDU1Y+WznS8Oq22K3/IrZicCzkH0e1aDGsuB
mEOVE1ELhYtmkDDWZkhAW5fMX68T4xQUfXWM4cBv5q8Uw3++9ern/L5+dGBZYTE9PyM2ifS3/EG3
U+LARsVlJcH1sd4/vJMYJayCmZtds5u71c7F0iUrYLOIKXTjJN+o7Cs1uSfTwkZwW85JnCVSCtQr
+DLasJVJimtEbrxRCgvHPIhYz6sySaVNpYJmScLie3uBzd6bvfHOaviilCp+4qivEOuReJLfct9I
lZTsN4jfRuE25BFr0sR8lR9JETe2SkaMuXV5DinBjY+B9RQVNWFSvr8pmokVRkwEzmHK6kcODsTn
AKhYpy++Bk6LSubsS6mcP57iQOtlJIx7ay1qkc6WKQoxzQfMp04tmvhVyEyDmO2BFtmWnq547BGu
G5Cqet9OYBJWwSzem52nwCaLGEOn10+5jUyRWm8bLvjBg52M1cDFxFP+rI4U5g1lZu1QIi9sUm9k
oPhQ+iMe9lzokdUroxRvxqumKvXfPC2BPYZWSGWZqEx5IB7lsSdUkT1MmawFqtx7jWx7iSrkhrFH
NmW1FOmL3l9Vmgbx3IpJrerLU0jFeK1n8e57aQx7D15DvngfNpUasPL6o061lR/vfPGVTPVlcvPk
+00/qW5mKo+NbDeRG440NcmwV92plqXvRSYCAREGgWORT1ZWZ/zeIZlwtTKi7kexWsqEhEHU5RRv
p2RCwiCq2TaV600m02NlxXHA8vAE0jE79tWQ9hcXprXBjsOkkS7kF9zbvhVO3Kdyxrpqh8ON9AS5
1JRXIeDlPQxfa+tXjTG93fIc1k+lVCKT3wcRXt7DKMQtmO/n8AopRSAoci/KE7GHLjzYVyo2fDE/
XkcgglHJrLaIfCMY054wYHIFm0uRmSSPxOyYj1fx1reUXxtZ5+o4oo7guj+MxRbRZhoDJXaLsbZJ
i2WN2X7GbIDioJuZVjcqpU0BfK6RMNb5IHEQARGmuHm53rPavhDPbdeRAz5VWNyUAhESwvCu3sd0
zV098vCNf9eJkxfCEfw0ef1DTtQ3YQomh75XGyn2L0j42KPM2c7FA3dwlNkeRthPkF8C9/tZ8T/a
vjQuSQb/gfNm17mxp2ZIlCIjMKXkcFH80E0hxXTyxwLkyzax05/Nz4ZKmtJodCKBth6ZHwwCEMsy
ZfOV6ZzYljJbAhUi1uPlXyxz/pyYlXuFeFxXJXMvij0Dtux40/luRHRGRSkBkVlQo5CKidGU3tvT
v5G2E5ARpGiH5k93i2cg0xJJgRphAU8DqC1iXKXqVVQihZFiJCGxeMZiYmS3Hk9HRKKp0DQKYUZ0
v1bo/k6o0HkC5JgUk03SRGBMFCO6NDQF5mbIT/1LGRpzXGhRtZssfS5b8IThbZKQwoEYK3n5dd5r
wcHswnfvKuh1eSdijtjwqN0j/H6RKKb0LF6cW3tBCksGbAccj9zwr+K5eBoy74Z3CXA4koscLjg1
fRceask+/1HtQnebapfbX5OW4bwEmX9s+/dUVxFyP6T6ypPR2Q1TpOuzLJ4P/SQXzejxrPxTdvEe
WgtamHYl92w7HVIcBhXdX/JdsD4Bt0rZyHdM0lyDYy05ZUW/WpiNPGmSHzJ/2voQjfl1VWxng9fV
+GFDtiqNMCFHEOb0OMBYNf0R1nl/fR7kIXhchZwEkSmYjhQ8TCXge+rYex7TLnS3vY37mtuFu+GZ
H0HuwNwavT0NrTTImanEghYlaJEuJFg8mWFQhvR41oYhOgU8TFaA92edpdH9nc2BKkDfNEw9Y5FG
ePh0Zo1TMjF1RjvR5WcxUzn/dTvIWS39+YgumxRMWeEOZAg+M1Y71c2BUfnmNToYsFuCqh3oHzuo
JNu4az7vnbp1Lr6VgAe+vHc2oYdnv2KO/dcjNH6o39QHNzYGeDydX/gsP9WVrPGcdWpuSMP8yXuz
J57NR22WZrfacGWvKVl60OU3xZzMmvMhZW/QEQZRJbRtzbcAJJpIE21rMsh605C5q7DyVkxXgrjb
22I3wN8TIQHjmh/6y46NshFEa/cg0+je3yAu51PZPLCsR8LCjI6O5lyk0fwlhN1jeooNVmnSb0Y/
bqTQYJKfS5OkMTOGdGjpM9m2AAmDCBLr8xnWxMT3zdEGGYUeqvKMZ+S8BhLJJJ7RJyfCL5jbbOyN
3AK8FXmahpjspGpPNgqTNHymB7pMD7vaoUcE2BKm8lOIf7PwHja3EPQwKvw0BjAmF0uT93eASvPX
UegVaDoJuYu7fmosMXuOPx2A3jWL/D3qA3Q8WQBCY4YM/IKmn+3VZEPCIALE0q57WWt4e5xOz0fb
pSydKy617Xmcu+4iIleWlLuY268/n4jeBpmhVoDoV5ep3/UO4e51gJ/lpB+Y25eUuwIQP7TnMX5j
YNdelgoPs1t8JE5b955iabi/t5NUmoF2cY2mnUrvaeKuf/9BqW2JTyrE7M/M8iuZT36Mzl1uEzOM
MLETv0vTX8+KTDacwyB2GLM9q16mR9WfgNUMSBjENiDF5dLu2WpLIOaQMAhEaIFzGAQCCYNAIGEQ
CCQMAoGEQSCQMAgEAgmDQCBhEIjq4P8DepZD9mJQnQwAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-12-18 14:29:05 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-005.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Oxycodone 10 mg plus paracetamol 650 mg, outcome: 2.2 Participants with at least one adverse event.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzAAAADgCAMAAADrAHObAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-12-03 09:37:07 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-05-13 10:48:45 +0100" MODIFIED_BY="Jessica R Thomas">
<APPENDIX ID="APP-01" MODIFIED="2009-05-13 10:48:45 +0100" MODIFIED_BY="Jessica R Thomas" NO="1">
<TITLE MODIFIED="2008-08-01 13:41:05 +0100" MODIFIED_BY="Sheena Derry">Search strategy for MEDLINE via Ovid</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-13 10:48:45 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. Oxycodone.sh.<BR/>2. (oxycodone OR OxyNorm OR OxyContin OR Percocet).ti,ab,kw.<BR/>3. OR/1-2<BR/>4. pain, postoperative.sh.<BR/>5. ((postoperative adj4 pain$) or (post-operative adj4 pain$) or post-operative-pain$ or (post$ NEAR pain$) or (postoperative adj4 analgesi$) or (post-operative adj4 analgesi$) or ("post-operative analgesi$")).ti,ab,kw.<BR/>6. ((post-surgical adj4 pain$) or ("post surgical" adj4 pain$) or (post-surgery adj4 pain$)).ti,ab,kw.<BR/>7. (("pain-relief after surg$") or ("pain following surg$") or ("pain control after")).ti,ab,kw.<BR/>8. (("post surg$" or post-surg$) AND (pain$ or discomfort)).ti,ab,kw.<BR/>9. ((pain$ adj4 "after surg$") or (pain$ adj4 "after operat$") or (pain$ adj4 "follow$ operat$") or (pain$ adj4 "follow$ surg$")).ti,ab,kw.<BR/>10. ((analgesi$ adj4 "after surg$") or (analgesi$ adj4 "after operat$") or (analgesi$ adj4 "follow$ operat$") or (analgesi$ adj4 "follow$ surg$")).ti,ab,kw.<BR/>11. OR/4-10<BR/>12. randomized controlled trial.pt.<BR/>13. controlled clinical trial.pt.<BR/>14. randomized.ab.<BR/>15. placebo.ab.<BR/>16. drug therapy.fs.<BR/>17. randomly.ab.<BR/>18. trial.ab.<BR/>19. groups.ab.<BR/>20. OR/12-19<BR/>21. humans.sh.<BR/>22. 20 AND 21<BR/>23. 3 AND 11 AND 22</P>
<P>For the earlier review the following brand names were also searched:</P>
<P>endone, proladone, supeudol, eukadol, roxicodone, percodan, endocet, endodan, oxycocet, oxyxodan, percocet, roxilox, roxiprin, tylox (<LINK REF="REF-Reynolds-1993" TYPE="REFERENCE">Reynolds 1993</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-05-13 10:48:11 +0100" MODIFIED_BY="Jessica R Thomas" NO="2">
<TITLE MODIFIED="2008-08-01 13:43:58 +0100" MODIFIED_BY="Sheena Derry">Search strategy for EMBASE via Ovid</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-13 10:48:11 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. oxycodone.sh.<BR/>2. (oxycodone OR OxyNorm OR OxyContin OR Percocet).ti,ab,kw.<BR/>3. OR/1-2<BR/>4. postoperative pain.sh.<BR/>5. ((postoperative adj4 pain$) or (post-operative adj4 pain$) or post-operative-pain$ or (post$ NEAR pain$) or (postoperative adj4 analgesi$) or (post-operative adj4 analgesi$) or ("post-operative analgesi$")).ti,ab,kw.<BR/>6. ((post-surgical adj4 pain$) or ("post surgical" adj4 pain$) or (post-surgery adj4 pain$)).ti,ab,kw.<BR/>7. (("pain-relief after surg$") or ("pain following surg$") or ("pain control after")).ti,ab,kw.<BR/>8. (("post surg$" or post-surg$) AND (pain$ or discomfort)).ti,ab,kw.<BR/>9. ((pain$ adj4 "after surg$") or (pain$ adj4 "after operat$") or (pain$ adj4 "follow$ operat$") or (pain$ adj4 "follow$ surg$")).ti,ab,kw.<BR/>10. ((analgesi$ adj4 "after surg$") or (analgesi$ adj4 "after operat$") or (analgesi$ adj4 "follow$ operat$") or (analgesi$ adj4 "follow$ surg$")).ti,ab,kw.<BR/>11. OR/4-10<BR/>12. clinical trials.sh<BR/>13. controlled clinical trials.sh<BR/>14. randomized controlled trial.sh<BR/>15. double-blind procedure.sh<BR/>16. (clin$ adj25 trial$).ab.<BR/>17. ((doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ab.<BR/>18. placebo$.ab.<BR/>19. random$.ab.<BR/>20. OR/12-19<BR/>21. 3 AND 11 AND 20</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-05-13 10:47:39 +0100" MODIFIED_BY="Jessica R Thomas" NO="3">
<TITLE MODIFIED="2008-08-01 13:45:28 +0100" MODIFIED_BY="Sheena Derry">Search strategy for Cochrane CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-13 10:47:39 +0100" MODIFIED_BY="Jessica R Thomas">
<P>1. MESH descriptor Oxycodone<BR/>2. (oxycodone OR OxyNorm OR OxyContin OR Percocet):ti,ab,kw<BR/>3. OR/1-2<BR/>4. MESH descriptor Pain, Postoperative<BR/>5. ((postoperative adj4 pain$) or (post-operative adj4 pain$) or post-operative-pain$ or (post$ NEAR pain$) or (postoperative adj4 analgesi$) or (post-operative adj4 analgesi$) or ("post-operative analgesi$")):ti,ab,kw<BR/>6. ((post-surgical adj4 pain$) or ("post surgical" adj4 pain$) or (post-surgery adj4 pain$)):ti,ab,kw<BR/>7. (("pain-relief after surg$") or ("pain following surg$") or ("pain control after")):ti,ab,kw<BR/>8. (("post surg$" or post-surg$) AND (pain$ or discomfort)):ti,ab,kw<BR/>9. ((pain$ adj4 "after surg$") or (pain$ adj4 "after operat$") or (pain$ adj4 "follow$ operat$") or (pain$ adj4 "follow$ surg$")):ti,ab,kw<BR/>10. ((analgesi$ adj4 "after surg$") or (analgesi$ adj4 "after operat$") or (analgesi$ adj4 "follow$ operat$") or (analgesi$ adj4 "follow$ surg$")):ti,ab,kw<BR/>11. OR/4-10<BR/>12. Clinical trial:pt.<BR/>13. Controlled Clinical Trial:pt.<BR/>14. Randomized Controlled Trial:pt.<BR/>15. MeSH descriptor Double-Blind Method<BR/>16. (clin$ adj25 trial$):ti,ab,kw.<BR/>17. ((doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)):ti,ab,kw.<BR/>18. placebo$:ti,ab,kw.<BR/>19. random$:ti,ab,kw.<BR/>20. OR/12-19<BR/>21. 3 AND 11 AND 20</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-05-13 10:47:03 +0100" MODIFIED_BY="Jessica R Thomas" NO="4">
<TITLE MODIFIED="2008-08-01 13:46:05 +0100" MODIFIED_BY="Sheena Derry">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-13 10:47:03 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Categorical rating scale: The commonest is the five category scale (none, slight, moderate, good or lots, and complete). For analysis numbers are given to the verbal categories (for pain intensity, none = 0, mild = 1, moderate = 2 and severe = 3, and for relief none = 0, slight = 1, moderate = 2, good or lots = 3 and complete = 4). Data from different subjects is then combined to produce means (rarely medians) and measures of dispersion (usually standard errors of means). The validity of converting categories into numerical scores was checked by comparison with concurrent visual analogue scale measurements. Good correlation was found, especially between pain relief scales using cross-modality matching techniques. Results are usually reported as continuous data, mean or median pain relief or intensity. Few studies present results as discrete data, giving the number of participants who report a certain level of pain intensity or relief at any given assessment point. The main advantages of the categorical scales are that they are quick and simple. The small number of descriptors may force the scorer to choose a particular category when none describes the pain satisfactorily.</P>
<P>VAS: Visual analogue scale: lines with left end labelled "no relief of pain" and right end labelled "complete relief of pain", seem to overcome this limitation. Patients mark the line at the point which corresponds to their pain. The scores are obtained by measuring the distance between the no relief end and the patient's mark, usually in millimeters. The main advantages of VAS are that they are simple and quick to score, avoid imprecise descriptive terms and provide many points from which to choose. More concentration and coordination are needed, which can be difficult post-operatively or with neurological disorders.</P>
<P>TOTPAR: Total pain relief (TOTPAR) is calculated as the sum of pain relief scores over a period of time. If a patient had complete pain relief immediately after taking an analgesic, and maintained that level of pain relief for six hours, they would have a six-hour TOTPAR of the maximum of 24. Differences between pain relief values at the start and end of a measurement period are dealt with by the composite trapezoidal rule. This is a simple method that approximately calculates the definite integral of the area under the pain relief curve by calculating the sum of the areas of several trapezoids that together closely approximate to the area under the curve.</P>
<P>SPID: Summed pain intensity difference (SPID) is calculated as the sum of the differences between the pain scores over a period of time. Differences between pain intensity values at the start and end of a measurement period are dealt with by the trapezoidal rule.</P>
<P>VAS TOTPAR and VAS SPID are visual analogue versions of TOTPAR and SPID.</P>
<P>See "Measuring pain" in Bandolier's Little Book of Pain, Oxford University Press, Oxford. 2003; pp 7-13 (<LINK REF="REF-Moore-2003" TYPE="REFERENCE">Moore 2003</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>